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ABSTRACT 
 
 
Studies into the pathogenesis of systemic sclerosis (SSc) skin fibrosis to date have 
concentrated on dermal changes in the disease. Little attention has been paid to the 
epidermis in SSc. Epithelial-fibroblast interactions are believed to regulate wound 
healing and contribute to a number of fibrotic diseases. Recent proteomic data from 
our laboratory reveals altered keratinocyte (KC) specific proteins in SSc skin 
consistent with a wound healing phenotype of the disease epidermis. I therefore 
studied SSc KCs focusing on differentiation and KC-fibroblast interaction. 
I found that KC maturation is altered in SSc with abnormal persistence of 
cytokeratins 1, 10 and 14 into suprabasal layers. Cytokeratins 6 and 16, induced in 
wound healing KCs, were shown to be expressed in SSc epidermis. In addition, IL-
1, a pivotal cytokine involved in KC and fibroblast events post epidermal injury, and 
its downstream signalling phosphoproteins p38 and JNK were elevated in SSc 
epidermis.  
I went on to study the effect of SSc epidermis on normal human fibroblasts. I found 
that SSc epidermis promoted fibroblast activation in an ET-1, TGF-β, and IL-1 
dependent fashion. I suggest a double paracrine loop initiated by KC-derived IL-1 as 
a mechanism for epidermal-dermal co-activation in the disease, similar to that 
previously demonstrated for wound healing. There is a need for developing 
antifibrotic agents targeting epithelium-derived factors and their signalling 
pathways. 
I went on to study normal epidermal wound healing. A paradox during epithelial 
repair is that KCs proliferate despite a TGF-β dominated environment, which is 
known to be anti-proliferative. Our laboratory previously showed that prostanoids   4
antagonise TGF-β-dependent events in human cells. The induction of prostanoids 
following injury could transiently free KCs from the anti-proliferative effects of 
TGF-β. I test this hypothesis by confirming transient induction of epidermal COX II 
and PGE2 following injury. I also show that PGE2 antagonises the anti-proliferative 
and pro-migratory effects of TGF-β on KCs. My work supports a model where 
induction of epidermal wound edge COX II leads to antagonism of TGF-β and 
allows KCs to proliferate prior to migration over the wound. 
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CHAPTER 1 
Introductory Review of Scientific Literature 
 
1.1.1 Scleroderma: definition and classification: 
Scleroderma (SSc) is a clinically heterogeneous disorder of unknown aetiology 
which affects small arteries, microvessels and the diffuse connective tissue of the 
skin and internal organs, resulting in uncontrolled scarring and fibrosis. Hidebound 
skin is the clinical hallmark of SSc, and organ compromise is the prognostic 
keystone (E. C. LeRoy et al. 1988a).  
Cases of skin disease compatible with scleroderma have been mentioned in the 
writings of Hippocrates (460-370 B.C.), Galen (131-201 A.D.), and Paulus Aegineta 
(625-690 A.D.). The first documented description, however, comes from Carlo 
Curzio from Naples in 1753. In ‘An Account of an Extraordinary Disease of the 
Skin, and its Cure’ he described a young woman with extensive tension, hardness, 
and woodiness of the skin. Dr Curzio claimed to have cured the young woman, 
which casts some doubt over the diagnosis. Following this, the disease was ‘re-
discovered’ in France in 1847 by Grisolle and Forget. The term scleroderma, 
however, was introduced by Gintrac, also in 1847, as the skin was the most obvious 
organ involved in the disease. 
The clinical presentation of SSc is a spectrum from localised skin fibrosis without 
internal organ pathology (localised scleroderma), to a systemic disorder with 
cutaneous and internal organ involvement (systemic sclerosis - SSc). The latter has a 
much higher mortality (V. D. Steen, T. A. Medsger 2007), and it is the pathogenesis 
of this form of the disease that we are interested in for the purposes of this study.    14
 
Figure 1.1: Diffuse skin sclerosis in SSc. 
 
SSc can be limited or diffuse. The American College of Rheumatology (former 
American Rheumatism Association - ARA) has defined criteria, that are 97 % 
sensitive and 98 % specific for SSc as follows (American Rheumatism Association 
1980b): 
 
Major criterion:  
•  proximal diffuse (truncal) sclerosis (skin tightness, thickening, non-pitting 
induration) 
Minor criteria:  
•  sclerodactyly (only fingers and/or toes)  
•  digital pitting scars or loss of substance of the digital finger pads (pulp loss)  
•  bibasilar pulmonary fibrosis  
 
The patient should fulfil the major criterion or two of the three minor criteria.  
However, it is currently felt that the criteria need revision in view of the recent   15
advances in immunological and capillaroscopic studies (U. F. Haustein 2002). The 
classification of SSc used by most researchers and clinicians is one devised by 
LeRoy et al. in 1988 (E. C. LeRoy et al. 1988b): 
 
Limited Cutaneous SSc: 
•  Raynaud's phenomenon for years at presentation  
•  Skin sclerosis limited to hands, feet, face, and forearms, or absent  
•  Significant late incidence of pulmonary hypertension, trigeminal neuralgia, 
calcinosis, and telangiectasia  
•  Dilated nail fold capillary loops, usually without capillary dropouts  
      detected by wide field nail fold capillaroscopy. 
Diffuse cutaneous SSc: 
•  Onset of Raynaud's phenomenon within 1 year of onset of skin changes  
•  Truncal and acral skin involvement  
•  Presence of tendon friction rubs  
•  Early and significant incidence of interstitial lung disease, oliguric renal 
failure, diffuse gastrointestinal disease, and myocardial involvement  
•  Presence of anti-DNA topoisomerase I (anti-Scl-70) antibodies  
•  Absence of anticentromere antibodies  
•  Nail fold capillary dilatation and destruction detected by wide field nail fold 
capillaroscopy  
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1.1.2 Epidemiology: 
The true incidence of SSc is probably underestimated since early features of the 
disease are often overlooked. However, it is estimated to be between 2.6 and 20 per 
million per year. The prevalence of SSc is reported to be 13 to 105 per million, 
although it can be as high as 290 in South California. There is a genetic, ethnic and 
environmental link in SSc expression (M. D. Mayes et al. 2003). The overall 
female/male ratio has been reported as 3:1. However, this ratio is larger in Great 
Britain (6:1), and in the USA (8:1). 
Survival seems to be directly related to the severity of internal organ involvement. 
However, the skin score is a useful marker of both disease severity and prognosis. 
Raynaud’s syndrome alone confers a 79-84% survival at 5 years, while truncal SSc 
at the onset of the disease reduces the survival rate to around 50% at 5 years (A. J. 
Barnett et al. 1988;E. V. Lally et al. 1988).  
 
1.1.3 Scleroderma Pathogenesis: 
SSc is a complex multifactorial disease. It is currently thought to be due to a 
combination of inflammatory, immunological and microvascular triggers, which 
result in massive fibroblast activation and extracellular matrix (ECM) deposition. 
This process ultimately leads to skin and internal organ fibrosis (D. J. Abraham, J. 
Varga 2005).  
Initiation triggers for the disease are not known but certain risk factors are identified. 
For example, polyvinyl chloride exposure in the US and Germany in 1930s resulted 
in a SSc-like illness in factory workers (P. J. Nietert, R. M. Silver 2000a). Exposure 
to silica dust in miners, stone masons, and others, exposure to aromatic and aliphatic   17
organic solvents, and exposure to epoxy resins and formaldehyde have all been 
linked to the occurrence of SSc (A. J. Silman, S. Jones 1992).  
Some genetic links have also been identified, although small family numbers have 
prevented linkage analysis. Genetic susceptibility to SSc is thought to be 
multifactorial. Monzygotic twin studies show a 4.7% concordance for clinical 
disease expression, while the concordance for having antinuclear antibodies is 90%, 
suggesting that genetic susceptibility alone is not enough to lead to the disease (C. 
Feghali-Bostwick et al. 2003). Examples of polymorphisms found to be associated 
with SSc are those in fibrillin-1 gene, IL-1α, CTLA4, IL-10 and SPARC (Y. 
Allanore et al. 2007). 
 
1.1.4 Scleroderma Histopathology: 
Fibrosis is defined as the formation or development of excess fibrous connective 
tissue in an organ or tissue as a reparative or reactive process, as opposed to 
formation of fibrous tissue as a normal constituent of an organ or tissue. Cutaneous 
scarring is defined as the macroscopic disturbance of the normal structure and 
function of the skin, arising as a consequence of wound healing, and owing to the 
changes in epidermal, dermal and subcutaneous tissue at the time of wounding (M. 
W. Ferguson et al. 1996).  
In its mild form fibrosis may result in hypertrophic scar or keloid formation, but in 
the most severe form fibrotic disease can occur with organ destruction and 
ultimately death. SSc is one such disease. 
Sclerosis of the skin is a predominant and defining feature of SSc. It usually starts in 
the distal limbs and gradually progresses to involve other areas of the skin. Skin 
sclerosis starts of as active inflammation and oedema, progresses to the fibrotic   18
stage, and ends in atrophy. The skin score has been shown to be a useful predictor of 
SSc outcome (P. J. Clements et al. 2000b).  
Histopathological findings in SSc depend on the stage of the disease. At the early 
stage one observes mild inflammatory infiltrates consisting of lymphocytes (mostly 
T helper cells), monocytes, histiocytes and plasma cells around the blood vessels and 
ducts of the eccrine sweat glands. The collagen fibres appear oedematous. In the 
later stage these infiltrates are reduced or disappear completely. The vessel walls are 
thickened and hyalinised, their lumen is narrowed leading to devascularisation (M. 
B. Kahaleh et al. 1979). Abundant accumulation of connective tissue and matrix 
proteins is first seen in the vicinity of blood vessels, in the reticular dermis, and at 
the border of the subcutaneous tissue. The combination of cellular infiltrates and 
connective tissue consisting of collagen, fibrillins and proteoglycans makes up 
extracellular matrix (ECM). Increased production and decreased breakdown of this 
fibrotic substance leads to progressive replacement of normal tissues and organs 
resulting in their functional impairment (J. Varga, D. Abraham 2007).   
Tissue fibrosis is felt to be due to the failure of normal wound healing processes to 
terminate appropriately (A. Desmouliere et al. 2005c). The cell responsible for 
fibrosis is the fibroblast. In its resident, migrating and activated forms fibroblasts 
play an important role in wound healing. This means that in order to understand 
fibrosis, we must understand normal wound healing as well as its dysregulation. 
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1.1.5 Wound Healing:  
1.1.5.1 Phases of normal wound healing: 
The process of normal wound healing is highly regulated (S. Werner, R. Grose 
2003g). It is thought of in three phases that occur sequentially and simultaneously.  
Inflammatory phase. Immediately after injury -5 days. 
In the inflammatory or reactive phase cell injury causes cytokines, growth factors, 
and other low molecular weight compounds to be released from serum of injured 
blood vessels and degranulating platelets. There is an influx of inflammatory cells 
which in turn release their own inflammatory mediators. Mechanical injury to the 
epidermis results in the release of IL-1 stored in the KC cytoplasm. Transforming 
growth factor β (TGF-β), resident in its latent form and bound to ECM, becomes 
activated. Some of the mediators (such as IL-1, TGF-β, PDGF, and EGF) contribute 
to the next phase of wound healing (B. J. Faler et al. 2006a).  
Proliferative phase. 2 days -3 weeks. 
The repair process restores tissue continuity through deposition of repair tissue. The 
proliferative phase starts with the migration and proliferation of KCs at the wound 
edge. This is followed by two fundamental processes: fibroplasia and angiogenesis. 
Massive angiogenesis leads to new blood vessel formation from capillaries growing 
towards the repair zone. There is migration and proliferation of dermal fibroblasts, 
which start laying down collagen and ECM. They are activated to form 
myofibroblasts and begin the wound contraction process. New nerve endings sprout 
around the wound edge. The resulting wound connective tissue is known as 
granulation tissue due to the granular appearance of the numerous capillaries it 
contains.  
   20
Remodelling phase. 1 week -2 years. 
During this final phase the granulation tissue is slowly converted to scar tissue. This 
phase overlaps with the proliferative phase and is predominantly facilitated by 
fibroblasts. They continue their ECM and collagen production. With maturity, 
collagen becomes orientated in line with local stresses. Type III collagen is replaced 
by the stronger Type I collagen. The goal of this process is to form a structure as 
similar as possible to parent tissue (S. Werner, R. Grose 2003f;B. J. Faler et al. 
2006b;J. J. Tomasek et al. 2002d).  
 
1.1.5.2 The role of fibroblasts and myofibroblasts in wound healing: 
1.1.5.2 (a) The fibroblast: 
Fibroblasts provide a structural framework for many tissues and play a critical role 
in wound healing. They secrete the precursors of all the components of ECM. 
Wound contraction is governed by two fibroblast-driven mechanisms: tractional 
forces generated by fibroblasts migrating into the wound, and differentiation of 
fibroblasts into highly contractile myofibroblasts (A. Desmouliere et al. 2005b).  
 
1.1.5.2 (b) The myofibroblast: 
The myofibroblast was initially discovered by means of electron microscopy in 
granulation tissue of healing wounds, which led to the suggestion that these cells 
have a role in granulation tissue contraction. Myofibroblasts are specialised 
mesenchymal cells with morphology and biochemical features between those of the 
fibroblast and the smooth muscle cell (G. Gabbiani et al. 1971). Myofibroblasts 
express αSMA and a complex array of stress fibres and adhesions. They are the key 
cells for the connective tissue remodelling that takes place during wound healing and   21
development of fibrosis (J. J. Tomasek et al. 2002c). They originate from three 
sources: resident mesenchymal cells, blood stream circulating fibrocytes and 
epithelial cells with the ability to undergo mesenchymal transiyion (Kalluri, Neilson 
2003). 
Morphologically, these cells are characterised by the presence of a contractile 
apparatus containing bundles of actin microfilaments in association with contractile 
proteins such as non-muscle myosin. Actin bundles terminate at the specialised area 
of the fibroblast - the fibro nexus - which acts to connect them to the extracellular 
fibronectin fibres via transmembrane integrins. The fibronexus serves to transmit the 
mechanical force generated by actin-myosin interaction to the ECM and carry 
extracellular signals back into the cells. Myofibroblasts are connected by gap 
junctions to form a multicellular lattice during granulation tissue contraction (J. J. 
Tomasek et al. 2002b). 
It has been shown that initiation of granulation tissue contraction does not require 
the presence of myofibroblasts, and that it is the tractional forces generated by 
migrating fibroblasts that are important in the initiation of wound closure (P. J. 
Clements et al. 2000a). Following this initial migration, fibroblasts transform to 
proto-myofibroblasts. These cells express β- and γ-cytoplasm actins that are also 
normally found in resident fibroblasts. A crucial signal for the transformation to 
proto-myofibroblasts is mechanical tension. This was confirmed in experiments that 
used granulation tissue tension changes to measure markers of fibroblast activation. 
It was proposed that tractional forces that develop in the closing wound cause the 
fibroblasts and collagen fibres to align along lines of stress and thus acquire the 
proto-myofibroblast phenotype (B. Hinz et al. 2001b).  
Proto-myofibroblasts, once formed, can be stimulated to develop into   22
myofibroblasts. It is proposed that this latter transformation does not occur before 
day four of wound healing, and requires both tension and additional growth factors 
such as TGF-β (P. Shephard et al. 2004a).  
 
1.1.5.2 (c) In experimental environments: 
Fibroblast populated three-dimensional collagen lattices are used in vitro to study 
reciprocal cell-matrix interactions (X. Shi-Wen et al. 2004c). There are three major 
FPCL models used: tension loaded (tethered or pre-stressed), stress-relaxed, and free 
floating. The difference is governed by whether the FPCL is restrained which 
determines the mechanical loading of the cells.  
The free floating collagen matrix is released immediately upon polymerisation. The 
fibroblasts remain relatively spherical with fine protrusions to contract the matrix (F. 
Grinnell 2000). 
The stress-relaxed system allows fibroblast pre-activation. Here FPCL remains 
attached to the container wall for 24 hours allowing morphological transformation 
and development of tractional force. During these first hours fibroblasts develop 
pseudopodial extensions. Contractional force on the lattice is then generated via cell 
attachment to fibronectin (which contains an ED-A domain) and traction without 
migration (M. Eastwood et al. 1996b). This is because as fibroblasts attach and pull 
on the substrate, the rear of the cell remains attached to the substrate. Fibroblasts 
tend to align themselves with the direction of maximal principle strain (M. Eastwood 
et al. 1998). In a circular 3D collagen model this means that the lattice is drawn in 
from 360 ˚, and the overall effect is centrifugal traction with a starburst appearance 
under electron microscopy (R. K. Sawhney, J. Howard 2002). Once the lattice is 
released, the mechanical tension together with a profibrotic stimulus such as TGF-β,   23
causes fibroblast differentiation to its active α-smooth-muscle actin containing 
contractile form - the myofibroblast (F. Grinnell 2003e). Since fibroblasts in 
restrained but not floating matrices can organize cell surface fibronectin matrix and 
develop fibronexus junctions, TGF-β only stimulates the differentiation of 
fibroblasts into myofibroblasts in restrained matrices. In addition matrix synthesis 
and cell proliferation can only occur in mechanically loaded lattices (F. Grinnell 
2003d). The result of fibroblast contraction is a visible decrease in lattice diameter 
which can be measured and compared (P. D. Arora et al. 1999b;B. Hinz et al. 
2001a). 
The tension loaded system is similar to the pre-stressed one, except it is not released 
at any point and contraction is measeured by tension monitors (M. Eastwood et al. 
1996a). 
1.1.5.2 (d) Summary: 
In summary, during normal healing, fibroblasts migrating into the wound area 
initiate wound contraction and lay down ECM. Tractional forces then confer the 
change to proto-myofibroblasts, following which the combination of traction and 
TGF-β cause their transformation to myofibroblasts (J. J. Tomasek et al. 2002a). 
 
1.1.5.3 From normal wound healing to pathological fibrosis: 
Physiological wound healing is spatially and temporally self-limiting. Normal 
fibroblasts can modulate their collagen production in response to tissue requirement, 
and once sufficient ECM is laid down and re-epithelialisation is complete they either 
revert to the quiescent state or undergo apoptosis. This way organ function is 
restored and cellular and collagen interactions are then remodelled gradually to 
strengthen the scar (S. O'Kane, M. W. Ferguson 1997). However, if fibroblast and   24
myofibroblast activity continues unabated, ECM secretion and tissue contraction 
will also persist. Pathological scar formation, and ultimately fibrosis will take place 
as a result. In support of this notion, myofibroblasts have been shown to persist in 
different fibrotic lesions including those of interstitial pulmonary fibrosis (IPF) and 
stromal tumours (H. F. Dvorak 1986;C. Kuhn, J. A. McDonald 1991). In addition, 
fibroblasts from SSc lesional skin grown in culture have been shown to produce 
more soluble collagen than the paired controls, and to have the capacity to synthesise 
collagen after up to fifteen subcultures (E. C. LeRoy 1974).  
The important question is what causes the switch from normal regulated cells to 
persisting and autonomous ones capable of destructive fibrosis? Possible 
explanations include activation of fibroblasts by immune cells, inappropriate 
expression and/or persistence of fibrosis enhancing growth factors, or persistent 
fibroblast activation following environmental stress or cell injury. 
 
1.1.6 Transforming growth factor β (TGF-β): 
1.1.6.1 Background: 
Since the early nineties investigators have been pursuing the role of TGF-β in 
fibrotic disease (G. C. Blobe et al. 2000). TGF-β is a multifunctional cytokine with 
proinflammatory as well as immunosuppressive activities (J. Massague 1990). TGF-
β signalling controls a diverse set of cellular processes. Its expression serves in both 
autocrine and paracrine modes to cause cell proliferation, differentiation, apoptosis, 
and production of extracellular matrix proteins, as well as to determine cellular 
developmental fate during embryogenesis and in mature tissues. TGF-β is also 
known to affect nearly all aspects of wound repair. 
Discovered in 1978 by Todaro and De Larco it was called the ‘sarcoma growth   25
factor’ (SGF). The name was given because this factor, produced by virally 
transformed cells, caused phenotypic transformation of a normal reader cell into one 
able to grow in soft agar, a characteristic usually attributed to malignant cells only. It 
was also noted that SGF induced the growth of many large colonies of normal rat 
kidney cells, and was therefore re-named TGF-β. In 1980s TGF-β was purified from 
various different tissues including placenta, liver and heart. And in 1984 the first 
discovery of the inhibitory action of TGF-β was made (M. B. Sporn 2006b). In 1985 
the complex nature of TGF-β was emerging in demonstration of its 
multifunctionality that depended on the local milieu. Thus, in the presence of PDGF, 
TGF-β caused stimulation of growth of reader cells, while in the presence of EGF, 
TGF-β functioned as a growth inhibitor (M. B. Sporn 2006a). 
1.1.6.2 TGF-β structure: 
Members of the TGF-β super-family are dimeric proteins with nearly 30 members in 
mammals that include TGF-β, bone morphogenic proteins (BMP), growth 
/differentiation factors (GDF), and anti-Mullerian hormone (AMH). All members 
have a conserved carboxyl terminal feature consisting of seven cysteine residues, six 
of which form a rigid cysteine knot. TGF-β exists in three isoforms: TGF-β 1, 2 and 
3 which share 64-85% amino acid sequence homology and reside in the extracellular 
matrix of uninjured tissues (J. Massague 1990). All three isoforms exert similar 
effects grouped into three broad areas: inflammatory cell function regulation, growth 
inhibition and differentiation, and ECM production (J. S. Munger et al. 1999c). 
TGF-β is secreted in latent form noncovalently associated with latency associated 
peptide (LAP), which renders it unable to bind its receptor (i.e.TGF-β is latent). This  
small latent complex (SLC) of LAP and TGF-β is joined by latent TGF-β binding 
protein 1 (LTBP) which is a matrix proteins similar to fibrillin (S. Sinha et al.   26
1998a). Serum proteins intimately associated with the wound healing response 
catalyse TGF-β activation. Plasmin and thrombospondin-1 integrin have been shown 
to cleave the active form from the complex (J. P. Annes et al. 2003). Integrin αvβ6 is 
expressed in the epithelium. It has been shown that SLC is a ligand for this integrin, 
and their binding acts to change the conformation of the complex to allow TGF-β 
binding to TGF-β receptor (J. S. Munger et al. 1999b).   
1.1.6.3 TGF-β signalling cascade: 
Over the last ten years researchers have focused on delineating the TGF-β signalling 
pathways (A. Nakao et al. 1997). The intracellular messengers involved are of 
considerable interest as potential antifibrotic therapeutic targets.  
The following signalling cascade is currently described (Figure 1.2).  
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Figure 1.2: Simplified diagram of the TGF-β signalling cascade.   27
Most cells express two types of TGF-β receptor (TβR I and II). Both are 
transmembrane serine/threonine protein kinases. TβRI (or ALK5) cannot bind a free 
ligand, only a ligand that is bound to TβRII. Upon binding to TβRII (which is a 
constitutively active kinase), TβRI is activated and phosporylates downstream 
targets. These targets are a conserved family of intracellular signalling effector 
proteins called SMADs named after the genes Mad and Sma discovered in 
Drosophila and Caenorhabdis elegans respectively. The receptor activated SMADs 
transiently interact with the activated receptor complex and are C-terminally 
phosphorylated (R. Derynck et al. 1998c). After phosphorylation, receptor-activated 
SMAD2 and SMAD3 form a heterooligomeric complex with SMAD4 (a common 
mediator). The complex then moves to the nucleus (a key step in signal transduction) 
to activate transcriptional promoters directly or by combining with other 
transcription factors (J. Massague, R. R. Gomis 2006). SMAD7 is an intracellular 
antagonist of TGF-β signalling. It associates with activated TβRs and prevents 
SMAD2/3 binding and consequent phosphorylation (Y. Shi, J. Massague 2003). It is 
believed that fine-tuning of cellular responses to TGF-β is performed through the 
interaction of the SMAD cascade with other signalling molecules. In fact, TGF-β is 
capable of acting through pathways other than SMAD, including the MAP kinase 
pathway, in a cell and tissue specific fashion (A. Moustakas, C. H. Heldin 2005). 
TGF-β/SMAD signalling can be controlled by the ras/MEK/ERK MAPK cascade 
with ERK phosphorylation sites existing on SMAD3 and 4 linker regions (K. M. 
Mulder 2000). The MAP kinase pathway has different effects on SMAD signalling 
depending on the cell involved. In fibroblasts, the MAP kinase pathway is required 
for SMAD-mediated CTGF induction by TGF-β. A prostacyclin derivative iloprost 
blocks TGF-β-driven fibrosis by suppressing MAP kinase signalling in a protein   28
kinase A (PKA)-dependent fashion (R. Stratton et al. 2002l).  
In kidney mesangial cells the MAP kinase system activation potentiates SMAD 
signalling (Y. Chen et al. 2002). In epithelial cells, on the other hand, this cascade is 
inhibitory of the SMAD pathway through blocking nuclear accumulation of SMADs 
(A. Leask, D. J. Abraham 2004). Since TGF-β is anti-proliferative in most cells, the 
latter could explain why in the context of oncogenesis ras activation causes 
uncontrolled cell proliferation (M. Kretzschmar et al. 1999).   
In general it is clear that TGF-β signalling is highly complex. Its exact effect 
depends on the cell and tissue and on the interaction with signalling cascades 
activated by other molecules, as well as its own target gene activation. 
 
1.1.6.4 Connective tissue growth factor (CTGF): 
One of the most important targets of TGF-β signalling is the CTGF gene. CTGF is a 
38kD heparin-binding cysteine-rich glycoprotein that functions as a downstream 
mediator of TGF-β-induced collagen deposition. It is a member of the CCN 
immediate early growth-responsive gene family which contains cyr61, nov, elm1, 
Cop1, and WISP-3 and 2 (E. E. Moussad, D. R. Brigstock 2000b). 
It was originally identified in the human umbilical vein endothelial cells through its 
cross-reactivity with an antibody to PDGF. However, it was shown to be a separate 
moiety with mitogenic activity for endothelial cell and fibroblasts. It was then 
designated CTGF (D. M. Bradham et al. 1991). The same investigators 
demonstrated coordinate expression of CTGF and TGF-β in normal wound repair, 
and showed that TGF-β stimulated CTGF production in human foreskin fibroblasts 
(A. Igarashi et al. 1993). Around the same time CTGF was isolated from TGF-β-
treated mouse cells (A. Brunner et al. 1991).    29
Epithelia of many normal tissues are also found to contain CTGF, where it is 
believed to be involved in regulation of cell differentiation and apoptosis (E. E. 
Moussad, D. R. Brigstock 2000a). The involvement of CTGF in wound repair is 
supported by the experiments showing activation of this growth factor in KCs 
following binding of factor VII to tissue factor (E. Camerer et al. 2000). 
Currently CTGF is thought to play an important role in wound healing and fibrotic 
reactions, and is implicated in pathogenesis of SSc. In fact, CTGF has been 
repeatedly identified in fibroblasts from sclerotic skin lesions of SSc patients. A 
positive correlation has been found between the level of skin sclerosis and CTGF 
mRNA content (A. Igarashi et al. 1995;A. Igarashi et al. 1996a). There is also a 
positive correlation between the level of skin sclerosis and the circulating levels of 
CTGF (S. Sato et al. 2000). Sampling of dermal interstitial fluid of SSc lesional skin 
demonstrated increases CTGF levels compared to healthy controls (R. Stratton et al. 
2001a). 
Various studies have been designed to confirm the role of CTGF as a downstream 
signal and a synergistic contributor to TGF-β activation and fibrotic action. It has 
been shown that in vitro, TGF-β-treated SSc fibroblasts produce greater amounts of 
CTGF than normal fibroblasts (K. Kikuchi et al. 1995). Recombinant CTGF and 
neutralising antibodies to this growth factor have been used to demonstrate that 
CTGF has a similar effect on fibroblast proliferation, ECM production, and 
granulation tissue formation as TGF-β (I. E. Blom et al. 2001;J. K. Crean et al. 
2002;B. S. Weston et al. 2003). In vivo, subcutaneous CTGF injection into neonatal 
mice resulted in granulation tissue formation and ECM synthesis. In situ 
hybridisation confirmed that TGF-β could induce CTGF production in dermal 
fibroblasts at that injection site (K. Frazier et al. 1996). CTGF and TGF-β injection   30
into new-born mice established the synergistic role of these two growth factors. 
Separate applications induced transient fibrosis only. However, when injected 
together, a lasting fibrotic response could be elicited (T. Mori et al. 1999a). This 
finding was confirmed in vitro, when collagen matrix contraction by TGF-β was 
shown to be generated by CTGF. The same investigators later established that CTGF 
maintains the TGF-β induced skin fibrosis by sustaining COL1A2 collagen gene 
promoter activity and by increasing the number of activated fibroblasts (S. Chujo et 
al. 2005;A. Holmes et al. 2003a).  
A recent study has confirmed that normal and SSc human skin fibroblasts produce 
CTGF after stimulation with TGF-β. However, the latter were much greater 
producers. The same study demonstrated an upregulation of the gene for CTGF in 
SSc fibroblasts, and showed that CTGF stimulated a two- to three-fold increase in 
proα1(I) collagen and fibronectin synthesis by dermal and lung fibroblasts. This 
produced significant contraction of FPCLs (X. Shi-Wen et al. 2000d). In an elegant 
experiment, the same investigators also attained evidence for the CTGF over-
expression as a cause of increased collagen synthesis by fibroblasts. They did this by 
transfecting CMV-CTGF cDNA constructs into normal fibroblasts. This caused an 
increase in the transcription of Colα2 promoter-reporter construct to the level seen in 
SSc fibroblasts. 
Normal dermal fibroblasts do not express CTGF unless stimulated by TGF-β, for 
example during normal wound healing (A. Igarashi et al. 1996b). However, 
fibroblasts from fibrotic lesions express CTGF genes constitutively, even in the 
absence of stimulation by TGF-β (X. Shi-Wen et al. 2000c). An increase in the basal 
promoter activity of the CTGF ccn2 gene has been found in dermal fibroblasts from 
SSc skin. Interestingly, CTGF promoter over-activity in lesional fibroblasts seemed   31
to be independent of the SMAD response element and the TGF-β response element 
which are responsible for CTGF expression in normal fibroblasts (A. Holmes et al. 
2001a;A. Leask et al. 2001;A. Leask et al. 2003). Instead, a novel promoter element 
containing an Sp1 binding site has been shown to be involved in CTGF over-
expression in SSc fibroblasts.  
 
1.1.6.5 TGF-β in wound healing: 
The presence of TGF-β is consistently found in the wound healing environment. 
Researchers have demonstrated TGF-β mRNA in incisional wounds of rats, as well 
as in activated macrophages harvested from wound chambers. Studies where TGF-β 
was added to wounds reported an accelerated rate of healing. When purified bovine 
TGF-β was injected into wire mesh chambers on the backs of rats, an accumulation 
of total protein, collagen, and DNA was observed (M. B. Sporn et al. 1983). McGee 
et al. reported that a single application of recombinant TGF-β1 accelerated incisional 
wound healing and increased tensile strength of rat wounds (G. S. McGee et al. 
1989). Supporting the role of TGF-β in healing was the fact the exogenous 
application of this growth factor accelerated wound closure delayed by 
glucocorticoids (L. S. Beck et al. 1991;L. S. Beck et al. 1993;G. F. Pierce et al. 
1989). It was demonstrated that the levels of TGF-β1 and 2 were decreased in the 
glucocorticoid-treated wounds. In a different model of impaired wounding -the 
elderly skin- TGF-β levels were also reduced (G. S. Ashcroft et al. 1995). 
These observations led to the conclusion that dysregulation of TGF-β expression 
could be responsible for abnormal wound repair (S. Frank et al. 1996;P. Schmid et 
al. 1993). More recent experimental data supports this notion. In rat tissue 
transfected with TGF-β1 expression constructs, wound repair was markedly   32
improved (S. I. Benn et al. 1996).  
TGF-β is important in all phases of wound healing. Released primarily from α 
granules of platelets and from the LAP-bound pool resident in the tissues, as well as 
from most inflammatory cells that migrate in, TGF-β is vital in the reactive phase of 
wound healing as a powerful chemoattractant (S. Sinha et al. 1998b;S. Werner, R. 
Grose 2003e). In fact, TGF-β is the most potent chemotactic factor described for 
human peripheral blood neutrophils (T. Parekh et al. 1994). In addition, TGF-β 
stimulates the influx of macrophages into the wounded area (C. P. Kiritsy et al. 
1993). It has been demonstrated that SMAD3 null mice have significantly fewer 
inflammatory cells in their wounds compared to wild-type mice. Also, macrophages 
from SMAD3 null mice showed dramatically reduced migration to a TGF-β 
stimulus, with suppressed ability to digest ECM and debris (G. S. Ashcroft et al. 
1999b). 
For the purposes of this thesis, the role of TGF-β in the proliferative and remodelling 
phases of wound healing, which are marked by fibroblast proliferation and ECM 
deposition, as well as angiogenesis and re-epithelialisation is particularly notable. It 
is the uncontrolled processes of these stages of wound healing that potentially lead 
to fibrotic disease. When injected subcutaneously into newborn mice TGF-β 
activates fibroblasts and causes angiogenesis, and thus granulation tissue formation 
(A. B. Roberts et al. 1986a).  A single TGF-β application accelerated healing of rat 
incisional wounds by 3 days, and elicited a 220% increase in wound strength after 
only 5 days. This was accompanied by increased fibroblast infiltration and collagen 
deposition (T. A. Mustoe et al. 1987). In addition, Quaglino et al. demonstrated the 
effect of TGF-β on excisional and incisional porcine wounds. After TGF-β 
application granulation tissue formation was significantly increased. In situ   33
hybridisation studies demonstrated upregulation of ECM protein expression, and 
downregulation of proteolytic enzyme expression. An auto-induction of TGF-β 
mRNA in the wounds was also noted (D. Quaglino, Jr. et al. 1990). 
In summary, TGF-β accelerates wound healing processes of normal and impaired 
wounds. 
 
1.1.6.6 TGF-β in fibrosis:  
TGF-β is a good candidate for a fibrogenic growth factor. It is a potent chemotactic 
factor for fibroblasts, and stimulates the synthesis of ECM by explanted cultured 
fibroblasts (G. F. Pierce et al. 1991b;G. F. Pierce et al. 1991a;A. E. Postlethwaite, J. 
M. Seyer 1990;A. B. Roberts et al. 1986b). It was demonstrated back in 1979 that 
fibroblasts from SSc lesional skin do produce increased amounts of procollagen type 
I and II (J. Uitto et al. 1979). The same investigators later confirmed increased co-
expression of type VII, type VI and type I collagen and TGF-β in the dermis of SSc 
patients (J. Peltonen et al. 1990e;L. Rudnicka et al. 1994a;J. Peltonen et al. 1990a). 
It has been shown that TGF-β stimulates the human promoter region of the Type I 
collagen gene (COL1A2) activity via SMAD signalling (S. J. Chen et al. 1999). The 
immunoreactivity of TGF-β in the skin of patients with diffuse SSc (as well as 
limited disease) was shown to be present prior to the onset of fibrosis and in its 
initial stages, indicating an early involvement of this factor in the disease (L. 
Rudnicka et al. 1994b).  
In its additional pro-fibrotic role, TGF-β stimulates the secretion of proteinase 
inhibitors such as plasminogen activator inhibitor and tissue inhibitor of 
matalloproteinases, and inhibits production of proteinases, thus preventing ECM 
breakdown in  preparation of the wound for the remodelling phase of healing (C. P.   34
Kiritsy et al. 1993).  
Many experiments have highlighted the role of TGF-β in fibrotic responses in vivo.  
When foetal rabbit subcutaneous sponge implants containing TGF-β1 were analysed 
7 days post wounding they were found to contain a large number of inflammatory 
cells and fibroblasts with marked collagen deposition (T. M. Krummel et al. 1988). 
In IPF, foci of activated fibroblasts resembling those found in healing wounds are 
responsible for the fibrotic process. Using in situ hybridisation and 
immunohistochemistry TGF-β was demonstrated adjacent to these foci and 
suggested to be the stimulus responsible for persistent expression of connective 
tissue genes (T. J. Broekelmann et al. 1991). 
Lung treatment with bleomycin induces pulmonary fibrosis and TGF-β upregulation. 
Neutralising antibody to TGF-β reduces this fibrotic reaction (S. N. Giri et al. 1993). 
I has been shown that foetal wounds heal without scarring, and with a diminished 
inflammatory and cytokine response than adult wounds. When adult rat healing 
dermal wounds were injected with a neutralising antibody to TGF-β they healed 
without scar-tissue formation, less inflammation, and lower collagen and fibronectin 
content than the paired controls (M. Shah et al. 1992). In support of this finding, it 
has been shown that TGF-β mRNA can be induced by wounding adult skin, but not 
foetal skin. However, when TGF-β was added to the foetal skin, TGF-β mRNA 
expression was found in the fibroblasts, an adult-like inflammatory response 
occurred, and the skin healed with scar formation. This confirmed that TGF-β was 
an important modulator of fibrosis in vivo (R. Y. Lin et al. 1995). 
Recently, a transgenic mouse model of fibrosis expressing a kinase-deficient type II 
TGF-β receptor on fibroblasts provided further evidence for the pivotal role of TGF-
β over-activity in fibrosis. These mice developed both dermal and lung fibrosis, their   35
fibroblasts over-producing CTGF and type I collagen. In this model the fibroblast to 
myofibroblast differentiation was also increased (C. P. Denton et al. 2005). 
 
1.1.6.7 TGF-β in fibroblast to myofibroblast transformation: 
The presence of myofibroblasts has been described in every known fibrotic situation.   
Most of the SSc fibroblasts are known to be myofibroblasts expressing α smooth 
muscle actin (αSMA) (A. P. Sappino et al. 1990). It has been shown that fibroblasts 
from lesional (scarred) skin of patients with SSc persist as active myofibroblasts, 
and when cultured, have enhanced ability to produce, adhere to, and contract ECM 
(Y. Chen et al. 2005e). 
TGF-β is responsible for the phenotypic change from fibroblast to myofibroblast (R. 
Abe et al. 2001;Y. Chen et al. 2005d). Desmouleir et al. demonstrated that in rats, 
subcutaneous injection of TGF-β caused an increase in αSMA-expressing 
granulation tissue fibroblasts. Moreover, TGF-β induced αSMA expression in 
growing and quiescent cultured fibroblasts, an effect partly inhibited by antibodies to 
TGF-β (A. Desmouliere et al. 1993). 
 
1.1.6.8 TGF-β in SSc: 
Uncontrolled ECM production as a consequence of disordered wound healing 
mechanisms, fibroblast and myofibroblast persistence, and ultimately fibrosis are the 
hallmarks of SSc. The evidence presented above implicates TGF-β in all these 
processes and thus in SSc pathogenesis. One of the first studies to demonstrate 
intense immunohistochemical staining for TGF-β in the dermis of SSc skin was by 
Sfikakis et al. in 1993. They asked the question as to the source of this growth 
factor, and proposed that it was unlikely to have been derived from the inflammatory   36
infiltrate as there was no perivascular inflammatory cell staining for TGF-β in their 
study. However, they did find positive staining in dermal fibroblasts, and the 
epithelial cells (P. P. Sfikakis et al. 1993c). This finding was in line with an earlier 
one by Gruschwitz et al., who found increased levels of TGF-β in dermal and 
epidermal cells of SSc skin (M. Gruschwitz et al. 1990b). 
Additional later experiments demonstrated increased TβR expression in fibroblasts 
from the dermis of SSc patients, with antibodies to TGF-β abolishing the increased 
mRNA expression as well as up-regulated transcriptional activity of the human 
alpha2(I) collagen gene (H. Ihn et al. 2001b). Chen et al. have demonstrated that 
enhanced matrix contraction by dermal fibroblasts from SSc patients required TGF-β 
and its signalling pathways (Y. Chen et al. 2005c). Also, a disordered signalling 
pathway, with increased SMAD2/3 phosphorylation and decreased expression of the 
inhibitory SMAD7 has been found in SSc fibroblasts (C. Dong et al. 2002). In 
murine models, SMAD7 deficiency has been shown to be associated with renal 
fibrosis (M. Schiffer et al. 2001;K. Uchida et al. 2000). However, two other studies 
failed to demonstrate a difference in SMAD7 expression between normal and SSc 
fibroblasts (A. Holmes et al. 2001b;Y. Mori et al. 2003f). A ligand-independent 
constitutive activation of the intracellular TGF-β/SMAD signalling axis in SSc 
fibroblasts has been shown, confirming the importance of disordered SMAD 
signalling in SSc pathogenesis and fibroblast autonomy (Y. Mori et al. 2003e). 
Various animal models of SSc confirm the importance of TGF-β and its signalling 
pathways in pathogenesis of this disease. A mouse model of SSc has been 
established by repeated subcutaneous injections with bleomycin. Here, anti-TGF-β 
antibody caused a significant reduction in cutaneous sclerosis and inflammation (T. 
Yamamoto et al. 1999b). In the same model Takagawa et al. demonstrated   37
predominantly nuclear localisation of SMAD3 and intense staining for pSMAD2/3 
in fibroblasts after bleomycin injection (S. Takagawa et al. 2003a). The role of 
SMAD3 and TGF-β in fibrosis was later confirmed in SMAD3 null mice injected 
with bleomycin. This transgenic model demonstrated a decreased fibrotic response, 
CTGF and collagen production, and αSMA expression. The SMAD3 null mice also 
had a decreased fibrotic response to TGF-β (G. Lakos et al. 2004). 
 A mouse graft-versus-host disease model of SSc has also been developed. It was 
shown to resemble the human condition more than the chemically-induced disease 
(M. C. Ruzek et al. 2004). This model was used to demonstrate that TGF-β 
inhibition with a neutralising antibody prevented the skin and lung fibrosis caused 
by TGF-β (L. L. McCormick et al. 1999). 
 
1.1.6.9 TGF-β in SSc skin fibrosis: 
Despite the evidence presented above for the role of TGF-β in SSc, some 
contradictory data exists regarding the role of TGF-β in the maintenance of SSc 
fibrosis. For example, Peltonen et al. found no elevation of TGF-β mRNA in SSc 
skin biopsy samples (J. Peltonen et al. 1990b), and TGF-β was unable to induce the 
SSc phenotype in normal fibroblasts, or to sustain this phenotype in vitro (A. 
McWhirter et al. 1994b). Kinase-deficient TβRI failed to down-regulate collagen 
synthesis by SSc fibroblasts (J. Pannu et al. 2004b). No correlation has been found 
between the circulating levels of TGF-β and SSc severity (M. Dziadzio et al. 
2005a;N. Snowden et al. 1994). Also, as mentioned previously, the inflammatory 
cell infiltrate in SSc skin does not stain for the growth factor (P. P. Sfikakis et al. 
1993b). 
It has been shown that TGF-β1 and 2 are present in the inflammatory skin of SSc   38
patients but not in the established sclerotic lesions (C. Querfeld et al. 1999b). In 
addition, TGF-β mRNA expression in lesional tissues is early and transient (T. 
Yamamoto et al. 1999c).  
It has been suggested that dysregulated signalling downstream of TβR could account 
for SSc pathogenesis independently of continued stimulation by TGF-β (S. 
Takagawa et al. 2003b). SMADs are a possible molecular candidate for autonomous 
over-activation. When increased SMAD2/3 phosphorylation and nuclear 
translocation were demonstrated in SSc fibroblasts, withdrawal of TGF-β stimulus 
failed to reverse this effect (Y. Mori et al. 2003d). 
Another candidate for an autonomous profibrotic agent is CTGF because its 
expression in SSc fibroblasts can be SMAD-independent (A. Holmes et al. 2001c). 
Since CTGF is consistently over-expressed in fibrotic lesions (M. Dziadzio et al. 
2005c), its amount correlating well with the extent of fibrosis, and it seems to be 
able to function independently from TGF-β signalling, it has been suggested that 
TGF-β is only important transiently in the early inflammatory phase of SSc and not 
during the established fibrotic stage (A. Leask 2004). It is thought that TGF-β acts 
via the downstream CTGF expression and synergistically with it during the initiation 
of fibrosis, following which CTGF works to sustain the fibrotic response (A. Holmes 
et al. 2003b). 
Another possibility, however, is that TGF-β is involved in the maintenance as well 
as initiation of fibrosis through the release of its active and latent forms from a 
source outside the dermis.  
Most previous studies give emphasis to alterations of the dermis in SSc and show 
increased dermal thickness, ECM abundance with increased collagen deposition, and 
deficiency of microvessels. The epidermis, on the other hand, has received relatively   39
little attention.  
 
1.1.7 The Epidermis: 
1.1.7.1 Definition: 
Epidermis is the outermost layer of the skin. It forms the waterproof protective cover 
for the body’s surface and is made up of stratified squamous epithelium with an 
underlying basal lamina. The epidermis is divided into five sub-layers: stratum 
corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum 
germinatum from the superficial to deep layers respectively. The cells of the 
epidermis are predominantly keratinocytes (KCs), but also include dendritic cells 
and melanocytes. KCs move through the sub-layers towards the surface and change 
shape and composition, until eventually they are sloughed off in a process called 
desquamation (E. Fuchs 1993). 
 
1.1.7.2 Epidermis is an active secretory organ: 
For many years the epidermis was considered to be a passive mechanical barrier that 
retards entry of microbes, prevents fluid loss from the body, and forms the lining of 
body structures. Under normal homeostatic conditions these are indeed the functions 
of the epidermis. In disease states, it used to be presumed that the epidermis was a 
passive target for immunological attack from infiltrating inflammatory cells, 
participating only in so much as presenting the antigen via MHC class II cells. 
However, since 1970s it has been demonstrated that KCs are capable of producing 
numerous cytokines involved in active biological processes. These cytokines act on 
immune and inflammatory cells such as fibroblasts, endothelial cells and 
lymphocytes to induce a host response to external stimulae locally and within the   40
dermis. In other words the epidermis is an active participant in inflammation (J. N. 
Barker et al. 1991b). 
To prove that the epidermis is active in inflammation, Nickoloff et al. showed that 
when the barrier function of the skin was abrogated by repeated tape stripping of 
healthy human volunteer skin, KCs became activated within six hours to produce 
various cytokines. These events preceded any inflammatory cell influx into the area 
and therefore reflected changes intrinsic to the epidermis (B. J. Nickoloff, Y. Naidu 
1994). 
Over the last two decades KCs have been shown to express the following factors and 
their receptors: IL-1, IL-6, IL-12, TGF, ET-1, EGF, FGF, VEGF , IL-21R, and GM-
CSF to name but a few (H. Uchi et al. 2000a). 
 
1.1.7.3 Epidermal-dermal cross-talk: 
The idea of epidermal-dermal crosstalk is not new. Interactions between epithelial 
and mesenchymal cells play a crucial role in the regulation of tissue development, 
homeostasis and repair. In embryogenesis epithelial-mesenchymal interaction is 
recognised to be critical (J. M. Shannon, B. A. Hyatt 2004). For example, TGF-β is 
implicated in lung and palate formation through this type of cross-talk (V. Kaartinen 
et al. 1995). 
In adult skin, this interaction was first demonstrated in the 1970s by Rheinwald and 
Green. They showed that normal human epidermal KCs require the presence of 
fibroblasts for efficient growth in tissue culture (J. G. Rheinwald, H. Green 1975). 
Later, a fibroblast-derived growth factor was identified and shown to stimulate the 
proliferation of a KC cell line. Owing to its unique activity, the new mitogen, which 
was shown to belong to the fibroblast growth factor (FGF) family, was termed   41
keratinocyte growth factor (KGF) (J. S. Rubin et al. 1995). Granulocyte–
macrophage colony stimulating factor (GM-CSF), interleukin 1 (IL-1), IL-6, PDGF 
and a new member of the TGF-β superfamily activin were next shown to be 
important in paracrine stimulation loops between the epidermis and fibroblasts (G. 
Hubner et al. 1999;H. Smola et al. 1993b;S. Werner et al. 2007f). 
TGF-β has been demonstrated to be co-expressed in all four layers of the 
differentiating epidermis as well as in the basal lamina and mesenchymal cells 
during excisional wound repair. This led to the suggestion that TGF-β had a role in 
epidermal-dermal interaction during wound healing (J. H. Levine et al. 1993). In 
addition, when SSc skin biopsies were examined for the presence of TGF-β, TGF-β3 
was found subepidermally (C. Querfeld et al. 1999a). This finding supported the 
notion of TGF-β diffusion through the basal lamina into the dermis. 
In a transgenic mouse model over-expressing TGF-β in the epidermis, type I 
collagen mRNA and hydroxyproline content were significantly increased in the 
wound area. This result also supported the idea that when TGF-β was released from 
KCs after wounding it penetrated to the underlying dermis and stimulated fibroblasts 
to produce collagen (L. Yang et al. 2001). 
The epidermal-dermal interaction has been studied in co-cultures of normal human 
KCs and dermal fibroblasts. When normal explanted fibroblasts were co-cultured 
with a normal epidermal cell line, ECM and smooth muscle cell associated gene 
transcripts were upregulated in fibroblasts, suggesting their differentiation into 
myofibroblasts. In addition IL-1 responsive genes such as the genes for KGF, IL-6, 
ET-1, heparin binding EGF, GM-CSF were upregulated in fibroblasts(S. Werner et 
al. 2007e). The effect required the presence of TGF-β. αSMA production did not 
occur until day four despite the presence of TGF-β. This was attributed to IL-1-   42
mediated NF-Kb induction and thus TGF-β inhibition from days one to three (P. 
Shephard et al. 2004g). A reciprocal paracrine loop between KCs and fibroblasts 
was proposedn where IL-1 released from KCs caused production of KGF by 
fibroblasts, which in turn stimulated KC proliferation and differentiation(N. Maas-
Szabowski et al. 1999g). 
Several experiments have demonstrated the importance of epidermal-dermal cross-
talk in fibrotic disease. Recent studies have proposed that the lung scarring condition 
IPF is caused by multiple cycles of epithelial injury and activation. The authors 
suggested that the resulting active alveolar epithelial cells (AECs) induce migration, 
proliferation and activation of the underlying mesenchymal cells. The formation of 
fibroblastic/ myofibroblastic foci and the exaggerated accumulation of ECM that 
ensues, mirrors abnormal wound repair, and accounts for the disease pathogenesis 
(M. Selman 2001;M. Selman, A. Pardo 2002). In pulmonary fibrosis epithelial cells 
initiate the fibrotic response via integrin-αVβ6 dependent activation of TGF-β, 
showing that epithelial cells can be involved in the induction of fibrotic response (R. 
G. Jenkins et al. 2006). αVβ6 knockout mice develop an enhanced inflammatory 
response, but no fibrosis (J. S. Munger et al. 1999a). 
It has been demonstrated that the receptor for IL-21 (IL-21R) is over-expressed in 
SSc skin KCs, accompanied by vascular endothelial growth factor (VEGF) over-
expression in KCs, fibroblasts and endothelial cells. This led to the suggestion that 
IL-21R induction in KCs may be causing dermal VEGF activation and thus the 
disturbed blood vessel morphology typically seen in SSc (J. H. Distler et al. 2005c). 
In support of TGF-β's involvement in epidermal-fibroblast crosstalk in fibrotic 
disease are the experiments performed with keloid scar cells. Keloids represent a 
pathological wound healing response. Co-culture of keloid-derived KCs with   43
fibroblasts from normal or keloid skin increased the fibroblast proliferation rate. 
Further studies demonstrated that these KCs expressed more of the TGF-β and its 
receptor than normal KCs, and addition of TGF-β antibody slowed the fibroblast 
proliferation in co-culture. In addition, the fibroblasts co-cultured with keloid KCs 
produced more ECM proteins and had increased levels of TGF-β activity (W. Xia et 
al. 2004a). 
Insummary, ample evidence exists for KC-fibroblast interactions both in wound 
healing and fibrotic disease, potentially resulting in fibroblast activation and 
pathological fibrosis. 
 
1.1.7.4 Epidermis in SSc: 
Perhaps the most idea leading to the current study is that the epidermis in SSc is 
fundamentally different from normal epidermis, with its structure and function 
significantly disordered. Relatively, little is published about the epidermis in SSc. 
A new technique of confocal laser scanning microscopy (CLSM) has been used to 
image the skin of patients with SSc non-invasively and in real time. The epidermis 
was found to be hypertrophied with a large number of melanocytes and an increased 
melanin content (K. Sauermann et al. 2002a). Changes in skin pigmentation which 
can be severe and widespread imply that the epidermis is also abnormal in the 
disease (H. Tabata et al. 2000a)]. ET-1 (H. Tabata et al. 2000b), TGF-β (L. 
Rudnicka et al. 1994c), monocyte chemo-attractant protein-1 (MCP-1) (O. Distler et 
al. 2001a), VEGF (C. A. Davies et al. 2006b) and IL-21 receptor (IL-21R) (J. H. 
Distler et al. 2005b) have all been shown to be up-regulated in the epidermis in SSc. 
Recent results from this laboratory demonstrate that the epidermis in SSc is 
thickened and has an expanded nucleated cell layer. Proteomic analysis revealed   44
altered abundance of proteins involved in extracellular matrix production, 
myofibroblast contractility, energy metabolism and response to oxidative stress. In 
addition, proteins specific to the epidermis and involved in epidermal cell 
differentiation were altered in abundance in the disease (N. Aden et al. 2008a). 
 
1.1.8 Regulation of KC migration and proliferation: 
1.1.8.1 TGF-β in KC migration: 
TGF-β has already been discussed as being important in wound healing. In the 
epidermis this growth factor has a pro-migratory, but an anti-proliferative effect on 
KCs.  
Cell migration is the rate-limiting step in wound healing. In the process of re-
epithelialisation KCs migrate from the wound edge across the wound bed to cover 
the defect. It is felt that the suprabasal KCs are the ones actively participating in this 
process (M. L. Usui et al. 2005b). 
The pro-migratory effect of TGF-β has been confirmed in several experiments. 
Epidermal cell outgrowth from partial-thickness porcine skin explants was used as 
an in vitro model of re-epithelialisation. TGF-β produced earlier initiation of 
outgrowth by 1-2 days compared to controls through facilitating KC migration (P. A. 
Hebda 1988f). 
In addition, exposure of KCs to serum rather than plasma has been found to promote 
epidermal cell migration, a phenomenon attributed to the presence of TGF-β (B. 
Bandyopadhyay et al. 2006f). In a transgenic model, mice over-expressing TGF-β1 
had an increased rate of closure of partial thickness wounds due to faster KC 
migration (E. B. Tredget et al. 2005b). 
KC migration is influenced by fibronectin and to a lesser extent thrombospondin.   45
TGF-β (at 10 ng/ml) induced a six fold increase in the secretion of fibronectin and a 
two-fold increase in thrombospondin production by human KCs. It was proposed 
that TGF-β may exert its effect on KC motility via endogenous production of ECM 
proteins by the cells themselves (N. E. Wikner et al. 1988). In line with this, more 
recent studies demonstrated that TGF-β increased the affinity of KC promigratory 
integrin α3β1 for an ECM protein βig-h3, which is known to be involved in KC 
adhesion and migration (H. W. Jeong, I. S. Kim 2004). 
                                                                                                                                                                       
1.1.8.2 TGF-β in KC proliferation: 
In addition to being a promigratory factor, TGF-β is also a potent inhibitor of 
cellular proliferation. This effect is noted even at concentrations as low as 1 ng/ml 
(Y. Choi, E. Fuchs 1990).  
An important observation is that TGF-β promotes the type of KC differentiation 
normally associated with wound healing. A temporally and spatially regulated 
expression of TGF-β has been shown to correlate with physiological changes during 
epidermal wound healing. TGF-β was rapidly induced in the epidermis within 5 
minutes following injury and progressed outward from the injury site. Initially TGF-
β was expressed in all KC layers, which corresponded to a transient block in the KC 
proliferation rate. However, after day three basal proliferating KCs were spared this 
inhibition (C. J. Kane et al. 1991d). This experiment provided conclusive evidence 
for the anti-proliferative effect of TGF-β in wound healing. 
To further investigate the effect of TGF-β on KC proliferation, a transgenic mouse 
model expressing a dominant negative type II TGF-β receptor in KCs was created. 
This loss of TGF-β signalling led to accelerated re-epithelialisation of full thickness 
excisional wounds, which was found to be due to increased KC proliferation and a   46
decreased rate of apoptosis (C. Amendt et al. 2002e). 
It is felt that the mechanism through which TGF-β inhibits KC proliferation is by 
prevention of cell cycle progression into S phase (K. Munger et al. 1992). In fact, 
this is also true for other cell types. For example, TGF-β maintains haematopoietic 
stem cells in a quiescent slow cycling state by decreasing their cell cycle entry (N. 
O. Fortunel et al. 2003). 
 
1.1.8.3 TGF-β - the overall effect: 
The overall physiological response to TGF-β signalling is dependent on the target 
cell and its extracellular milieu. As described previously, TGF-β is pro-proliferative 
in fibroblasts, but anti-proliferative and pro-migratory in KCs.  
SMAD2 has been shown to be responsible for re-epithelialisation of incision wounds 
through the induction of suprabasal KC migration, whereas SMAD3 is implicated in 
the anti-proliferative action of TGF-β (R. Hosokawa et al. 2005;G. S. Ashcroft et al. 
1999a). These data indicate that 'natural' wound healing might involve suppression 
of SMAD3 and upregulation of SMAD2 levels.  
The SMAD signalling pathway is under modulation at multiple levels. For example, 
SMAD1 (which has similar phosphorylation sites to SMAD2 and 3) receives 
opposing regulatory inputs by the fibroblast growth factor and bone morphogenic 
protein (member of the TGF-β family) via protein kinases, and it is this balance that 
determines the level of SMAD1 activity in the nucleus, and so possibly the cell fate 
(M. Kretzschmar et al. 1997). IL-1 alleviates the inhibitory effect of TGF-β on the 
proliferation of haematopoietic progenitors. Via its downstream mediator TAK1, IL-
1inhibits SMAD3-mediated TGF-β target gene activation (G. F. Benus et al. 2005).   47
In addition, the inhibitory SMAD7 can be stimulated by numerous agents, including 
TNFα, IFNγ, UV light, and norepinephrine (J. Varga 2002). In doing so, these 
stimuli influence the overall outcome of TGF-β signalling. 
Previous data from this laboratory showed that TGF-β signalling could be modified 
by prostanoids (R. Stratton et al. 2002k). Since a member of the prostanoid family 
PGE2 is induced during wound healing and KCs express PGE2 receptors (see 
below), I went on to study the effect of PGE2 on TGF-β driven KC activities.   
 
1.1.9 Prostaglandin metabolism in KCs: 
Human KCs are known to produce prostaglandins and to express all 4 types of PGE2 
receptor (E-series PG receptors: EP1, EP2, EP3 and EP4) (S. Narumiya 1995). 
However, the role of PGs in KC function is not clear.  
Prostaglandins are ubiquitous molecules. They are important epidermal cytokines. 
Just like TGF-β they influence wound healing and KC proliferation. Prostaglandin 
production is catalysed by cyclo-oxygenase (COX) from arachidonic acid. Two 
isoforms of COX have been identified: COX I and COX II. COX I is constitutively 
expressed in many tissues and cell types. It is presumed to be involved in cell 
homeostasis, whereas COX II is transiently induced after mitogenic or inflammatory 
stimulation. 
Studies have suggested that prostaglandins are pro-proliferative autocoids for the 
epidermis. Intradermal injection of PGE1 and PGE2 increases epidermal proliferation 
(C. B. Bentley-Phillips et al. 1977a). 
NSAIDs (pharmacological prostaglandin inhibitors) reduce the proliferation rate of 
KCs. Topical addition of PGI2 to indomethacin-treated non-confluent KC cell 
cultures restored their normal proliferation rate (A. P. Pentland, P. Needleman   48
1986a). The same investigators also confirmed that PGE2 is synthesised only by 
non-confluent KCs to enhance their proliferation rate. This synthesis stopped as soon 
as KCs became confluent.  
In vivo studies support the role of prostaglandins in KC proliferation. Prostaglandins 
are required for skin tumour development, with indomethacin and colecoxib 
inhibiting the UV-induced tumourgenesis (S. M. Fischer et al. 1999a).  
There is conflicting evidence regarding the influence of PGE2 on wound healing. 
Partial thickness burns in mice devoid of fatty acid precursors for prostaglandin 
synthesis take longer to heal (T. K. Hulsey et al. 1980). On the other hand, there is a 
five-fold increase in epidermal cell proliferation in fatty acid-deficient rats, with 
topical PGE2 application restoring the slower normal rate of proliferation (J. L. 
McCullough et al. 1978). The differences in these results could be related to 
experimental design variations (which include animal models, intervals of treatment, 
doses and prostaglandin types used) as well as the fact that total prostaglandin 
content was measured without differentiating between different prostaglandin 
subtypes. More recent data reports that the presence of PGE2 or active COX II 
enzyme is beneficial to the healing process in various models of tissue repair. This 
has been demonstrated by exogenously adding the stable PGE2 analogue 16, 16-
dimethyl prostaglandin E2-methyl ester (T. Brzozowski et al. 1993b), COX II 
inhibitors (L. E. LeDuc et al. 1993b), or agents that increase 
plasma PGE2 levels (B. Gonul et al. 1993a). 
 
It has previously been found that prostanoids are able to antagonise TGF-β 
signalling in human cells. Prostaglandins elevate cellular cAMP and protein kinase 
A (PKA) levels (R. Stratton et al. 2002j). Studies have shown that agents which   49
increase intracellular cAMP production, such as isoprenaline and PGE2, cause 
fibroblasts to suppress the amount of collagen they produce (L. E. Saltzman et al. 
1982). It has also been found that iloprost (a prostanoid derivative) suppresses TGF-
β signalling in human fibroblasts via PKA and cAMP production (R. Stratton et al. 
2002i).  
Prostaglandins have an important antifibrotic role. In line with this, it appears that 
their levels are decreased in IPF due to reduced expression of COX II by the 
fibroblasts (J. Wilborn et al. 1995), and COX deficient knockout mice develop more 
severe lung fibrosis following exposure to bleomycin compared to the wild type 
controls (J. C. Bonner et al. 2002). In addition, reduction in alveolar epithelial cell 
(AEC) prostaglandin production has been linked to interstitial lung fibrosis (M. 
Selman, A. Pardo 2002).  
Overall, PGE2 is an important wound healing regulator with TGF-β inhibitory 
properties in fibroblasts. It is found in epithelial cells and implicated in epithelial-
mesenchymal antifibrotic functions. 
This thesis will explore the influence of PGE2 on TGF-β dependent effects on 
human KCs (migration and proliferation).   
 
1.1.10 Endothelin: 
The endothelins are peptides of 21 amino acids that are produced
 in a wide variety of 
cells. Isoforms ET-1, ET-2 and ET-3 have been identified (P. Teder, P. W. Noble 
2000). Endothelins are synthesized from precursors known as preproendothelins 
(ppET), comprising 212 amino acid residues, which are cleaved by membrane-
bound metalloendopeptidases.    50
Most tissues contain more ET-1 than ET-2 or ET-3, with the highest levels of ET-1 
found in the lung. It is secreted by endothelial
 cells, epithelial cells, alveolar 
macrophages, polymorphonuclear leukocytes, and fibroblasts.
  ET-1 was initially 
characterised as a potent smooth-muscle spasmogen, but accumulating evidence
 is 
supporting its role as a pro-fibrotic cytokine. ET-1 has been shown to be an 
endogenous modulator of myofibroblast-mediated granulation tissue and ECM 
contraction (I. Appleton et al. 1992), and a fibroblast mitogen (C. Guidry, M. Hook 
1991). Later experiments confirmed that ET-1 was able to enhance fibroblast 
proliferation and collagen synthesis in a dose-dependent manner (M. B. Kahaleh 
1991a).  
In vivo studies support the role of in ET-1 fibrosis. Transgenic mice over-expressing 
ET-1 together with its promoter had accelerated glomerulosclerosis and lung fibrosis 
(B. Hocher et al. 1997). In addition, bile duct ligation induced liver fibrosis was 
accompanied by a rise in ET-1 expression by liver parenchyma (D. C. Rockey et al. 
1998). 
Patients with
 IPF have increased ppET-1 messenger
 RNA expression and intense 
immunoreactivity in airway epithelial
 cells, proliferating type II pneumocytes, and 
endothelial and
 inflammatory cells. In patients
 with pulmonary fibrosis associated 
with systemic sclerosis, bronchoalveolar
 lavage fluid contains 5-fold greater ET-1 
levels than those of
 controls (A. D. Cambrey et al. 1994). 
Recent evidence also suggests that ET-1 plays a significant role in SSc fibrotic 
processes. Studies have shown increased plasma and tissue ET levels in SSc patients 
(R. Vancheeswaran et al. 1994d;R. Vancheeswaran et al. 1994a). ET-1 was found to 
induce a fibrogenic phenotype in normal dermal fibroblasts which resembled that 
seen in fibroblasts grown from lesional SSc skin (S. Xu et al. 1998). In addition,   51
when ET-1 was applied to normal lung fibroblasts it activated expression of pro-
contractile proteins such as αSMA and moesin and enhanced fibroblast ability to 
contract FPCL. The ability of SSc lung fibroblasts to express pro-contractile proteins 
and contract FPCL was greatly reduced by antagonising ET-1 signalling (S. W. Xu 
et al. 2004e).  
Interestingly, antifibrotic agents prostacyclins have been found to
 inhibit the 
production of ET-1 through a common mechanism
 involving the generation of cyclic 
guanosine monophosphate (E. R. Levin 1995).  
Diffuse pigmentation is one of the main skin signs in systemic sclerosis. The 
presence of binding sites for ET-1 in the epidermis and hair follicles does suggest a 
possible mitogenic function for this factor in human skin (G. A. Knock et al. 1993).  
It has been shown that human KCs produce ET-1 which works as an intrinsic 
mitogen for human melanocytes, especially under UV stimulation (G. Imokawa et 
al. 1992). A correlation has been found between the amount of KC derived ET-1 and 
epidermal pigmentation in SSc (H. Tabata et al. 2000c). 
It is reasonable to suggest that ET-1 secreted by human KCs could contribute to 
dermal fibroblast activation. 
 
1.1.11 IL-1: 
IL-1 was one of the first cytokines to be described. Its initial discovery was as a 
factor that could induce fever and regulate lymphocytes (M. J. Kluger 1991). IL-1 is 
now known as a pivotal pro-inflammatory cytokine involved in local and systemic 
immune responses. There are two isoforms of IL-1: IL-1α and IL-1β. They are 
similar in structure and bind the same receptors, which results in activation of 
transcription factors including NFkB and AP1. Among the genes induced by IL-1   52
are growth factors and cytokines involved in the response to tissue injury, including 
KGF, GM-CSF, TNF-α, IL-6, IL-18 and more IL-1. In addition, IL-1 causes KCs to 
express promigratory cytokeratins K6 and K16(P. Angel, A. Szabowski 2002). 
Below is a simplified diagram of IL-1 signalling (Figure 1.3) (H. E. Barksby et al. 
2007a). 
KC at the wound edges respond immediately with the release of pre-formed IL-1, 
which acts in an autocrine and paracrine fashion to activate surrounding KCs and 
dermal cells respectively (I. M. Freedberg et al. 2001g). 
It is known that IL-1 activates dermal fibroblasts causing them to migrate, 
proliferate and secrete ECM (A. Mauviel et al. 1993c;A. Mauviel et al. 1991a). IL-1 
is recognised to complete the paracrine epithelial-mesenchymal activation loop by 
feeding back to activate KCs, partly through stimulating  keratinocyte growth factor 
(KGF) production by these cells (N. Maas-Szabowski et al. 1999f). 
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Figure 1.3: IL-1 cytokine signalling cascade.    54
 
1.1.12 Summary, Hypothesis and Aims: 
SSc is a systemic disorder of unknown aetiology, characterised by uncontrolled 
fibrosis of the skin and internal organs. Fibrosis is a pathological process that occurs 
when the normal wound healing events continue unabated with excessive deposition 
and contraction of ECM. Fibroblast activation is thought of as key to the 
pathogenesis of SSc. But what causes the switch from regulated cells involved in 
normal wound healing to persisting autonomous ones capable of destructive 
fibrosis? 
Most previous studies give emphasis to alterations in the dermis of SSc skin. The 
epidermis, on the other hand, has received relatively little attention. SSc epidermis 
undergoes pigmentary change, it is capable of secreting pro-fibrotic mediators for 
dermal fibroblast activation, and, most importantly, it has an abnormal phenotype 
with persistence of wound-healing type characteristics.  
 
Hypothesis: SSc epidermis is abnormal and could be contributing to fibroblast 
contraction via release of pro-fibrotic mediators. 
The hypothesis will be addressed under the following three experimental aims. 
Aims: 
1.  To determine whether the SSc epidermis has an altered structural and 
signalling phenotype.  
2.  To determine whether the SSc epidermis activates normal human fibroblast 
in vitro. 
3.  To determine whether PGE2 modifies the responses of KCs to TGF-β.  
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CHAPTER 2 
Materials and Methods 
 
2.1 Effect of SSc epidermis on FPCL contraction: 
2.1.1 Patient selection: 
Scleroderma was defined according to internationally agreed guidelines (American 
Rheumatism Association 1980a).  Patients selected for inclusion in the study were 
from the diffuse SSc subset and were within 2 years of the onset of skin changes. 
Local ethical committee approval was obtained for the study from the ethical 
committee of the Royal Free Hospital.   
 
2.1.2 FPCL contraction studies: 
FPCLs were set up in 24 well plates as follows. 24-well tissue culture plates were 
pre-coated with bovine serum albumin (BSA). Trypsinised normal fibroblasts were 
suspended in DMEM medium and mixed with collagen solution (1 part of 0.2 M 
HEPES, pH 8.0, 4 parts rat dermal collagen type I (First Link, UK ), and 5 parts of 
DMEM), yielding a final concentration of 80,000 cells/ml and 1.2 mg/ml collagen. 
Collagen/cell suspension (1 ml) was added to each well. 
Skin punch biopsies (4 mm) were obtained from the forearms of patients with recent 
onset active diffuse SSc (within 24 months), and normal control subjects. The 
epidermis was separated after incubation with 0.05 mg/ml trypsin and 10 ml of PBS 
at 37°C for 120 minutes. The epidermal sheets were removed using fine forceps and 
allowed to settle in wells containing FPCLs. Control wells were left untreated. The 
other wells were exposed to either SSc or normal epidermal discs, or TGF-β (10 
ng/ml) (R&D Systems, 240-B-002). TGF-β was used at a concentration of 10 ng/ml   56
because we have previously found this concentration to efficiently contract  FPCL. 
Maximal stimulation is known to be achieved between 7.5-15 ng/ml, with higher 
doses causing contraction inhibition (R. A. Brown et al. 2002). Further FPCLs 
containing the neutralising anti-TGF-β antibody 1D11 (1μg/ml) (R&D Systems), or 
bosentan Ro 47-0203 (10 μM), or IL-1 Receptor antagonist (100 ng/ml) (Imgenex, 
IMR- 245) were also co-cultured with control and SSc epidermis. Gel contraction 
was determined by photography and measurement of maximum diameter, and 
expressed as a percentage of the original diameter (well size). 
At the end of the assay some FPCLs were lysed in Western lysis buffer (laemmli 
buffer) (see section II.1.3); and others were fixed in formalin and then sectioned at 5 
μm prior to staining for CTGF using immunohistochemistry (see section II.1.4).  
 
2.1.3 Western blot assay: 
Western blots of the fibroblast gels were performed to detect levels of TGF-β, 
CTGF, ET-1, αSMA, and IL-1. The FPCLs were lysed with 200 µl of Western lysis 
buffer (laemmli buffer), and then heated for 5 minutes at 95°C and spun for 5 
minutes to remove the sediment. Samples were loaded on 4-12% Tris-glycine gels 
(Invitrogen, Paisley, UK) at 12 µl per well and run with broad range protein 
markers. Proteins were electrophoretically transferred to nitrocellulose (Hybond-C 
extra; Amersham Pharmacia Biotech), which was then left in PBS with 5% milk 
protein and 0.05% Tween 20 for 2 hours, in order to block non-specific binding. The 
nitrocellulose filters were stained with primary antibodies overnight at 1:1000 
dilution in blocking buffer (PBS with 0.05% Tween 20 and 5% milk powder) ( see 
Appendix 1).    57
The nitrocellulose transfers were then washed three times in 0.05% Tween 20 in 
PBS and stained with biotinylated species-specific secondary antibody (Vector, anti-
mouse BA-9200, anti-rabbit BA-1000, anti-goat BA-9500) for 1 hour and again 
washed three times before staining with biotin substrate ABC (VECTASTAIN; 
Vector Laboratories, Peterborough, UK), then chemiluminescent substrate 
(Amersham Pharmacia Biotech), and developed against photographic film 
(Hyperfilm ECL; Amersham Pharmacia Biotech). 
 
An additional Western blot assay of SSc and normal epidermal lysates was 
performed for pSMAD2/3. Sample preparation as per ELISA (Section II.1.5), 
Western blot assay performed as above. Primary pSMAD2/3 antibody was obtained 
from Santa Cruz Biotechnology (Appendix 1) and used at 1:200 dilution. 
 
2.1.4 Immunohistochemistry: 
Relevant slides (with tissue or cell material) were prepared and stained using the 
following method. 
•  Dewaxing sections:  
Slides were immersed in xylene for 10 minutes and then immersed in 100% alcohol 
to remove the wax solvent. The slides were dipped in and out of the alcohol several 
times to allow thorough rinsing. They were subsequently immersed in a trough of 
95% alcohol for 5 minutes, and then in a trough of 70% alcohol for 5 minutes. 
Lastly, the slides were immersed in distilled water (DH2O) for 5 minutes to remove 
all traces of alcohol.    58
Once dry, the sections were circled using a hydrophobic pen and allowed to dry for a 
few minutes. The sections were then re-hydrated by immersing in PBS 3 times for 5 
minutes each time. The slides were boiled in citrate for 10 minutes.  
•  Adding serum: 
25% secondary antibody species-specific serum was made up (horse serum for 
pSMAD 2/3, LAP TGF-β and CTGF) to block non-specific binding. 40μl of the 
serum was aliquoted onto each of the sections, the section slides then placed in the 
humidity chamber for 10 minutes.  
•  Adding the antibodies: 
The primary antibody was made up: LAP-TGF-β (1:100 dilution), pSMAD (1:100 
dilution), pERK1/2 (1:100 dilution), CTGF (1:50 dilution) as before (see section 
2.1.3), ET-1 from Abcam (1:100 dilution), ET-A Receptor (1:100 dilution), ET-B 
Receptor (1:100 dilution), COX II (1:100 dilution), IL-1α (1:100 dilution), IL-1α 
Receptor (1:100 dilution) (Appendix 1); and 40μl aliquoted onto each section 
covering each entire section. Tissue slides were placed back into the humidity 
chamber for 1 hour. 
The slides were then rinsed with PBS 3 times for 5 minutes each time. 
The secondary species specific antibody was made up, 40 μl aliquoted onto each 
section. Tissue slides were placed into the humidity chamber for 30 minutes.   
The slides were then rinsed with PBS 3 times for 5 minutes each time. 
•  Antibody detection by fluorescence: 
Sections were incubated in FITC-Avidin D (1:500 Vector Labs) in PBS for 30 
minutes at room temperature. Slides were protected against UV light with 
aluminium foil. They were washed in PBS three times for 2 minutes each time.   59
•  Antibody detection by colour change: 
The ABC (Vectastain Elite) was made up 30 minutes before usage by adding 1.5 ml 
of PBS to 1 drop of reagent A and 1 drop of reagent B. 40μl of the ABC was 
aliquoted until all the sections were totally covered, the slides then left for 30 
minutes. After 30 minutes the slides were rinsed with PBS 3 times for 5 minutes 
each time. 
•  Mounting: 
The sections were mounted with Vector-shield DAPI mounting solution, covered 
with Vector aqueous Anti-fade fluorescent mounting medium, and sealed with nail 
polish. The slides were stored in the dark at 4°C. 
 
2.1.5 ELISA: 
Commercially obtained Enzyme-Linked Immunosorbent Assays were used to 
quantify PGE2, TGF-β, ET-1 and IL-1 content of prepared mouse or human tissue 
(all R&D Systems). 
Human skin tissue: 
4 mm tandard forearm skin punch biopsies from six SSc patients and six normal 
subjects were taken. Epidermal layers were separated surgically and snap frozen in 
liquid nitrogen. Once thawed, the epidermal discs were lysed in buffer containing 10 
mM Tris buffered saline, 0.1%SDS, 1% Nonidet p40, 5 mM EDTA and one tablet of 
complete mini protease inhibitor (Roche). A microhomogeniser was used to break 
down the samples on ice. The samples were centrifuged for 5 minutes.  
ELISA amounts were normalised per total biopsy rather than being expressed as 
ng/mg of tissue. The results are are per unit area of epidermis so they relate to total 
body burden and local fibroblast exposure.   60
•  TGF-β ELISA: 
20 µl of sample supernatant was mixed with 180 µl Assay Dilutent (RD1-21) 
provided for a 1:10 dilution. Half was used for the standard ELISA protocol to 
detect free TGF-β. The other half was activated using acidification/neutralisation to 
release TGF-β bound to LAP. The samples were then used in the ELISA assay. The 
activated sample TGF-β concentrations were then multiplied by 1.4 (the dilution 
factor). All TGF-β concentrations were then multiplied by the dilution factor of 10 to 
achieve the final result. 
•  ET-1/IL-1 ELISA: 
10 µl of sample supernatant was mixed with 90 µl sample Dilutent provided for a 
1:10 dilution. R&D Systems ELISA kit was then used to assay ET-1 and IL-1 
concentrations.  
All ET-1/IL-1 concentrations were then multiplied by the dilution factor of 10 to 
achieve the final result. 
Mouse wound tissue:  
All animal protocols were approved by the local animal ethics
 committee at 
University College London. 6- to 8-week-old female
 mice were anesthetized with 
avertin (500 mg/kg). The dorsum
 was shaved and cleaned with alcohol. Four 
equidistant 4-mm full-thickness
 excisional wounds were made on either side of the 
midline of
 the mouse. Wounds were harvested daily after animal sacrifice on days 0-
14. Tissue was fixed in formalin, embedded in wax and sectioned prior to staining 
for COX II. Whole wound tissue was snap frozen in liquid nitrogen and 
homogenized in a lysis buffer containing 10mM Tris Buffered saline, 0.1%SDS, 1% 
Nonidet p40, 5mM EDTA and one tablet of Complete mini protease inhibitor 
(Roche). After adding 2 ml of ice-cold ethanol the proteins were pelleted by   61
centrifugation (10 min at 3000g and 4°C) and then dissolved in 8M urea. The sample 
was mixed 50:50 with the ELISA kit sample buffer (R&D Systems). PGE2 was 
quantified using the standard ELISA kit (R&D Systems).  
 
2.1.6 Phosphoprotein microarray: 
Four SSc and four normal control forearm skin biopsies were obtained. The samples 
were immediately frozen in liquid nitrogen in order to prevent the decay of 
phosphorylation events. Epidermal cell layers were then separated surgically. 
Samples were shipped to Kinexus Bioinformatics (Canada), where they were lysed 
and processed using phospho-site specific antibodies. This service uses the KAM-
1.2 chip with two samples analyzed at a time utilising 500 pan-specific antibodies 
(for protein expression) and 300 phospho-site-specific antibodies (for 
phosphorylation) in duplicate for at least 248 different phospho-sites, 193 protein 
kinases, 24 protein phosphatises and 150 regulatory subunits of these enzymes and 
other cell signalling proteins that regulate cell proliferation, stress and apoptosis. 
 
2.2 Effects of TGF-β and PGE2 on KC migration: 
 
2.2.1 KC cell culturing: 
Normal human epidermal KCs (Invitrogen) were cultured in Keratinocyte Serum 
Free Medium (K-SFM) (Invitrogen) supplemented with growth factor concentrate 
and gentamicin (5 μg/ml). Cryo-preserved cells were initially cultured in 25 ml 
flasks. When 70-80% confluent, KCs were detached from adhesion by the addition 
of trypsin/EDTA (0.025% trypsin/0.01% EDTA,) obtained from GIBCO. After 2 
minutes at 37
0C in a 5% CO2 incubator, cells were detached by a blow to the flask. 
Once 90% of the cells were dislodged, the trypsin reaction was stopped by adding   62
10-15 ml of DMEM with 10% FCS.  The cells were then transferred into a 50 ml 
centrifuge tube and spun at Speed-1500 rpm, 5 min, Temp-20 
0C.  Once centrifuged, 
trypsin was removed and the cells washed in K-SFM twice by re-suspension and re-
spinning.  The cells were then seeded into labelled T75- flasks or the appropriate 
welled plates, passage number marked, and placed in the 37 
0C 5% CO2 incubator to 
grow.  Media were exchanged every 48 hours. 
 
 
2.2.2 Scratch Assay:  
Normal human KCs were grown to confluence on 6 well plates. Four plates were 
treated with TGF- β (4 ng/ml), one left as control, and one treated with 10 μmol 
solution of PGE2 only (Calbiochem 538904). Dose response was tested by adding 
PGE2 of increasing concentrations to the three remaining TGF- β containing wells 
(0.1; 1; and 10 μM).  A scratch was then induced by scoring with a pipette. KCs 
were maintained in K-SFM with mitomycin C (10 μg/ml) for 48 hours to suppress 
proliferation. Migration of KCs into the defect and defect closure were determined 
by photography at 12 hour intervals. The width of the scratch defect was measured. 
 
2.2.3 Inhibition of the promigratory effect of TGF-β on KCs by the MEK 1/2 
inhibitor U0126: 
 
Human KCs were grown to 80% confluence on a 6 well plate. Prior to the 
experiment cells were washed in K-SFM. Cells were then treated for 1 hour with 
three different concentrations of U0126 solution (Invitrogen) in SFM:  0 μM 
(Control), 5 μM (Solution B), 10 μM (Solution A), and 12 μM (Solution C) at 2 ml 
total solution per well (Y. Imamichi et al. 2005a;R. Stratton et al. 2002h;R. Stratton 
et al. 2002g;S. W. Xu et al. 2004d). After 1 hour the cells were treated with 4 ng/ml   63
of TGF-β. A scratch wound was then induced by scoring with a pipette. KCs were 
maintained in tissue culture with mitomycin C (10 μg/ml) for 48 hours to suppress 
proliferation. Migration of KCs into the defect and defect closure were determined 
by photography at 12 hour intervals for 48 hours. The width of the scratch defects 
was measured. 
 
2.3 Effect of PGE2 on ERK phosphorylation in human KCs: 
2.3.1 Timecourse of pERK1/2 induction after treatment of KCs with TGF-β and 
PGE2:  
 
Passage 2-3 sub-confluent primary human KCs were trypsinised and seeded into 
Lab-Tec chamber slides and allowed to adhere overnight. 
The cells were then pre-treated with 10μM PGE2 for 30 minutes in chamber slides. 
TGF-β (4ng/ml) was then added to the chambers and left for 15, 30, and 60 minutes. 
In other experiments cells were treated with 4ng/ml TGF-β only for 15, 30, and 60 
minutes. After treatment, the cells were washed twice in PBS-Tween and fixed with 
4% formalin for 10 minutes at room temperature. They were then permeabilised 
with 0.5% of Triton X-100 (in PBS-Tween) for 5 minutes at -20
oC. 
Immunohistochemistry protocol (section 2.1.4) was then followed to stain for 
pERK1/2. 
 
2.3.2 Effect of TGF-β and PGE2 on total cellular ERK phosphorylation in KCs: 
 
Human KCs were grown to 80% confluence on a 12 well plate. Prior to the 
experiment cells were washed in re-warmed K-SFM. KC wells were treated with 
TGF-β (4ng/ml) and lysed in laemmli buffer at time points as follows: baseline, 5 
minutes, 15 minutes, and 30 minutes. The remaining KC wells were pre-treated with   64
PGE2 at 10 μM 30 minutes prior to addition of TGF-β (4ng/ml). The cells were then 
collected and lysed in laemmli buffer at time points as above. Control well was 
exposed to 2 ml of medium only and lysed in laemmli buffer.  All lysates were 
heated at 95°C and subjected to Western blot analysis for ERK/pERK1/2 (see 
section 2.1.3).  Solution of PGE2 in SFM medium was added to 6 wells and left for 
30 minutes to achieve pathway inhibition. 1 ml of pure K-SFM was added to the 
other 6 wells. 4ng/ml of TGF-β solution was the added to all 12 wells. Each time 
frame at 5 min, 15 min, and 30 minutes saw TGF-β added to the paired wells: one 
containing medium only, and one containing medium and PGE2. The KCs were then 
collected from each well with 100 μl of laemmeli buffer added to each for lysis. 
Western blot for ERK1/2 and pERK1/2 was then performed (see Western blot 
protocol and Appendix 1) 
  
2.4 KC proliferation assays: 
Normal human epidermal KCs were cultured to confluence on 6 well plates.  Cell 
numbers were quantified at baseline by Coulter counting.  Cells were cultured for a 
further 48 hours in K-SFM with or without the addition of TGF-β 10 ng/ml. At the 
end of 48 hours the cells were removed by trypsinisation and counted using a 
Coulter counter.  Subsequently, PGE2 at 3 different concentrations (0.1 μM, 1 μM, 
and 10 μM) was co-added with TGF-β at the start of the experiment in order to 
measure its effects on TGF-β driven inhibition of KC proliferation. 
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2.5 Statistical methods: 
In general the studies presented in this thesis are based on small numbers of biopsy 
specimens taken from SSc patients and healthy controls.  The total number of 
biopsies available is constrained by the relatively low incidence of the disease with 
approximately one new diffuse SSc patient per month presenting to the clinic, and 
not all patients willing to undergo skin biopsy.  Immunohistochemistry and gel 
contraction experiments were performed based on biopsies derived from 6 patients 
with diffuse SSc and 6 healthy control individuals.  Studies with these sample sizes 
are designed to detect large biologically important differences in outcome between 
disease and control groups.   
Data for mean gel diameter were expressed as means and standard error of means, 
and the means of different groups compared by parametric analysis.  Student’s t test 
was used for comparison of mean gel diameter between treatment groups eg. 
untreated FPCL vs SSc epidermis treated FPCL, using a threshold of p<0.05 to 
establish the statistical significance of changes seen (Y. Chen et al. 2005b).  
Phosphorylation arrays (Kinexus) were used to make multiple comparisons between 
phosphoprotein abundance in SSc and control epidermal biopsy samples (both n=4).  
In total 632 phosphorylation sites were assayed in SSc and control biopsies. There 
are a number of issues regarding the statistical analysis of this sort of array data.  
One problem is to decide what threshold of increase is of biologic importance.  Our 
approach to this has been to look at the preliminary results generated in the present 
thesis to see if there is a suitable cut off threshold above or below which a 
reasonable number of potential targets for further studies are generated.  In this 
instance we found that a threshold of 2 fold increase or decrease in phosphorylation   66
site abundance gave a reasonable cut off with 19 increased phosphorylation sites and 
22 decreased.   
The other issue in interpreting the array data is the problem of multiple comparisons.  
Because we are making 632 comparisons between SSc and control samples one 
would expect a large number of false positives. For example if  a p value of <0.05 is 
used for statistical significance of comparison of means then one would expect 0.05 
X 632 = 32 positive results by chance alone, even if there were no important 
differences between disease and control samples.  The traditional approach to this 
problem was to use a correction for the effect of multiple comparisons (Bonferroni’s 
correction) reducing the threshold for statistical significance in proportion to the 
number of comparisons made. In this instance it would mean reducing the p value to 
0.05 ÷ 632 = 0.00008.  The problem with this approach when applied to array data is 
that it is overly stringent and the majority of potential positive findings are greatly 
diminished i.e. there are many false negatives.  For example when we applied the 
Bonferroni’s correction to the array data in the present study we obtained no positive 
results with a twofold change in abundance and a statistical significance at p< 
0.00008.    
Because of these  problems more modern statistical models have been developed for 
the interpretation of array data and these have been recently reviewed (P. de Winter 
2009). The technique described compares a property such as t or the mean of the 
observed data for each gene or protein assayed against multiple random 
permutations of the data (permutation test).  The observed mean value for each 
phosphoprotein is compared against a frequency distribution generated by the 
multiple permutations.     67
In the present thesis permutation testing of each array data point was performed 
using an Excel add-in, called Significance Analysis of Microarray Data (SAM) (V. 
G. Tusher et al. 2001). The False Discovery Rate was then calculated using a 
method described in 1990 (Y. Hochberg, Y. Benjamini 1990).Using Benjamini and 
Hochberg’s False Discovery Rate procedure the p value for each comparison is 
made as follows. First rank all the p values obtained from the significance test from 
lowest to highest, then starting with the lowest p value divide its rank by the total 
number of tests (632 in this instance) and multiply by 0.05. Compare this result with 
the original p value, and if the result is greater than the original value then  there is a 
significant difference, and if the calculated value is less than the original value then 
the result is considered non significant. The technique has been refined further and 
the SAM software calculates a refined p value termed the q value. 
The data were analysed using a two-class unpaired test with 5000 permutations and 
Student’s t as the computed statistic. A twofold change in phosphorylation site 
abundance was selected as the threshold for biological relevance with a false 
discovery rate (FDR) of 15%. 
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CHAPTER 3 
Scleroderma Epidermis Characteristics 
 
Introduction 
The SSc epidermis has previously been found altered in terms of its structure and 
function. In a previous study confocal laser scanning microscopy (CLSM) was used 
to image the skin of patients with SSc non-invasively and in real time. The 
epidermis was found to be hypertrophied with a large number of melanocytes and an 
increased melanin content (K. Sauermann et al. 2002b). SSc skin is often 
hyperpigmanted and a correlation has been found between the amount of KC derived 
ET-1 and epidermal pigmentation in the disease (H. Tabata et al. 2000d). Another 
group has shown interleukin 21 receptor levels to be increased in SSc epidermis, 
although the functional significance of these changes is not clear (J. H. Distler et al. 
2005a).  
Recent results from this laboratory used proteomic analysis followed by 
mass spectroscopy to separate and define the high abundance proteins present in 
unfractionated skin biopsy material from SSc patients and healthy controls. Proteins 
of altered abundance in SSc of recent onset were identified.  Prominent among these 
were proteins specific for the epidermis and involved in the differentiation of 
epidermal cells, such as cytokeratins 1, 14 and Galectin 7. 
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Protein Gene 
ontology 
molecular 
function 
Gene 
ontology 
biological 
process 
Abundance 
in control 
n=12 
(mean, sem) 
Abundance 
in SSc 
n=12 
(mean, sem) 
Cytokeratin 1  Structural 
constituent of 
cytoskeleton 
 
Epidermis 
development 
47 (1.14)  144 (18.0) 
P=0.0002 
Cytokeratin 14  Structural 
constituent of 
cytoskeleton 
 
Epidermis 
development 
507 (93.9)  1814 (295) 
P=0.0012 
Cytokeratin 5  Structural 
constituent of 
cytoskeleton 
 
Epidermis 
development 
2095 (364)  615 (105) 
P=0.0021 
Caspase 14 
precursor 
Caspase 
activity 
Epidermis 
development 
347 (35.4)  660 (92.3) 
P=0.0081 
Galectin 7  Sugar 
binding 
Heterophilic 
cell adhesion 
13928 (1370)  4469 (1280) 
P=0.0003 
Heat-shock 
protein beta-1 
(HSP 27) 
Protein 
binding 
Response to 
unfolded 
protein 
254 (23.0)  1498 (323) 
P=0.0023 
40S ribosomal 
protein SA 
Laminin 
receptor 
activity 
Cell adhesion  116 (3.90)  1753 (201) 
P<0.0001 
  
Table 3.1: Proteins of altered abundance in SSc skin biopsy material vs healthy 
control. For full details see Appendix 3 article ‘Proteomic analysis of scleroderma 
lesional skin reveals activated wound healing phenotype of epidermal cell layer’ (N. 
Aden et al. 2008b). 
 
Following on from these findings I began to study the epidermis in SSc.  
Normal human interfollicular epidermis contains postmitotic differentiating KCs, 
whose fate is to become suprabasal (spinous) cells and undergo terminal 
differentiation. These differentiating KCs can be distinguished by the pattern of 
cytokeratin expression (M. L. Usui et al. 2005a). The basal progenitor cells, which 
are mitoticaly active, appear relatively undifferentiated and express cytokeratins 5,   70
14 and 15. They renew a stratified epithelial layer adapted to protection from 
mechanical injury and microbial invasion from the environment (W. G. Nelson, T. 
T. Sun 1983a). Differentiating and migrating upwards these cells switch to 
expression of cytokeratins 1 and 10, progressively flatten, cross link envelope 
proteins via the action of transglutaminase, and extrude nuclei and organelles 
culminating in a phenotype adapted to mechanical strength and barrier function (E. 
Fuchs 1993).  This process is greatly altered following injury to the skin so that KCs 
at the wound edge withdraw from terminal differentiation and take on an activated 
phenotype characterised by loss of peripheral cytoplasmic cytokeratin filaments 
which become restricted to a perinuclear distribution, loosening of desmosomal 
attachment to adjacent cells, and increasing motility (F. Grinnell 1992a). The 
activation of KCs adjacent to wounds is associated with a change in the pattern of 
cytokeratin expression with persistence of cytokeratin 14 into suprabasal layers, and 
expression of inducible cytokeratins 6, 16 and 17 normally absent in the 
interfollicular epidermis (M. L. Usui et al. 2005c). The switch to suprabasal 
cytokeratin 16 expression disrupts and shortens intermediate filaments so that 
peripheral cytoplasmic cytokeratin filaments are largely lost and replaced by 
cytokeratin 16 positive perinuclear filaments (R. D. Paladini et al. 1996a). These 
changes are presumed to allow for greater motility of the cells required for their 
migration over the wound.    
This chapter is aimed at exploring the SSc epidermal characteristics. Differences 
between normal and SSc epidermis structure and signalling content are examined. 
Comparisons between the SSc epidermis and an epidermis activated after wounding 
are made. 
Study of the epidermis in SSc is a new area and because of this I have taken a broad   71
screening approach using biopsy material from new onset diffuse SSc patients and 
normal subjects. With the small number of subjects used (due to the rare nature of 
the disease) I was looking for strong biological effects and large expression 
differences between disease and control. 
 
Results 
3.1 SSc epidermis structural changes: 
3.1.1 KC Differentiation Program: 
Skin biopsy material from the forearm of healthy controls (n=5) and from SSc 
patients (n=5) involved forearm skin were stained for DAPI and cytokeratins.   
Figure 3.1 shows that the SSc epidermis is thickened in comparison to the healthy 
control. A similar nucleated cell expansion can also be found in wound healing, and 
represents KC proliferation and differentiation necessary in the re-epithalialisation 
process (M. L. Usui et al. 2005d). 
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Figure 3.1: Staining of normal and SSc skin. Panels a and b represent H&E 
staining; panels c and d represent DAPI immunohistochemical staining of epidermal 
cell nuclei (arrow). Panels a and c show normal epidermis; panels b and d show SSc 
epidermis. Inserts in panels c and d highlight the differences between normal and 
SSc epidermis cell thickness (n=2).  
 
 
 
 
 
 
 
 
Normal epidermis  SSc epidermis 
a b
c  d
100 μm   73
3.1.2 Cytokeratin Differentiation Program: 
Skin biopsy sections were subsequently stained for the cytokeratins which define 
KC position and differentiation in the epidermis. In SSc epidermis cytokeratin 14 
expression was no longer confined to the basal layer but expressed in the superficial 
cell layers as well. A more superficial expression of differentiation markers 
cytokeratins 1 and 10 was also noted (Figure 3.2). This suggested a delay in KC 
maturation and terminal differentiation as they migrated to the epithelial surface, i.e. 
the cells maintained their basal phenotype. 
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Cytokeratin 14 
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Figure 3.2: 
Immunohistochemical 
staining of normal and SSc 
skin for cytokeratins 1, 10, 
and 14 and α6 integrin. 
Panels a, c and e represent 
normal epidermis, 
panels b, d and f represent SSc epidermis. Panels a and b show cytokeratin 14 staining; 
panels c and d show cytokeratin 1 and 10 staining; panels e and f show alpha6 integrin 
staining; panel g shows IgG control (n=3). Arrows and brackets show areas of interest. 
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3.1.3. Cytokeratins defining wound healing phenotype: 
Because of these findings, and the suspicion that basal cell layer characteristics were 
being displayed by suprabasal cells in the disease, the expression of α6 integrin was 
studied. This integrin is normally concentrated at the basement membrane zone in 
association with β4 integrin, which is in turn associated with hemidesmosomes and 
the intermediate filament system (T. Tennenbaum et al. 1996a). In healthy control 
specimens a sharply demarcated basal expression adjacent to the basement 
membrane is seen, consistent with the role of α6 as an anchor integrin between 
epidermal basal cells and hemidesmosomes. In SSc the expression of the α6 integrin 
was no longer confined to the basal layer (Figure 3.2). Previous studies have shown 
that suprabasal expression of α6 integrin is highly abnormal, and that it is associated 
with the hyperproliferative phenotype of the epidermis in situations of wound 
healing response (M. D. Hertle et al. 1992f). These findings lead to the initial 
comparison between the changes in the SSc epidermis and those described during 
wound healing when the epidermis becomes expanded and shows persistence of the 
basal phenotype cells into superficial layers (M. L. Usui et al. 2005e).  
Because of this I went on to explore whether SSc  epidermis is taking on an 
activated wound healing phenotype by staining for cytokeratin 16 and 6,  markers of 
KC activation during wound healing.   
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Figure 3.3: Immunohistochemical staining of normal and SSc skin for 
cytokeratins 6 and 16. Panels a and c show normal epidermis; panels b and d show 
SSc epidermis. Panels a and b show cytokeratin 16 staining; panels c and d show 
cytokeratin 6 staining (n=3). Arrows show areas of interest. 
 
Expression of cytokeratins 6 and 16 was found in SSc but not in healthy control 
epidermis (Figure 3.3). These cytokeratins are usually induced during wound healing 
and are not expressed in uninjured forearm skin (M. L. Usui et al. 2005f). 
Collectively these data are supporting the idea that the epidermis in SSc is altered 
with changes resembling those seen during wound healing, displaying delayed cell 
maturation, abnormal stratification, and persistence of the basal cell layer markers 
throughout the epidermis. 
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3.2 SSc epidermis signalling changes: 
3.2.1  Kinexus microarray: 
Because of the above findings I became interested in determining which signalling 
pathways were altered in SSc epidermis. 
Kinex
TM  antibody microarray was used for detection of phosphorylation of more 
than 240 protein kinases, 28 phosphatases and 90 other cell signalling proteins that 
regulate cell proliferation, stress and apoptosis. While direct functional implications 
of protein phosphorylation cannot be made using this assay alone, phosphoprotein 
analysis proved very useful in assessing large differences between SSc and control 
epidermis phosphorylation activities, thus directing further studies into specific 
proteins and receptors that may be important in disease pathogenesis (Tables 3.2, 
3.3). 
Statistical analysis and correction for multiple testing were performed using 
Significance Analysis of Microarrays (SAM) software for 628 sites detected by the 
array. The data were analysed using a two-class unpaired test with 5000 
permutations and t as the computed statistic. A fold change of two was selected as 
the threshold for biological relevance with delta at 0.592 and a false discovery rate 
(FDR) of 15%. 
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  3.2.2 Phosphoproteins upregulated in SSc epidermis: 
     
Phosphoprotein 
Functional Class 
Phosphoprotein 
Site 
Fold 
Increase
Full Target Protein Name 
 
Receptor Kinases  Y1003  2.89  Hepatocyte growth factor (HGF) 
receptor-tyrosine kinase 
  Y1189/Y1190 2.15  Insulin  receptor/Insulin-like 
growth factor 1 receptor 
Transcription 
Factors 
S63  2.37  Jun proto-oncogene-encoded AP1 
transcription factor 
  Y705  2.18  Signal transducer and activator of 
transcription 3 
Signal 
Transduction  
Pan-specific 2.63  Protein-serine phosphatase 4 - 
regulatory subunit (PPX/A'2) 
  S674  2.57  Protein-serine kinase C eta  
  T514 2.23  Protein-serine kinase C gamma 
  Pan-specific 2.18  Dual  specificity protein kinase 
  T180+Y182 2.13  Mitogen-activated protein-serine 
kinase p38 alpha 
  Pan-specific  2.10  PCTAIRE-1 protein-serine kinase
ECM/Integrins/ 
Cytoskeletal 
components 
Pan-specific 2.17  Integrin-linked  protein-serine 
kinase 1 
  S605  2.62  Synapsin 1 isoform Ia 
Cell 
cycling/metabolism 
S70  5.55  Tyrosine hydroxylase isoform a 
  Pan-specific  2.43  Male germ cell-associated 
protein-serine kinase 
  Pan-specific  2.38  Wee1 protein-tyrosine kinase 
  Pan-specific 2.29  NIMA  (never-in-mitosis)-related 
protein-serine kinase 7 
  Pan-specific 2.09  NIMA  (never-in-mitosis)-related 
protein-serine kinase 4 
 
 
 
 
 
Table 3.2: Upregulation of signalling molecule phosphorylation in SSc epidermis. 
Phosphoprotein microarray data demonstarating the mean fold increase in signalling 
protein phosphorylation in SSc epidermis biopsies versus normal controls. The twofold 
increase has been used as a cut off. Phosphoproteins have been subdivided according to 
class, the fold change shown in descending order for each class (control epidermis n=4, 
SSc epidermis n=4). 
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  3.2.2 Phosphoproteins downregulated in SSc epidermis: 
 
Phosphoprotein 
Functional 
Class 
Phosphoprotein 
Site 
Fold 
Decrease
Full Target Protein Name 
 
Apoptosis  Pan-specific  3.2  Diacylglycerol kinase zeta 
  Pan-specific  3  Bcl2-like protein 1 
  Pan-specific 2.9  Pro-caspase  3 
  Pan-specific 2.77  caspase  5 
Signal 
Transduction  
Pan-specific  2.56  Janus protein-tyrosine kinase 2 
Cell Cycling  Pan-specific 2.56  Cyclin-dependent protein-serine kinase 4
  Pan-specific 2.5  Cell  division cycle 25B phosphatase 
  Pan-specific 2.4  Cell  division  cycle 2-like protein-serine 
kinase 5  
  Pan-specific 2.38  Cyclin-dependent protein-serine kinase 5
  Pan-specific  2.32  p21-activated serine kinase 5 
(Serine/threonine-protein kinase PAK 7) 
  Pan-specific  2.12  Large tumor suppressor 1 protein-serine 
kinase (WARTS) 
Metabolism  Pan-specific  2.5  Cyclo-oxygenase 2 (prostaglandin G/H 
synthase 2 precursor) 
  Pan-specific  2.5  Heme oxygenase 2 
  Pan-specific 2.5  Calcium/calmodulin-dependent  protein-
serine kinase 2 alpha 
  S36 2.27  Caveolin  2 
  Pan-specific 2.32  Calcium/calmodulin-dependent   
protein-serine kinase 2 beta 
  Pan-specific 2.22  Calcium/calmodulin-dependent   
protein-serine kinase 1 delta 
  S789 2.08  Caldesmon 
Receptor 
Kinases 
Y612  2.5  Insulin receptor substrate 1 
  Pan-specific  2.27  Leukocyte common antigen CD45 
receptor-tyrosine phosphatase  
Transcription 
Factors 
S129+S133  2.4  cAMP response element binding protein 
1 
Other  Pan-specific  2.17  Heat shock 70 kDa protein 1 
 
 
 
Table 3.3: Downregulation of signalling molecule phosphorylation in SSc epidermis. 
Phosphoprotein microarray data demonstarating the mean fold decrease in   signalling 
protein phosphorylation in SSc epidermis biopsies versus normal controls. The twofold 
decrease has been used as a cut off. Phosphoproteins have been subdivided according to 
class, the fold change shown in descending order for each class (control epidermis n=4, SSc 
epidermis n=4). 
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For a False discovery rate of 15%, nineteen differentially phosphorylated sites were 
identified by SAM (Table 3.4).  Of these, three would be expected to be false 
positives.  Eleven sites exhibited greater phosphorylation in SSc compared with 
normal control subjects and 8 sites exhibited less phosphorylation in SSc.   
 
Target protein name  Phospho 
site 
Fold 
change 
q-value 
(%) 
Increased phosphorylation in SSc 
Hepatocyte growth factor (HGF) receptor-
tyrosine kinase 
Y1003 2.89  15.5 
 
Protein-serine phosphatase 4 - regulatory 
subunit (PPX/A'2) 
Pan-specific 2.63 0 
Synapsin 1 isoform Ia  S605  2.62  15.5 
Protein-serine kinase C eta   S674  2.57  15.5 
NIMA (never-in-mitosis)-related protein-
serine kinase 7 
Pan-specific 2.29 0 
Signal transducer and activator of 
transcription 3 
Y705 2.18  15.5 
Dual specificity protein kinase Pan-specific 2.18  12.3 
Protein-serine kinase C gamma  T674  2.18  15.5 
Integrin-linked protein-serine kinase 1  Pan-specific 2.17  15.5 
Mitogen-activated protein-serine kinase p38 
alpha 
T180+Y182 2.15 15.5 
PCTAIRE-1 protein-serine kinase  Pan-specific 2.10  12.3 
Decreased phosphorylation in SSc 
Pro-caspase 3 (apopain, cysteine protease 
CPP32) 
Pan-specific 0.31 8.2 
Caspase 5 (ICH3 protease, ICE(rel)-III) Pan-specific 0.36  8.2 
Cyclin-dependent protein-serine kinase 4  Pan-specific 0.39  12.3 
Cyclo-oxygenase 2 (prostaglandin G/H 
synthase 2 precursor) 
Pan-specific 0.40 0 
Cell division cycle 25B phosphatase Pan-specific 0.40  0 
Heme oxygenase 2  Pan-specific 0.40  0 
Cell division cycle 2-like protein-serine 
kinase 5 
Pan-specific 0.41 0 
Leukocyte common antigen CD45 receptor-
tyrosine phosphatase (LCA, T200) 
Pan-specific 0.44 8.2 
Table 3.4: Differentially phosphorylated sites in epidermis from SSc patients 
compared with normal control subjects (n=4, P<0.05).   81
Out of over 500 phosphoproteins screened by Kinexus 78 are found to be over-
expressed and 61 are under-expressed in SSc (see full list in Appendix 2). I used a 
twofold cut off to demarcate a biologically important change (X. Shi-Wen et al. 
2000b).  
The phosphoproteins over-expressed in SSc represent those involved in signal 
transduction pathways from receptors to transcription factors, as well as cell cycling 
and cell metabolism participants. Many are involved in wound healing and fibrotic 
processes. 
For instance, phosphorylation of a member of the AP 1 family of transcription 
factors c- Jun is more than doubled in SSc epidermis. c-Jun is the name of a gene 
and protein which, in combination with c-Fos, forms the AP-1 early response 
transcription factor. It is activated through double phosphorylation by the JNK 
pathway but has also a phosphorylation-independent function (H. J. Rahmsdorf 
1996b) (Figure 1.3). c-Jun is phosphorylated in response to UV radiation, and is now 
recognised as a regulator of cell proliferation, cell death, DNA repair and 
metabolism (M. Karin, E. Gallagher 2005b). It is known that TGF-β acts via c-Jun to 
activate fibronectin production (B. A. Hocevar et al. 1999b). Fibronectin is an ECM 
component important in both wound healing and fibrosis (D. Greiling, R. A. Clark 
1997a;G. Serini et al. 1998a). Thus c-Jun over-expression in SSc epidermis is 
possibly a marker of TGF-β activity which could be contributing to skin fibrosis in 
the disease. 
Tyrosine hydroxylase phosphorylation is raised more than five times in SSc 
epidermis. It is an intermediate enzyme in ET-1 driven melanogenesis, the latter well 
described in SSc skin pigmentation (G. Imokawa et al. 1995c;X. Shi-Wen et al. 
2001d).   82
Integrin linked kinase (ILK) is
 a serine-threonine kinase that couples integrins 
(primarily the β1 integrin) to downstream
 signalling pathways that regulate a variety 
of cellular functions
 including cell viability. I found that phosphorylated ILK is 
increased two-fold in SSc epidermis. ILK is required for TGF- β dependent 
epithelial-mesenchyme transition in the epidermis as well as KC migration (Y. I. Lee 
et al. 2004b;Y. Yang et al. 2008a). It is interesting that this kinase is known to 
inhibit fibroblast apoptosis in response to ECM contraction in FPCLs thus leading to 
persistence of fibroblasts in this environment. Knockout studies showed that 
hyperactive ILK and wild type
 ILK protected fibroblasts from collagen
 matrix 
contraction-induced apoptosis compared to knockout animals. Thus fibroblasts 
continue to be active where they are normally removed in the setting of controlled 
tissue repair (Y. Li et al. 2003a;R. S. Nho et al. 2005b).  
In addition HGF receptor tyrosine kinase phosphorylation at the site normally 
activated by HGF itself (Y1003) is almost tripled in SSc epidermis. HGF is released 
in response to tissue injury. In the epidermis it is involved in fibroblast-epithelial 
cross talk thus controlling epithelial cell recovery (R. Zarnegar 1995). The role of 
HGF is SSc is also well described. It is interesting that in fibroblasts its role is 
antifibrotic (T. Iwasaki et al. 2006;R. Sherriff-Tadano et al. 2006). It may be that in 
the epidermis HGF has different role to the one in the fibroblasts, alternatively it is 
there as a feedback mechanism to try and prevent excessive fibrosis. 
In conclusion, the results highlight changes in signalling pathways responsible for 
fibrosis and wound healing. 
 
 
   83
3.3 Assays of growth factors and cytokines in SSc epidermis: 
Since both the structural and some of the signalling properties of the SSc epidermis 
resemble those of a healing wound, I looked for any alterations in soluble mediators 
that would confer a wound healing phenotype in the disease. I looked at three 
mediators: IL-1, ET-1, and TGF-β. 
IL-1, because it is one of the most important cytokines involved in the wound 
healing process. KCs are known to contain cytoplasmic reservoirs of IL-1, which get 
rapidly released upon cell injury and activate surrounding KCs and dermal cells (A. 
Mauviel et al. 1993b;A. Mauviel et al. 1991b). In addition, IL-1 is known to act via 
PKC and to induce p38 and c-Jun signalling, which are notably raised in SSc 
epidermis (Table 3.2). 
TGF-β is also involved in all aspects of wound repair, from inflammation to re-
epithelialisation and remodelling (S. Werner, R. Grose 2003d). In addition, several 
molecules over-expressed in SSc epidermis are involved in TGF-β signal 
transduction pathways (eg. HGF and c-Jun).  
ET-1 is primarily involved in fibroblast activation and contraction post wounding, 
and has been noted to be important in SSc fibrosis (S. Xu et al. 1998). In addition 
Tyrosine Hydroxylase, which is highly raised in SSc epidermis, is involved in ET-1 
driven melanogenesis (G. Imokawa et al. 1995b). 
Four SSc patient and four normal control epidermal discs were lysed after surgical 
separation from the dermis and examined using ELISA for the presence of the above 
mediators. Quantification of the average concentrations of IL-1, ET-1, and TGF-β in 
healthy control and SSc epidermal samples is presented below. 
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Signalling molecule           Normal epidermis 
(mean and range) 
 
SSc epidermis 
(mean and range) 
 
TGF-β (active)  168.09 
(139.64-194.68) 
 
135.25 
(100.56-153.16) 
 
LAP-TGF-β 
 
1222.76 
(1101.44-1404.74) 
 
1436.12 
(1291.01-1499.77) 
 
ET-1 668.89 
(651.44-686.12) 
 
687.79 
(672.03-705.06) 
 
IL-1 2.99 
(0.5-10.5) 
 
74.2 
(4.66-170.54) 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.5: Results of ELISA immunoassay of normal and SSc epidermal 
lysates for active and LAP-TGF-β, ET-1 and IL-1. Signalling molecule 
concentrations were measured by ELISA of epidermal biopsy material from SSc 
patients (n=6) and healthy controls (n=6).     85
3.3.1 TGF-β content in SSc epidermis: 
 
 
 
 
    
 
 
 
 
Figure 3.4: Histogram to show TGF-β (active and LAP) content of normal and 
SSc epidermal lysates as determined by ELISA. Lower level of detection is 11 
pg/ml. *p=0.044  
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3.3.2 ET-1 content in SSc epidermis: 
 
 
 
 
 
 
Figure 3.5: Histogram to show ET-1 content of normal and SSc epidermal lysates 
as determined by ELISA. Lower level of detection is 600 pg/ml. p=0.11 
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3.3.3 IL-1 content in SSc epidermis: 
 
 
 
 
Figure 3.6: Histogram to show IL-1 content of normal and SSc epidermal lysates 
as determined by ELISA. Lower level of detection is 0.4 pg/ml. p<0.05 
 
 
 
ELISA immunoassay was used to measure the active TGF-β and LAP-TGF-β 
content in SSc and normal epidermal lysates (Figure 3.4, Table 3.4).  
There was no significant difference between the total TGF-β content of the four 
normal and four SSc epidermial samples taken from eight different subjects 
(p=0.069). There was no significant difference in the active TGF-β content of the 
samples (p=0.129). LAP-TGF-β was only marginally increased in SSc epidermis 
compared to control (SSc epidermis LAP-TGF-β concentration 1436 pg/ml, normal 
epidermis LAP-TGF-β concentration 1222.7 pg/ml; p=0.044).  
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ELISA immunoassay to measure ET-1 concentrations in the SSc and normal 
epidermal lysates was also performed (Figure 3.5, Table 3.4). No significant 
difference between these concentrations was found (normal epidermis mean ET-1 
concentration 668.9 pg/ml, SSc epidermal mean ET-1 concentration 687.8 pg/ml; 
p=0.11). It is important to note that the levels of ET-1 were very low on the ELISA 
detection curve making it difficult to interpret the differences between the samples.  
IL-1 concentration of SSc epidermal lysates was significantly higher than that of 
normal controls as measured by ELISA (SSc epidermal mean ET-1 concentration 
74.2 pg/ml versus normal epidermis mean IL-1 concentration 2.98 pg/ml; p=0.05) 
(Figures 3.6, Table 3.5).  
 
3.4 Assays of normal and SSc epidermis for TGF-β, ET-1 and IL-1 activity: 
3.4.1 TGF-β axis: 
3.4.1.1 Immunohistochemistry for TGF-β: 
 
Immunohistochemical staining was used to visualise LAP-TGF-β and ET-1 levels in 
the disease and control epidermal samples (Figures 3.7, 3.11). Sections were also 
stained for pSMAD2/3 as a marker of TGF-β signalling activation in KCs (Figure 
3.8, 3.9). Western blotting of two normal and two SSc epidermal lysates was used to 
further quantify pSMAD2/3 expression (Figure 3.10).  
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Figure 3.7: Immunohistochemical staining of normal and SSc epidermis for 
active and LAP- TGF-β (n=3). 
 
3.4.1.2 Immunohistochemistry for pSMAD: 
 
          
 
 
  
   
 
 
 
 
 
Figure 3.8: Immunohistochemical staining of normal and SSc epidermis 
pSMAD2/3 (arrow). (x20 magnification). The inserts show magnified areas of the 
epidermal sections (n=3). 
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Immunohistochemical staining of SSc epidermis versus normal control highlights 
the elevated expression of LAP-TGF-β (Figure 3.7) and pSMAD2/3 (Figures 3.8, 
3.9) in the disease. pSMAD2/3 expression appears elevated in SSc sections in the 
epidermal layers as well as the adjacent epidermal-dermal junction. Of note is also 
the increased thickness of the SSc epidermis compared to control.  
 
3.4.1.3 Western blot for pSMAD: 
Western blotting confirms increased pSMAD2/3 production in SSc epidermal lysate 
compared to normal control (Figure 3.10), indicating a more active TGF-β signalling 
pathway. It is notable that Kinexus phosphoprotein array has highlighted an increase 
in SMAD phosphorylation in SSc epidermis 1.64 fold over the control (Appendix 1). 
 
Figure 3.9: Immunohistochemical staining of normal and SSc epidermis  
pSMAD2/3 (arrow). (x40 magnification) (n=3). 
Normal epidermis pSMAD2/3  SSc epidermis pSMAD2/3 
50 μm 
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3.4.2 Immunohistochemistry for ET-1 and ET receptors: 
 
Immunohistochemical staining for ET-1 and its receptors ETA and ETB in SSc and 
normal epidermal biopsies was also performed (Figure 3.12, 3.13). 
   
 
Figure 3.11: Immunohistochemical staining of normal and SSc epidermal 
biopsies for ET-1 (X20 magnification) (n=3). 
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Figure 3.10: Western blot of 2 normal and 2 SSc epidermises for pSMAD2/3. 
GAPDH protein loading control shown.   92
 
 
 
 
ET-1 expression was seen in the cytoplasm of basal cells of both the disease and 
normal epidermis, and appears to be increased in the disease (Figure 3.11). Staining 
for the ET-1 receptors A and B also demonstrates an increase in the disease 
epidermal biopsy compared to the control (Figure 3.12).  However both ET-1 and its 
receptor expression is patchy in the samples. Therefore it is not surprising that 
ELISA data from epidermal lysates did not yield significantly differences between 
disease and control samples (Figure 3.5). 
 
 
 
 
Normal epidermis ETA  SSc epidermis ETA  
Normal epidermis ETB  SSc epidermis ETB 
Figure 3.12: Immunohistochemical staining of SSc and normal epidermal biopsies for 
ET-A and ET-B receptors (X20 magnification) (n=3).   93
3.4.3 Immunohistochemistry for IL-1 receptor: 
 
                
    Normal epidermis IL-1R                                   SSc epidermis IL-1R 
 
Figure 3.13: Immunohistochemical staining of SSc and normal epidermal 
biopsies for IL-1 receptor (IL-1R) (X20 magnification) (n=3). 
 
Staining for IL-1 receptor shows increased expression in SSc epidermis (Figure 
3.13). 
          
100 μm   94
Discussion 
The SSc epidermis has been noted to be altered in the past. Pigmentary changes, 
which can be severe and widespread, are a common feature and imply abnormalities 
of the epidermis in the disease (H. Tabata et al. 2000e). The studies presented in the 
current thesis are the first studies, however, that closely examine changes in its 
structure and signalling capacity, and note the similarities with a wound healing 
epidermis.   
1. Altered cytokeratin expression in SSc epidermis: 
The results of staining SSc and normal epidermal biopsies show a pattern of delayed 
and abnormal KC maturation and terminal differentiation with expansion of the 
nucleated cell layer and abnormal persistence of the basal cytokeratin 14 into 
suprabasal layers. There is little variation between samples with cytokeratin 14 
consistently basal in controls.  Cytokeratins 1 and 10 also move to a more superficial 
location in SSc, suggesting that their expression is delayed (Figure 3.2). These are 
robust and consisitent findings present in all of the biopsies studied. These findings 
lead to a comparison between the changes in SSc epidermis and those described 
during wound healing during which the epidermis becomes expanded and shows 
persistence of the basal phenotype into superficial layers (M. L. Usui et al. 2005g;G. 
K. Patel et al. 2006a).  I went on to confirm that in SSc KCs are taking on an 
activated wound healing phenotype with suprabasal expression of the inducible 
cytokeratins 16 and 6, which are normally absent from an intact epidermis (Figure 
3.3) (M. D. Hertle et al. 1992e). These changes were seen in all the SSc biopsies and 
none of the control samples (6 out of 6 SSc biopsies, 0 out of 6 control biopsies, chi-
square=12, p=0.001, 1 degree of freedom).   95
Other indirect evidence supports the comparison between SSc and a wounded 
epidermis.  The basal α6 integrin lost its clear basement membrane demarcation in 
the disease showing strong expression into the suprabasal layers consistent with a 
wound healing response (Figure 3.2) (M. D. Hertle et al. 1992d). 
I therefore went on to determine whether the signalling pathways activated in the 
disease also resemble those activated after normal epidermal wounding in order to 
gain insite into activation of the epidermis in SSc. 
2. Altered protein phosphorylation in SSc epidermis: 
2.1 Upregulation of signalling molecule phosphorylation in SSc epidermis: 
 
Phosphoprotein microarray analysis of SSc and normal epidermal samples was 
performed and has highlighted several differences (Tables 3.1 and 3.2). 
2.1.1 Upregulation of enzyme phosphorylation in SSc epidermis: 
 
The signalling molecule whose phosphorylation is most noticeably raised in SSc 
epidermis (over a five fold increase) is Tyrosine Hydroxylase (TH). This enzyme is 
responsible for the first step in the biosynthesis of catecholamines in human KCs, 
which is in turn responsible for melanocyte pigmentation via beta2 adrenergic 
receptors (K. U. Schallreuter et al. 1992). TH is also required for melanogenesis 
within melanocytes themselves via L-Dopa production (L. K. Marles et al. 2003). 
This finding is not surprising as pigmentation of SSc skin is well recognised 
clinically. ET-1 is known to be important in pigmentation in general and hyper-
pigmentation of SSc skin in particular. It has also previously been shown that ET-1 
acts via TH to cause UV-induced melanocyte stimulation (G. Imokawa et al. 1995a). 
It is possible, therefore, that some of the pigmentary action of ET-1 in SSc epidermis 
is via activation of TH.   96
Phosphorylation of the Hepatocyte growth factor (HGF) receptor-tyrosine kinase is 
increased 2.89 fold in SSc epidermis compared to normal controls. The 
phosphorylation site Y1003 is the same as that activated by HGF binding itself. HGF 
was originally identified as a potent mitogen in hepatocytes (E. Gohda et al. 1988). 
However, it has also been identified in platelets and is thought to be important in 
wound healing regulation (T. Nakamura et al. 1986). In line with its importance in 
epidermal healing processes, HGF has been shown to stimulate both migration and 
proliferation of normal human KCs (K. Matsumoto et al. 1991). HGF is also found 
to stimulate matrix metalloproteinase (MMP-1) production by KCs. This collagenase 
is normally expressed by migrating cells at the front of the re-epithelialising edge in 
chronic wounds. Persistent HGF-driven MMP-1 over-expression may be important, 
therefore, in wound chronicity (S. E. Dunsmore et al. 1996). 
In addition to its role in wound healing, HGF seems to be important in preventing 
cell death. HGF has potent anti-apoptotic properties, which have been confirmed in 
developing hepatocytes, and are known to act via a Bcl-2-like protein BAG-1 (A. 
Bardelli et al. 1996). Interestingly, Bcl-2-like protein, known to be an apoptotic 
signal, is found to be reduced three fold in SSc epidermis.  
Thus HGF may be a significant player in confirming the pro-proliferative as well as 
persistent wound healing phenotype of the SSc epidermis.   
TGF-β is known to stimulate HGF production, which in turn has inhibitory anti-
TGF-β and anti-fibrotic properties in SSc fibroblasts (T. Iwasaki et al. 2006;M. 
Jinnin et al. 2005). We need to reconcile the fact that HGF is anti-fibrotic in nature 
with increased presence of its receptor tyrosine kinase in SSc epidermis. One 
possibility is that HGF is indeed activating its epidermal receptors in a natural 
inhibitory feedback mechanism in order to counteract the action of the pro-fibrotic   97
surrounding environment of the SSc epidermis. On the other hand, HGF production 
by SSc fibroblasts may be feeding back to the epidermis to induce its migratory and 
proliferative wound healing-type phenotype. In fact it is believed that following 
tissue injury mesenchymal cells release HGF which in turn regulates epithelial cell 
repair. HGF synthesis is induced by IL-1 (R. Zarnegar 1995).  In this case, a loop 
between epidermis and dermis would be established. The outcome of this feedback 
would depend on the overall environment and duration of the disease. 
Phosphorylation of Protein kinase C (PKC) is found to be more than doubled in SSc 
epidermis compared to normal control. It is a kinase involved in transmembrane 
signal transduction, and is thought to be important in epidermal function. PKC is 
known to be involved in promotion of epidermal proliferation, its over-expression 
implicated in psoriasis pathogenesis (L. Hegemann et al. 1991;L. Hegemann et al. 
1994). Along with HGF kinase, PKC may be responsible for the increased activation 
of disease KCs. 
Phosphorylation of integrin-linked protein-serine kinase 1 (ILK) is doubled in SSc 
versus normal epidermis. This kinase is known to be important in epithelial integrin-
dependent cell cycle progression regulation as well as inhibition of apoptosis (G. E. 
Hannigan et al. 1996;S. Persad et al. 2000;G. Radeva et al. 1997). In addition, 
phosphorylation of NIMA kinases is more than doubled in SSc epidermis suggesting 
that these cells are more mitoticaly active and have increased survival kinetics 
compared to normal cells.  
2.1.2 Upregulation of transcription factor phosphorylation in SSc epidermis: 
 
Phosphorylation of the members of the transcription factor activator cascade is also 
increased in SSc epidermis. Signal Transducers and Activators of Transcription 
(STATs) are transcription factors that are phosphorylated by JAK kinases in   98
response to cytokine activation of cell surface receptor tyrosine kinases. 
Phosphoprotein microarray has highlighted doubling of STAT3 phosphorylation in 
SSc epidermis. Upon activation, the STATs dimerise and are localised to the nucleus 
where they activate transcription of cytokine-responsive genes. Cytokines and 
growth factors that activate STAT3 include growth hormones such as HGF, IL-6 
family cytokines, and G-CSF. STAT3 induces progression through the cell cycle, 
prevents apoptosis, and regulates cell migration (M. Kira et al. 2002). In the 
epidermis, STAT3 is essential for wound healing, and is found in the leading wound 
edge. Transgenic mice over-expressing STAT3 are found to have abnormal KC 
activation which results in the development of psoriasis-like lesions (S. Sano et al. 
2005). Epithelial tubule formation required for cell differentiation, is also regulated 
by HGF through STAT3 signalling (C. Boccaccio et al. 1998). 
Phosphorylation of c-Jun AP-1 transcription factor is increased 2.3 fold in SSc 
epidermis. This transcriptional factor is widely responsible for gene regulation in 
response to a variety of stimuli which activate the MAPK cascade. It is found in the 
epidermis, and is thought to be important in KC differentiation and cell cycle 
progression, as well as cell proliferation. AP-1 is activated by IL-1 via MAPK 
signalling that involves JNK and p38. The products of this activation include KGF 
and GM-CSF, which are thought to be involved in epithelial-mesenchymal crosstalk 
(J. Ninomiya-Tsuji et al. 1999;H. E. Barksby et al. 2007b;L. Florin et al. 2004b). I 
find that phosphorylation of p38, which is upstream of c-Jun AP-1, is also increased 
in SSc epidermis (Table 3.1). IL-1 and its signalling cascade are activated after 
epidermal injury (Figure 1.3), and the above data supports the notion that SSc 
epidermis has wound healing characteristics.   99
Another group of proteins with increased phosphorylation prophiles in SSc 
epidermis are cell-cycling promoters. 
Several other biologically important proteins have increased phosphorylation 
profiles in SSc versus normal epidermis and are worth mentioning even though their 
fold increase falls below the twofold cut off. These are: TGF-β activated protein 
serine kinase1, MAPK/ERK kinase kinase 2 and inhibitor of NF-kB protein serine 
kinase β (Appendix 1). The first is clearly involved in TGF-β signalling cascade, and 
the latter two are important in IL-1 signalling (Figure 1.3). This supports the idea of 
SSc epidermis having activated TGF-β and IL-1 pathways. 
2.2 Downregulation of signalling molecule phosphorylation in SSc epidermis: 
2.2.1 Downregulation of cell cycling protein phosphorylation in SSc epidermis: 
The phosphoproteins with reduced phosphorylation in SSc epidermis represent 
inhibitors of cell cycle progression. For example Diacylglycerol kinase (DGK), with 
three fold reduced phosphorylation in SSc versus normal control epidermis, is 
known to both interfere with cell cycle progression and has been found to be anti-
fibrotic in cardiac muscle (C. Evangelisti et al. 2007;M. Harada et al. 2007). Under-
expression of DGK would therefore encourage cell proliferation in the epidermis 
and could potentially have pro-fibrotic consequences.  
In addition, phosphorylation of p21 is found to be reduced in SSc epidermis.  
The picture is a little more complicated, however, since we find that certain cell 
cycling promoters are actually under-expressed in SSc epidermis: cell division cycle 
kinases and phosphatases, as well as cyclin-dependent protein kinases are more than 
halved, highlighting the abnormal cycling dynamics of the disease cells. 
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2.2.2 Downregulation of apoptosis related protein phosphorylation in SSc 
epidermis: 
 
Further proteins with reduced phosphorylation include those involved in stimulation 
of apoptosis: Bcl-2 like protein (see above), heat shock protein, Capsase-5, and 
Calcium/calmodulin-dependent protein kinases (K. M. McGinnis et al. 1999;T. R. 
Soderling 1999;L. Zhuang et al. 2000). Their reduced function in SSc epidermis 
would promote cell survival and thus abnormal proliferative dynamics.  
2.2.3 Downregulation of COX II phosphorylation in SSc epidermis: 
Phosphoprotein array demonstrates that phosphorylation of COX II is suppressed in 
SSc epidermis. Chapter 5 of this thesis addresses the role of prostaglandins in 
epidermal function. Importantly, prostaglandins are known to inhibit TGF-β 
signalling in KCs, and are also known to be antifibrotic through inhibition of CTGF 
in human fibroblasts (R. Stratton et al. 2002f). Reduction of prostaglandin synthesis 
in SSc epidermis would be consistent with the profibrotic state of this organ. 
In summary, phosphoprotein microarray data indicates that the SSc epidermis differs 
from normal in its protein expression pattern with pro-proliferative, wound healing-
like features. 
In view of these findings, changes in soluble mediator expression by SSc epidermis 
were addressed. 
2.3 Immunohistochemistry of normal and SSc epidermis for TGF-β, ET-1, and 
IL-1 axis: 
 
Immunohistochemical staining showed that the active TGF-β levels in SSc epidermis 
are not significantly different from those of the normal control group (Figure 3.8). 
This free active TGF-β form is patchy in the epidermis and may reflect the variable 
need for this growth factor in every day epidermal functions. This correlates with the   101
fact that previous published experimental evidence involving SSc skin biopsy staining 
produced highly varied results with regards to TGF-β presence and quantity in the 
epidermis (M. Gruschwitz et al. 1990a;A. McWhirter et al. 1994a;J. Pannu et al. 
2004a;J. Peltonen et al. 1990c;P. P. Sfikakis et al. 1993a). In line with these results 
are the findings in the serum of patients affected by SSc. It has been demonstrated that 
active TGF-β is actually reduced in early disease, and the quantity is inversely 
correlated with skin score (M. Dziadzio et al. 2005b). 
LAP-TGF-β and pSMAD levels, on the other hand, were increased in SSc epidermis 
(Figures 3.8-3.11). The LAP-TGF-β result was confirmed by ELISA performed on the 
homogenised epidermal samples from normal and SSc affected subjects (Figure 3.5). 
The mean active TGF-β concentration was slightly reduced in the SSc epidermal 
samples compared to the healthy controls, although the difference was not statistically 
significant (p=0.129). However, when LAP-TGF-β was measured by subtracting the 
active from the total TGF-β concentration, the difference between the means was 
statistically significant with higher LAP-TGF-β concentration in SSc epidermis 
(p=0.044). This may be a significant finding as TGF-β has an important role in wound 
healing in general and epithelial re-surfacing in particular (C. Amendt et al. 2002d;S. 
Werner, H. Smola 2001d;S. Werner, R. Grose 2003c). 
ET-1 has a well established role in fibrosis (M. B. Kahaleh 1991b;S. Xu et al. 1998). 
It is found in epithelial cells and fibroblasts. ELISA immunoassay demonstrated no 
difference between normal and SSc epidermal ET-1 content (Figure 3.6). One 
explanation could be the limitation of the ELISA method in detecting very low 
levels of the factor. Another explanation could be that the nature of ET-1 expression 
in the epidermis is patchy and disease duration sensitive. Immunostaining of SSc   102
epidermis for ET-1 and its receptors demonstrates an increased expression compared 
to normal controls (Figures 3.12, 3.13). This result confirms previous published 
experimental data where increased ET-1 production in SSc epidermis was linked to 
increased pigmentation of the diseased skin (H. Tabata et al. 2000f). Previous 
published work describes the role of ET-1 in epithelial wound healing and fibrosis 
(Y Hamada 1999), thus supporting my hypothesis of a wound healing phenotype in 
SSc epidermis. 
ELISA immunoassay and immunostaining demonstrated greatly increased IL-1α and 
its receptor content in SSc epidermis (Figures 3.7, 3.14). IL-1 is of course vital in 
driving the early stages of wound healing, its increased expression in SSc epidermis 
supporting the idea of a wound healing epidermal phenotype in the disease. 
 
Conclusions 
•  SSc epidermis has a wound healing phenotype of cytokeratin, integrin and 
signalling molecule expression. 
•  SSc epidermis also has an increased expression of soluble mediators known to 
be important in wound healing and fibrosis.  
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CHAPTER 4 
 
Scleroderma Epidermis has Fibroblast Activating Properties 
 
 
 
Introduction 
 
It has previously been shown that the SSc epidermis has an abnormal structure and 
growth factor content (K. Sauermann et al. 2002c;S. Werner et al. 2007d;H. Tabata 
et al. 2000g). Results from the previous chapter showed that the SSc epidermis has 
an altered phenotype with persistence of wound-healing type characteristics.  
Epithelial-mesenchymal interactions are a well recognised phenomenon in scarring 
conditions and wound environments (N. Maas-Szabowski et al. 1999e;P. Shephard 
et al. 2004f). In the latter the KC-fibroblast co-activation loop is thought to be that 
of double paracrine signalling, with KCs instructing fibroblasts to produce and 
secrete growth factors which are in turn capable of KC activation (I. M. Freedberg et 
al. 2001f). I hypothesised that the abnormalities of the epidermis in SSc are 
responsible in part for fibroblast activation and fibrosis in the adjacent dermis. 
The study of fibroblast behaviour under the influence of various factors has been 
made possible by the FPCL system which mimics the complex interactions between 
cells and their surrounding matrix found in real tissues (F. Grinnell 2003c). The 
tension loaded restrained system was chosen for this study since I was interested in 
fibroblast activation and contraction under the influence of pro-fibrotic factors which 
include/induce TGF-β. TGF-β has a stronger impact on the differentiation of 
fibroblasts into myofibroblasts in restrained matrices where fibroblasts organise cell 
surface fibronectin and develop fibronexus junctions (P. D. Arora et al. 1999a;F. 
Grinnell 2003b). Restrained matrices are allowed to develop tension overnight   104
before they are released. In doing so fibroblasts are encouraged to align along stress 
axis promoting a contractile phenotype. 
 
Figure 4.1: FPCL contraction in a tension loaded system. FPCL was treated with 
an epidermal disc and left for 12 hours. The lattice was then released with a pipette 
and allowed to contract. 
 
 
Three mediators are known to be involved in fibrotic processes as well as in 
epidermal-fibroblast cross-talk: TGF-β, ET-1, and IL-1. 
IL-1 is one of the most important cytokines involved in wound healing. KCs are 
known to contain cytoplasmic reservoirs of IL-1, which get rapidly released upon 
cell injury and activate surrounding KCs and dermal cells (A. Mauviel et al. 
1993a;A. Mauviel et al. 1991c). It is known that IL-1 activates dermal fibroblasts 
and participates in paracrine epithelial-mesenchymal signalling. IL-1 is believed to 
initiate KC-fibroblast interaction and lead to induction of gene expression in 
fibroblasts including KGF and G-CSF (N. Maas-Szabowski et al. 1999d;Y. Chen et 
al. 2005a).  
TGF-β is a well known fibrotic factor involved in SSc pathogenesis (T. Yamamoto 
et al. 1999a). Chen et al. have demonstrated that enhanced matrix contraction by 
dermal fibroblasts from SSc patients required TGF-β and its signalling pathways (W. 
12 hrs  24 hrs 
SSc 
epidermis 
FPCL   105
Xia et al. 2004b). In a mouse model of SSc anti-TGF-β antibody caused a significant 
reduction in cutaneous sclerosis and inflammation (R. Vancheeswaran et al. 
1994c;R. Vancheeswaran et al. 1994b). In support of TGF-β involvement in 
epidermal-fibroblast crosstalk in fibrotic disease are the experiments performed with 
keloid scar cell co-culture, which demonstrated  increased fibroblast proliferation 
rate and ECM production after exposure to keloid KCs (S. Xu et al. 1998).  
ET-1 is also important in SSc fibrosis. Studies have shown increased plasma and 
tissue ET-1 levels in SSc patients (S. W. Xu et al. 2004c). ET-1 was found to induce 
a fibrogenic phenotype in normal dermal fibroblasts which resembled that seen in 
fibroblasts grown from lesional SSc skin. The contribution of ET-1 to KC-fibroblast 
cross-talk was also demonstrated in co-culture experiments (P. Shephard et al. 
2004b). 
Results from the previous chapter demonstrate significant alterations in ET-1, TGF-
β and IL-1 content and signalling components of SSc epidermis. 
I therefore examined whether normal human fibroblast are activated by SSc 
epidermis, proposing that ET-1, TGF-β and IL-1 are involved. 
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Results 
 
4.1. Contraction of fibroblast collagen lattices by SSc epidermis:      
 
FPCLs were treated for 48 hours with SSc or normal epidermial biopsy discs (Figure 
4.2). In the same experiment FPCLs were treated with different concentrations of 
TGF-β.   Contraction was seen with 8/8 SSc epidermis samples and 0/8 control 
samples (Figure 4.3). 
 
                                                   
                                                   
 
 
 
 
                             
                                                                              
                          
 
 
 
 
 
 
Normal epidermis 
SSc epidermis  
 
 
       TGF-β               TGF-β             TGF-β                   Negative Controls      
      1 ng/ml               2 ng/ml           10 ng/ml                     (FPCL only) 
Figure 4.2: FPCL contraction after exposure to TGF-β, normal epidermis, 
and SSc epidermis. Normal dermal fibroblasts in FPCL were co-cultured with 
SSc epidermal cell layer (n=8), healthy control epidermis (n=8), TGF-β (4 
ng/ml), or with medium only for 48 hours. Gel diameter was measured by 
photography.  Co-culture with SSc epidermal cell layer and treatment with TGF-β 
lead to FPCL contraction. Contracted gels are highlighted with a black line for 
ease of visualisation.    107
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.1 CTGF expression in FPCLs: 
Since I observed activation of normal fibroblasts to a contractile state, I 
hypothesised that treatment with SSc epidermis was causing the induction of CTGF, 
a marker of fibroblast activation in SSc. I went on to measure CTGF expression in 
the fibroblast lattices by Western blot analysis and by immunohistochemistry.  
 
 
Figure 4.4: Histogram of the mean FPCL sizes. Contraction means were 
expressed as percentage (%) of baseline for each well type after treatment with 
control medium, TGF-β, normal epidermis and SSc epidermis. n=8 *p<0.01 
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Figure 4.4: CTGF content of FPCLs. Western blot assay and histogram of CTGF 
content of FPCLs (n=3) that had been exposed to: medium only (control), SSc epidermis, 
normal epidermis, and TGF-β.    109
 
 
Figure 4.5: CTGF content of FPCLs - immunostaining. Immunohistochemical 
staining for CTGF of FPCLs that had been exposed to normal and SSc epidermis for 
48 hours (n=4).  
 
Western blot for CTGF (Figure 4.4) was used as a surrogate marker for TGF-β 
signalling activation in treated fibroblasts. The normal epidermis caused a rise in 
CTGF that was little more than the background expression in the untreated FPCL. 
As expected, TGF-β caused a significant rise in CTGF expression. The SSc 
epidermis caused a rise in CTGF expression to over and above the level seen with 
TGF-β treatment. 
Immunohistochemical staining of treated FPCLs was used to confirm the above 
Western blot results (Figure 4.5). Staining of the untreated FPCL demonstrated a 
weak background staining for CTGF only, similar to that of IgG control. Normal 
epidermis FPCL treatment did not increase the lattice CTGF staining. SSc epidermis 
treatment, however, caused a pronounced increase in the intensity of CT 
 
SSc Epidermis 
IgG control  Normal  
Epidermis   110
 
4.2 Contraction of fibroblast collagen lattices by SSc epidermis  is TGF-β, ET-1, 
and IL-1 dependent: 
 
I was interested in the mechanism by which SSc epidermis activates normal 
fibroblasts in vitro. Therefore further studies were performed using inhibitors of 
growth factors and cytokines involved in paracrine signalling between epithelial 
cells and fibroblasts (T. Krieg et al. 2007). I began by studying the effect of a 
neutralising anti-TGF-β antibody 1D11. 
 
 
 
FPCL treatment 
 
Mean FPCL size 
(% of baseline)   
S.E. 
Control 84.76  15.12 
 
4.2.1 Contraction of fibroblast collagen gels by SSc epidermis is TGF-β 
dependent. 
   
Normal  
Epidermis
SSc epidermis 
SSc epidermis  
+ 1D11 
 
  TGF-β 
Figure 4.6: 1D11 inhibits SSc epidermis driven FPCL contraction. As before 
FPCL contraction was induced by co-culture with SSc epidermal cell layer and TGF-
β for 48 hours. Addition of TGF-β antagonist 1D11(1 μg/ml) at baseline antagonised 
FPCL contraction by SSc epidermal cells (n=3). Summary figure of two 
representative contraction experiments is shown. Epidermal discs from the same 
patients were used to treat standard and 1D11 impregnated FPCLs.  
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In these experiments two punch biopsies were taken from each subject’s forearm. 
One was embedded in the standard fibroblast collagen gel, and the other was 
embedded in a gel containing the TGF-β neutralising antibody 1D11 (1μg/ml). The 
SSc epidermis produced contraction of the non-1D11 treated lattices as observed 
previously, down to 58.65% of the original gel size. However, pre-treatment with 
1D11 prevented this contraction, with the lattice remaining at 88.47% of the baseline 
size. The contraction of the 1D11 pre-treated lattices exposed to the SSc epidermal 
disc was in fact similar to the contraction of the control untreated FPCLs (84.8%) 
and those of the 1D11-treated ones exposed to TGF-β (75.92%) (Figsure 4.6). The 
experiment was perfomed with three replicates   (Figure 4.7). The difference 
Effect of SSc Epidermis, TGF-β and 1D11 on 
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Figure 4.9: Histogram of SSc epidermis driven FPCL contraction after 
treatment with 1D11. Histogram of mean sizes of FPCLs after exposure to medium 
only (control), TGF-β, and SSc epidermis with and without 1D11 for 48 hours 
expressed as percentages of the baseline size. n=3; *p<0.01, **p<0.01   112
between the contraction produced by the SSc epidermal discs in the untreated FPCLs 
and ones pre-treated with 1D11 was statistically significant (p<0.01).  
 
A further experiment was performed to determine the role of ET-1 in SSc epidermis-
driven fibroblast activation. Two biopsies were taken from each of the forearms of 
three patients with early onset diffuse SSc and three control subjects. One epidermal 
disc from the biopsy was embedded in the standard FPCL. The other one from the 
same individual was embedded in the lattice containing ET-1 inhibitor bosentan. A 
concentration of bosentan (10 μM) known to inhibit ET-1 A and B receptors in cell 
culture experiments was used (S. Xu et al. 1998). The FPCL contraction elicited by 
the SSc epidermis was significantly inhibited by ET-1 inhibitor bosentan The 
experiment was repeated three times and the average SSc epidermis induced FPCL 
contraction was 56.26% , versus 90.7% with bosentan treatment (p=0.01) (Figures 
4.8-4.11).  
 
 
 
 
 
 
 
 
 
 
4.2.2 Contraction of fibroblast collagen gels by SSc epidermis is ET-1 
dependent.   113
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 (a,b): Bosentan inhibits SSc epidermis driven FPCL contraction. As  
before FPCL contraction was induced by co-culture with SSc epidermal cell  
layer for 48 hours. Addition of the endothelin receptor antagonist bosentan  
(10 μM) at baseline antagonised FPCL contraction by SSc epidermal cells (n=3).  
Pictures were taken at (a) baseline and (b) 48 hours. 
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A further experiment was performed to determine whether ET-1 was involved in 
TGF-β driven FPCL contraction as suggested in the past (X. Shi-Wen et al. 2001c) 
(Figure 4.10). 
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Figure 4.9: Histogram of SSc epidermis driven FPCL contraction after 
treatment with bosentan. Histogram showing mean FPCL sizes as percentage (%) 
of baseline size after 48 hours of treatment with SSc epidermal discs with and 
without the presence of bosentan in the lattice, as well as control and normal 
epidermis treated FPCL sizes. n=3, *p<0.01   115
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 (a,b): FPCL contraction after exposure to TGF-β (4 ng/ml) with 
and without bosentan. Addition of the endothelin receptor antagonist bosentan  
(10 μM) at baseline antagonised FPCL contraction by TGF-β.  
Pictures were taken at (a) baseline and (b) 48 hours. n=3 per well. 
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Figure 4.11: Histogram of FPCL contraction after treatment with TGF- β  
the presence and absence of bosentan. n=3; p<0.001 
 
 
TGF-β driven FPCL contraction was inhibited by bosentan suggesting that a 
pathway involving ET-1 is important downstream of TGF-β stimulation. 
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Contraction 
  
0 
20 
40 
60 
80 
100 
TGF-β TGF-β + bosentan
m
e
a
n
 
g
e
l
 
s
i
z
e
 
(
%
 
o
f
 
b
a
s
e
l
i
n
e
)  117
  
No 
inhibitor
+IL-1 R 
antagonist
Normal epidermis SSc epidermis
      
+IL-1 R 
antagonist
SSc epidermis Normal epidermis
No 
inhibitor
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b 
Figure 4.12 (a,b): IL-1 R antagonist inhibits SSc epidermis driven FPCL 
contraction. Normal dermal fibroblasts were cultured within FPCL in the presence 
of SSc epidermal layer (n=4) or normal epidermis (n=2). Paired biopsies were taken 
from the same subjects. As before FPCL contraction was seen following 48  
hours co-culture. Addition of IL-1 Receptor antagonist (100 nM) at baseline 
antagonised FPCL contraction. 
Pictures were taken at (a) baseline and (b) 48 hours. 
4.2.3 Contraction of fibroblast collagen gels by SSc epidermis is IL-1 
dependent. 
 
 
A further experiment was used to determine the importance of IL-1 in SSc 
epidermis-driven FPCL contraction. 
a   118
 
 
 
 
Paired biopsies were taken from SSc patients (n=4) and control subjects (n=2). One 
was embedded in the standard fibroblast collagen gel, and the other was embedded 
in a gel containing a recombinant human IL-1R antagonist (100 nM). SSc epidermis 
caused contraction of standard FPCLs as previously described (Figure 4.2). Normal 
epidermis produced minimal contraction of the lattices. IL-1 Receptor antagonist 
inhibited contraction of SSc-treated FPCLs (p<0.001) (Figures 4.12, 4.13).  
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Figure 4.13: Histogram of SSc epidermis driven FPCL contraction after 
treatment with IL-1R antagonist. Mean FPCL sizes are shown as percentages 
(%) of baseline size after 48 hours of treatment with SSc and normal epidermal 
discs with and without the presence of IL-1 Receptor antagonist. *p<0.001 
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These results mean that fibroblast activation to contractile state by SSc epidermis is 
IL-1, TGF-β, and ET-1 dependant. I went on to try to determine whether these 
factors were derived from the epidermis or were induced in fibroblasts under 
epidermal influence. 
 
 
4.3 SSc epidermis leads to induction of ET-1 and TGF-β in normal human 
fibroblasts. 
 
 
Since I had found the SSc epidermis activating normal human fibroblasts into a 
contractile state, I hypothsised that SSc epidermis was inducing the expression of 
pro-fibrotic growth factors in these fibroblasts. Therefore I measured the induction 
of TGF-β, ET-1 and IL-1 in protein extracts obtained by lysis of FPCLs after 
exposure to SSc epidermis, normal epidermis and TGF-β. 
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4.3.1 Western blot of FPCLs for ET-1: 
I began by measuring the induction of ET-1 following treatment of standard and 
bosentan impregnated FPCLs by SSc epidermis and TGF-β (Figure 4.14). 
 
 
 
 
 
 
 
Figure 4.14: Western blot assay of ET-1 expression in FPCLs (with and without 
bosentan) following exposure to SSc epidermis, TGF-β (4 ng/ml), normal epidermis 
and control medium. GAPDH was used as protein loading control. 
 
 
Treatment with SSc epidermis and TGF-β lead to induction of fibroblast ET-1 
expression, which was antagonised by the ET A and B receptor antagonist bosentan 
(10 μM). Untreated FPCLs and normal epidermis treated ones had similar low levels 
of ET-1 expression (Figure 4.14, 4.17). 
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4.3.2 Western blot of FPCLs for TGF-β: 
TGF-β expression in the FPCLs treated with SSc epidermis was also measured 
(Figure 4.15). 
 
 
 
 
Figure 4.15: Western blot assay of TGF-β expression in FPCLs (with and 
without bosentan) following exposure to SSc epidermis, TGF-β (4 ng/ml), normal 
epidermis and control medium. GAPDH was used as protein loading control. 
 
 
TGF-β caused increased expression of TGF-β in the FPCL, this expression was not 
inhibited by bosentan. SSc epidermis treatment also caused increased TGF-β 
production in the lattice, but to a lesser extent than TGF-β treatment. Bosentan 
partially inhibited this production. Control untreated lattices and lattices treated with 
normal epidermis had negligible TGF-β expression. 
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4.3.3 Western blot of FPCLs for IL-1: 
                  
I went on to test whether IL-1 was being induced in FPCLs. I suspected that IL-1 
was in fact being released by the epidermal cells to cause fibroblast activation as 
shown in some previous co-culture experiments (P. Shephard et al. 2004h).  
 
 
 
Figure 4.16: Western blot assay of IL-1 expression in FPCLs following exposure 
to SSc epidermis, TGF-β (4 ng/ml), normal epidermis and control medium. GAPDH 
was used as protein loading control. 
 
 
Consistent with previous experimental data I did not observe IL-1 induction in 
FPCLs treated with SSc epidermis or TGF-β, only low level basal expression was 
seen (Figure 4.16). 
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Therefore, based on these studies I concluded that fibroblast activation by SSc 
epidermis was being driven by IL-1 derived from KCs, which in turn lead to TGF-β 
and ET-1 induction in fibroblasts. 
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Figure 4.17: Gel intensity scan. Results for Western blots performed above for ET-1 
and TGF- β content of standard and bosentan impregnated FPCLs treated with SSc or 
normal epidermis, TGF-β, or medium only (control) expressed as percentage  (%) of 
control values and adjusted for GAPDH loading variability.    124
Discussion 
SSc epidermis has a wound healing phenotype both structurally and functionally. It 
is known that in the setting of normal skin healing KCs are capable of secreting 
profibrotic mediators that can activate dermal fibroblasts and cause fibrosis (P. 
Shephard et al. 2004c;P. Shephard et al. 2004i;W. Xia et al. 2004c).  
Experimental work presented in this chapter was designed to test whether the SSc 
epidermis in its capacity as a wound healing-like structure had fibroblast activating 
properties in vitro. It was hypothesised that persistent activation of the SSc 
epidermis contributes to disease pathogenesis, maintaining a wound healing, matrix 
overproducing phenotype in the disease.  
The normal human FPCL contraction studies provided a convenient model for 
studying the in vitro epidermal-dermal interaction. Pre-stressed FPCLs mimic the 
tension of dermal matrix which causes fibroblast contraction after tension is released 
and growth factor stimulation is applied (F. Grinnell 2003a).  
I showed that SSc epidermis activated normal fibroblasts in vitro, equivalent to the 
result seen with exogenous TGF-β application (Figures 4.2, 4.3).  
The ability of the SSc epidermis to cause contraction of normal human fibroblasts is 
a new finding. It was therefore important to determine which mediator had a role in 
this interaction. Well known fibrotic mediators TGF-β and ET-1, as well as an 
important wound healing mediator IL-1 were studied. 
1. Contraction of fibroblast collagen gels by SSc epidermis is TGF-β dependent: 
The attention was first turned to TGF-β. TGF-β is a well recognized stimulus of 
fibroblast contraction (T. Mori et al. 1999b;S. A. Cotton et al. 1998). The pro-
contractile effect of the SSc epidermis was reversed by the neutralising antibody to   125
TGF-β (1D11) added to the lattice at baseline (Figures 4.6, 4.7). This result suggests 
that TGF-β is important in SSc epidermis driven FPCL contraction. I went on to 
consider whether TGF-β was involved at the level of the epidermis or downstream 
of epidermal stimulation. 
Immunoblotting of the FPCLs treated with SSc and normal epidermal discs and 
TGF-β was conducted. TGF-β was found to be stimulated in the lattice fibroblasts 
by exposure to TGF-β itself (a positive control) as well as the SSc epidermis (Figure 
4.17). Untreated and normal epidermis treated fibroblasts did not produce TGF-β. 
CTGF expression was also assessed in the fibroblasts as a marker of TGF-β pathway 
activation in the lattice, and found to be significantly increased after both TGF-β and 
SSc epidermis treatment, but not after control or normal epidermal exposure. This 
was confirmed by immunostaining the FPCLs for CTGF (Figure 4.5).  
Results from the previous chapter have shown that the SSc epidermis has increased 
expression of LAP-TGF-β compared to normal control (Figure 3.4, 3.7). 
Since the difference in SSc versus normal epidermal LAP-TGF-β content is slight, its 
release from the epidermis might not explain the large and consistent difference in the 
ability of SSc epidermis to activate and contract human fibroblasts.  
One explanation for the contraction inducing properties of SSc epidermis could be 
that the absolute value of LAP-TGF-β is not important for the epidermal-dermal 
interaction. Since TGF-β is normally secreted in its latent form, the biological 
function of this growth factor is thought to be largely determined by its activation 
from the latent state. LAP-TGF-β is known to be activated by epithelium-specific 
integrins such as αvβ6 and αvβ8 via the integrin-binding sequence (RGD) of the 
LAP that allows LAP-TGF-β sequestration to the cell surface where its activation   126
via a conformational change or proteolytic cleavage is locally controlled (J. S. 
Munger et al. 1998;D. Mu et al. 2002). These integrins are expressed during 
epithelial wound healing to allow KC migration over the wound defect. As part of 
the wound-healing phenotype SSc KCs would be expected to express these integrins, 
which could result in the release of the free TGF-β form. Sine TGF-β has the ability 
to stimulate the expression of αvβ6 integrins in epithelial cells, a positive feedback 
could ensue resulting in unchecked TGF-β activation (D. Sheppard et al. 1992). 
A similar integrin - TGF-β interaction is thought to be important in epithelial-
mesenchymal interplay of lung development. Since αvβ8 is over-expressed in adult 
lung epithelium exposed to an injury or inflammatory stimuli, and epithelial injury is 
known to promote lung fibrotic reactions, this provides a potential link between 
epithelial injury, LAP-TGF-β activation and fibrosis (J. Araya et al. 2006).  
In addition, the same levels of TGF-β in the epidermis could have very different 
effects in a dermis pre-sensitised to its stimulation. In fact, several studies have 
found raised TGF-β receptor levels in SSc fibroblasts (H. Ihn et al. 2001a;T. 
Kawakami et al. 1998). In the disease, active TGF-β released from the latent form, 
or free TGF-β could be immediately sequestered by the disease fibroblasts as part of 
SSc pathogenesis.  
Another reason absolute amounts of TGF-β may not be important, is if it is the 
temporal pattern of factor release that determines the fibroblast response. A snap 
shot concentration may not represent the fact that these factors would be constantly 
produced by the disease epidermis. Once bound to their receptors TGF-β molecules 
would have their effect and get immediately degraded to be replaced by newly 
released ones. In healthy skin the pro-fibrotic mediators would be there transiently in   127
response to a specific stimulus, and not be continuously produced. 
Having considered the possibility of epidermal TGF-β release causing dermal 
fibrosis in SSc, one has to consider the fact that TGF-β actions may be restricted to 
dermal fibroblasts only. It is well known that SSc fibroblasts have increased levels 
of TGF-β expression (J. Peltonen et al. 1990f;J. Peltonen et al. 1990d;L. Rudnicka et 
al. 1994d). Findings in this chapter show increased levels of TGF-β in normal 
human fibroblasts after exposure to SSc epidermis (Figure 4.17). TGF-β could be 
responsible for maintaining dermal fibrosis after the initial stimulation from the 
epidermis is applied to the area. 
2. Contraction of fibroblast collagen gels by SSc epidermis is ET-1 dependent: 
ET-1 is known to be important in skin fibrosis (Y Hamada 1999;M. B. Kahaleh 
1991c;S. Xu et al. 1998). Previous experimental evidence supports the role of ET-1 
in fibroblast activation downstream of TGF-β (X. Shi-Wen et al. 2004b;P. Shephard 
et al. 2004d). ET-1 antagonist bosentan was found to reverse the FPCL contraction 
caused by SSc epidermis (p=0.01) (Figures 4.8, 4.9). Bosentan also inhibited TGF-
β-driven FPCL contraction (Figures 4.12, 4.13), confirming the role of ET-1 
downstream of TGF-β.  
The next step is to determine whether the involvement of ET-1 in FPCL contraction 
is at the level of the epidermis or the fibroblasts.  
Results from the previous chapter show increased ET A and B receptor content in SSc 
epidermis, but no difference was found in terms of ET-1 itself (Figures 3.5, 3.11, 
3.12). This result does not exclude epidermal ET-1 secretion since even if the 
expression of ET-1 is only slightly increased in the disease, one can speculate that 
when secreted from the epidermis, ET-1 works on the fibroblasts that are pre-  128
sensitised to its effects. We know that SSc fibroblasts have reduced ET A receptor 
expression (X. Shi-Wen et al. 2001b). This could mean that either the receptor is 
more sensitive to ET-1 stimulation, or that the already activated downstream 
mechanisms in SSc fibroblasts/myofibroblasts are hyper-responsive to its effects in 
vivo.  
Just as discussed above for the role of TGF-β, absolute amounts of epidermal ET-1 
may not be important if it is the temporal pattern of factor release that determines the 
fibroblast response.  
Having considered the possible epidermal ET-1 contribution to SSc pathogenesis, 
one should consider its role at the level of the dermis. ET-1 is well known to activate 
fibroblasts in SSc (S. Xu et al. 1998;S. W. Xu et al. 2004b). I found increased levels 
of ET-1 in normal human fibroblasts after their stimulation by SSc epidermis for 48 
hours (Figure 4.14). The levels were similar to those after TGF-β stimulation, and 
both were inhibited by bosentan. This would strongly support the role of ET-1 in 
maintaining fibrosis at the level of the dermis, and implies that ET-1 induction is 
required for fibroblast activation by SSc epidermis.  
3. Contraction of fibroblast collagen gels by SSc epidermis is IL-1 dependent: 
IL-1 is an important pleiotropic cytokine involved in KC and fibroblast activation 
after injury. IL-1 is vital in KC response to epidermal disruption, but can also be 
found in fibroblasts (I. M. Freedberg et al. 2001e). Cultured dermal fibroblasts from 
SSc patients have been reported to have higher levels of IL-1α than normal controls 
(Y. Kawaguchi 1994). IL-1 is also known to prolong SSc myofibroblast survival 
time and cause epidermis driven fibroblast activation (I. M. Freedberg et al. 
2001d;P. Shephard et al. 2004j;T. Z. Kirk, M. D. Mayes 1999).    129
I found that IL-1 Receptor inhibitor reversed SSc epidermis-driven FPCL 
contraction, a result consistently repeatable over three experiments (Figures 4.12, 
4.13). I needed to determine whether IL-1 was driving FPCL contraction from the 
SSc epidermis or whether it was being induced at the level of the fibroblasts. 
ELISA immunoassay and immunostaining demonstrated greatly increased IL-1 and 
its receptor content in SSc epidermis (Figures 3.6, 3.13), with no increase in IL-1 
levels in SSc epidermis treated fibroblasts from the lattice (Figure 4.16). It is notable 
that previous experimental evidence suggests that IL-1α and β are both capable of 
IL-1β gene induction in normal skin fibroblasts (N. Maas-Szabowski et al. 1999c). It 
is possible that the epidermal IL-1 does not induce IL-1α in dermal fibroblasts, or 
requires a different time scale to achieve this induction (FPCL contraction was 
achieved within 7 hours of SSc epidermal exposure, whereas IL-1 gene induction 
required 24 hours of treatment). 
Previous experimental evidence confirms the ability of IL-1 to induce ET-1 
production in human cells and in KC-fibroblast co-culture (X. Shi-Wen et al. 
2000a;Y. Mori et al. 2003c). This ET-1 induction seems to be important in early 
fibroblast contraction before TGF-β (inhibited by NFkB activation) or αSMA 
expression come into play.  
 
In summary, the experimental data presented above demonstrates that TGF-β and 
ET-1 are induced in normal human fibroblasts by the SSc epidermis. This implies 
that these mediators are important at the level of the dermis, and may play a 
significant role in maintaining fibroblasts in an activated state. IL-1, on the other 
hand, is not found to be increased in SSc epidermis treated fibroblasts, which leaves 
it as a potential candidate for an epidermis-derived pro-fibrotic agent.   130
IL-1 is likely to be the trigger that sets up a loop causing local autocrine KC 
stimulation as well as the paracrine activation of dermal fibroblasts. The latter 
respond by secreting TGF-β and ET-1 and setting up their own autocrine cycling to 
produce pathological ECM secretion and ultimately fibrosis.  
4. Mechanism of SSc epidermis-driven activation of dermal fibroblasts: 
I suggest that the most likely mechanism involved in SSc epidermis-driven 
activation of dermal fibroblasts is that of an epidermal-dermal paracrine loop, which, 
once initiated, then goes on to self-potentiate and maintain the pro-fibrotic cycle 
(Figure 6.1). 
This type of loop has previously been demonstrated for IL-1/KGF production in 
normal cell epithelial-mesenchymal interactions examined in the setting of healing 
and repair (Y. Asano et al. 2006b;Y. Asano et al. 2006a). In this environment, the 
absolute quantities of the secreted factors are not important as positive feedback 
mechanisms are set in motion. On the other hand, any interruption to such a loop, as 
achieved with ET-1, TGF-β or IL-1 inhibitors in the above experiments, would have 
a major impact on continuation of the fibrotic processes. 
The concept of epidermal-dermal stimulation implies either a direct cellular 
interaction between KCs and dermal fibroblasts, and/or factor diffusion across the 
basement membrane. Normally, an intact basement membrane would prevent the 
interaction. This may change, however, if the skin layers were to be disturbed as in 
the situation of wounding or after the onset of inflammation. We know that SSc 
epidermis has a wound healing phenotype. This may allow the epidermal-dermal 
interplay in SSc the way it does in wound healing. 
In addition, it is important to bear in mind that at some stage activated fibroblasts 
can become autonomous. In this case they stop requiring stimulation from the   131
epithelium and continue secreting ECM which eventually leads to the skin sclerosis 
seen in SSc in an entirely unchecked manner (Y. Mori et al. 2003b;H. Gardner et al. 
2006;Y. Mori et al. 2003a;F. K. Tan et al. 2005). 
In line with the autonomy theory, recent studies demonstrated that αvβ5 integrin 
found to be over-expressed in SSc fibroblasts, promoted the formation of the TGF-β/ 
TGF-β receptor complex and subsequent establishment of autocrine TGF-β 
signalling in these cells leading to constitutive myofibroblast phenotype of SSc 
fibroblasts (L. Chung, P. J. Utz 2004;P. Q. Hu et al. 2003). In addition, ligand-
independent SMAD signalling and gene activation has been demonstrated in SSc 
fibroblasts (S. S. Baroni et al. 2006).  
The question of what sets the positive feedback in motion remains, however. An 
attractive idea is that of serum immunoglobulins causing the initial KC and/or 
fibroblast activation. Several autoantibodies are associated with SSc and implicated 
in disease pathogenesis. These are anti-endothelial, anti-fibroblast, anti matrix 
metalloproteinase, anti-DNA topoisomerase, and anti-fibrillin-1 antibodies (S. 
Narumiya 1995).  
A recent paper finds PDGFR antibodies in serum of patients affected by SSc, and 
links them to fibroblast oxidative damage via Ras/ERK signalling. This cascade is 
thought to be responsible for fibroblast activation in the disease (E. J. Goetzl et al. 
1995b).  
Recent unpublished data from this laboratory demonstrates increased binding of 
serum antibodies from SSc patients to normal human KCs. KCs exposed to SSc 
patient serum release greater levels of IL-1 than those exposed to serum from normal 
controls. This supports the hypothesis of antibody-mediated skin activation in SSc,   132
with KCs as a primary target. 
Other factors initiating KC/fibroblast activation could be epithelial injury or 
chemical exposure, both of which have been linked to SSc (P. J. Nietert, R. M. 
Silver 2000b). 
 
Conclusions 
•  The data presented above demonstrates for the first time that SSc epidermis 
is capable of activating normal human fibroblasts in an in vitro model of 
epidermal-dermal cross-talk.  
•  SSc epidermis induces contractile and CTGF-expressing phenotype in 
normal human fibroblasts in vitro. 
•  Activation of fibroblasts by SSc epidermis is TGF-β, ET-1 and IL-1 
dependent.   
•  SSc epidermis leads to the induction of TGF-β and ET-1, but not IL-1 in 
human fibroblasts. 
•  IL-1 levels are significantly raised in SSc epidermis. 
•  It is reasonable to suggest that the SSc epidermis is an active secretory organ 
where wound healing-like epidermis driven mechanisms cause persistent 
downstream fibroblast activation. 
•  I put forward a model where epidermis-derived IL-1 causes TGF-β and ET-
1 dependant fibroblast activation.
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CHAPTER 5 
 
The Role of PGE2 in TGF-β Driven KC Function 
 
 
Introduction 
 
Previous chapters demonstrate that the SSc epidermis has a wound healing phenotype 
in terms of its structure, signalling capacity, raised IL-1 content and the ability to 
activate underlying matrix. I also showed that the SSc epidermis caused human 
fibroblast activation suggesting that epithelial processes need to be tightly controlled 
if the correct skin structure is to be maintained. A similar epidermal-fibroblast 
interplay is known in the setting of wound healing (P. Shephard et al. 2004k). 
     
                     
 
Figure 5.1: Comparison is made between SSc epidermis and a wound healing 
epidermis based on experiments in Chapter 3. The similarities lead to the interest 
in KC wound healing biology with potential implications for dermal fibrosis. 
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Because of this I became interested in the regulation of KCs during wound repair. 
I went on to study epithelial cell biology in the setting of wound healing in order to 
explore the idea of altering epithelial processes to control dermal fibrosis. 
One of the most fundamental properties of skin healing is epithelial re-surfacing. 
When skin is injured wound healing consists of simultaneous repair of dermal 
extracellular matrix and proliferation and differentiation of epidermal KCs (T. Sato et 
al. 1997d). A balance of KC migration and proliferation establishes wound coverage, 
these cells also stimulating the underlying dermal fibroblasts to complete skin closure 
(S. Werner, H. Smola 2001c;S. Werner, R. Grose 2003b;S. Werner et al. 2007c). 
Cell-cell interactions between KCs and dermal fibroblasts are known to contribute to 
the correct organisation of the epidermis (T. Sato et al. 1997c). PGE2 has been shown 
to be involved in KC proliferation and differentiation and is a crucial mediator of 
epidermal repair (G. Furstenberger, F. Marks 1978b;A. P. Pentland, P. Needleman 
1986b). It has been found that in KC-fibroblast co-culture experiments fibroblast 
derived PGE2 production is dependent on IL-1 release from epidermal KCs , 
suggesting a feedback mechanism between theses cells (T. Sato et al. 1997b). 
I found increased IL-1 and decreased COX II expression in SSc epidermis 
(Chapter3). KCs are known to secrete prostaglandins, but the contribution of PGE2 
and COX II to wound repair is not clear.  
One interesting aspect of wound healing is that KCs proliferate and the epidermis 
expands in a TGF-β dominated environment which is anti-proliferative and pro-
migratory in nature (C. Amendt et al. 2002c;P. A. Hebda 1988e;C. J. Kane et al.   135
1991c;S. Werner, H. Smola 2001b;B. Bandyopadhyay et al. 2006e). Results from this 
laboratory have previously demonstrated that prostanoids are able to antagonise 
TGF-β dependent events in human cells (R. Stratton et al. 2001b;R. Stratton et al. 
2002e). I hypothesised, therefore, that the induction of prostanoids during wound 
healing frees KCs from the anti-proliferative effects of TGF-β. I went on to measure 
the induction of PGE2 and COX II during wound repair, and studied the effect of 
PGE2 on TGF-β-driven KC functions. 
 
Results 
5.1 COX II and PGE2 induction in excisional mouse wounds: 
 
Mice were anaesthetised and underwent excisional wounding (4x4 mm biopsies of 
dorsal skin) (see Methods). Mice were then euthanised at various time points (0, 1, 3, 
7, 11, and 14 days), wound sites were excised and stored in liquid nitrogen for PGE2 
ELISA or fixed in formalin for histochemistry. 
 
5.1.2 Staining for COX II in mouse skin: 
Immunohistochemistry was used to localise COX II expression in sections obtained 
from mouse wounds during wound healing. COX II was induced in the epidermis on 
days 1-3 post wounding, the induction resolved by day 9 (Figure 5.2). 
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5.1.2 Timecourse for PGE2 induction in mouse wound: 
Total wounds were then extracted and PGE2 measured by ELISA of wound 
homogenates. Rapid induction of PGE2 (up to 3 μg/mg of tissue) was seen (Figure 
5.3). This induction  peaked on day 1, diminishing thereafter. 
 
 
 
 
 
 
 
 
 
Figure 5.2: Induction of COX II (red staining) in the mouse epidermis 
during excisional wound healing. Cox II is visible on Day 1 post wounding (red 
staining, arrows) and is absent by Day 9.   137
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I concluded that following tissue injury COX II is rapidly induced in the epidermis 
and PGE2 synthesis increases in parallel. 
 
5.2 PGE2 partially blocks the anti-proliferative effects of TGF-β in human KCs: 
 
Because of the above findings of increased COX II and PGE2 production in early 
wounds and because we had found that prostaglandins antagonised TGF-β in human 
cells, I hypothesised that PGE2 was freeing KCs at the wound edge from the anti-
proliferative effects of TGF-β. I began by measuring the effect of PGE2 at various 
concentrations on TGF-β inhibition of rapidly proliferating normal human KCs. 
Normal human KCs were cultured in 6 well plates in K-SFM with or without the 
addition of TGF-β (10 ng/ml). After 48 hours KC number was determined by 
counting of the cells in a haemocytometer. 
 
   
Figure 5.3: PGE2 levels during excisional wound healing in the mouse. n=3 
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TGF-β antagonised KC proliferation (Figure 5.4). Antagonism of KC proliferation by 
TGF-β was partially blocked in a dose dependent manner by PGE2.  
 
I then went on to explore whether TGF-β driven KC motility was also affected by 
PGE2. 
 
 
5.3 PGE2 blocks TGF-β induced motility in human KCs: 
 
KCs were grown on 6 well plates in K-SFM to 90% confluency. A scratch was 
induced with a pipette tip. TGF-β was added to the medium with or without co-
addition of PGE2 (0.1-10 µM). 
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Figure 5.4: The effect of PGE2 on TGF-β suppression of proliferation in human KCs. 
Normal human KCs were allowed to proliferate for 48 hours in the presence or absence of 
TGF-β, with or without PGE2. TGF-β suppressed KC proliferation, and this effect was 
antagonised by PGE2 (n=3).   139
I demonstrated that TGF-β (4 ng/ml) enhanced KC motility using a scratch model of KC 
migration. I then went on to test whether PGE2 (0.1-10 μM) was able to antagonise TGF-β 
stimulated KC migration (Figure 5.5). 
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Table 5.1: The effect of PGE2 and TGF-β on human KC migration. Scratch defect 
widths measured as percentages of day 1 width after treatment as indicated over 36 hours 
total. Photographs taken at 12 hour intervals (n=3).   140
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Figure 5.5 (a,b): Summary figure comparing scratch defects after treatment 
with TGF-β and PGE2 as indicated at 12 hour time points. Lines and arrows 
indicate areas of interest. 
Figure 5.5(b)   142
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure 5.6: Scratch widths as percentages of baseline. Line graph to show scratch 
widths measured as percentages of baseline at 12 hour intervals for each well after 
treatment with 4 ng/ml TGF-β, 4 ng/ml TGF-β plus PGE2 (0.1 μM, 1 μM, 10 μM), 
or 10 μM PGE2 only. 
 
 
The pro-migratory action of TGF-β on cultured human KCs was confirmed (Figure 
5.5). PGE2 inhibited the pro-migratory action of TGF-β on KCs in a dose-dependent 
manner. Figure 5.5 delineates scratch closure patterns after treatment with TGF-β 
with or without PGE2 and compares them to each other at 12 hour time points over a 
total of 36 hours. The control untreated KCs displayed some migration at 48 hours. 
At 48 hours the well containing TGF-β only had an almost completely closed scratch 
defect as expected, thus demonstrating a strong pro-migratory influence of TGF-β 
on KCs. At 0.1 µM concentration PGE2 had no effect on the pro-migratory action of 
TGF-β. However, PGE2 at 1 µM had an inhibitory effect on TGF-β induced KC 
migration, and at 10 µM PGE2 almost completely inhibited scratch defect closure 
despite the presence of TGF-β.  
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Interestingly, the PGE2 only wells showed less scratch defect closure than the 
control wells. This suggests that either there is background TGF-β activity in the 
control KCs, or that PGE2 can act on a different pathway to inhibit scratch closure. 
 
5.4 Effect of ERK signalling inhibition on TGF-β driven KC migration: 
 
Because we had found previously that ras/MEK/ERK signalling was required for 
TGF-β dependent events in fibroblasts, I investigated whether this pathway was 
involved in TGF-β stimulated KC motility (R. Stratton et al. 2002). I used the small 
molecule inhibitor of MEK 1/2 U0126 to inhibit ras/MEK/ERK signalling (Y. 
Imamichi et al. 2005;J. V. Duncia et al. 1998) (Figure 5.7). I found that U0126 had a 
modest inhibitory effect on TGF-β dependent KC motility, which was not as great as 
the inhibitory effect of PGE2 on KC motility observed in Figures 5.6, 5.7.  
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Figure 5.7: Summary figure comparing scratch defects after treatment with 
TGF-β and U0126. The baseline and 48 hour results are shown. Lines and arrows 
indicate areas of interest.  
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Photo time 
 
Well treatment 
Baseline  12 hours  24 hours  36 hours        48 hours 
Control  100    88.9  66.7  66.7              
 
55.5 
 
TGF-β only  
(4 ng/ml) 
100  70  70  55                  0 
U0126 (5 μΜ)+ 
TGF-β (4 ng/ml) 
100  77.8  72.2  69.4               61.5 
U0126 (10 μΜ)+ 
TGF-β (4 ng/ml) 
100  100  100  66.7               55.55 
U0126 (12 μΜ)+ 
TGF-β (4 ng/ml) 
100  89.5  78.9  73.7               63.16 
 
Table 5.2: The effect of U0126 on human cultured KC migration. Scratch defect 
widths measured as percentages of day 1 width after treatment as indicated over 48 
hours total. Photographs taken at 12 hour intervals (n=3). 
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Figure 5.8: Scratch widths as percentage of baseline. Graph to show scratch 
widths measured as percentages of day 1 width at 12 hour intervals for each well 
after treatment with 4 ng/ml TGF-β only, or 4 ng/ml TGF-β plus U0126 (5μM, 10 
μM, 12 μM).  
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The MEK 2/3 inhibitor U0126 reversed the promigratory effect of TGF-β on human 
KCs in a scratch assay (Figures 5.7, 5.8, Table 5.2). The effect of U0126 was dose-
independent at the 48 hour end-point with the 5 µM, 10 µM, and 12 µM solutions 
allowing scratch defect closure to 61.5%, 55.5%, and 63.16% of baseline 
respectively. TGF-β, however, caused a complete closure of the scratch defect after 
48 hours. 
 
5.5 Effect of PGE2 on TGF-β driven timecourse of ERK phosphorylation in 
human KCs: 
 
Previously we found that prostanoids prevent TGF-β signalling in fibroblasts via 
inhibition of ras/MEK/ERK pathways. Because of this I went on to determine 
whether these effects extend to KCs.  
 
5.5.1 Timecourse KC pERK1/2 induction in the presence of TGF-β: 
To begin with the time course of ERK phosphorylation following exposure of KCs 
to TGF-β was shown using immunostaining with and without DAPI nuclear staining 
(Figure 5.9). 
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Figure 5.9 Timecourse of TGF-β driven KC pERK1/2 induction. KCs were 
grown on chamber slides following exposure to TGF-β (4ng/ml) for 15, 30, and 
60 minutes. Immunohistochemical staining (arrow) for pERK1/2 with and 
without DAPI nuclear staining (blue) was performed.    148
I found that under basal conditions phosphorylated ERK was present within the KC 
cytoplasm and that after 15 minutes of exposure to TGF-β (4 ng/ml) the pERK 
migrated to the nucleus. This effect was transient, however, and pERK appeared 
cytoplasmic again after 30 minutes of TGF-β treatment. pERK was still detected in 
the cytoplasm after 60 minutes. 
 
5.5.2 Timecourse of KC pERK1/2 induction in the presence of TGF-β and 
PGE2: 
 
The effect of PGE2 on TGF-β driven timecourse of ERK phosphorylation was 
studied by adding the two factors to the KC culture wells and staining for pERK at 
15, 30 and 60 minutes post exposure (Figure 5.10) with and without DAPI nuclear 
staining. 
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Addition of PGE2 (10 μM) did not affect pERK migration to the nucleus. 
I concluded that ERK was phosphorylated under basal conditions in KCs grown in 
serum-free conditions, and that following exposure to TGF-β pERK rapidly 
translocated to the nuclear compartment. PGE2 had no effect on this process. 
 
5.6 Effect of TGF-β and PGE2 on total cellular ERK phosphorylation in KCs: 
 
In these experiments KCs were cultured on 6 well plates and treated with TGF-β with 
and without PGE2 and lysed at various time points in Western lysis buffer containing 
protease inhibitors. Western blot analysis confirmed the presence of pERK1/2 under 
basal conditions.  
Exposure to TGF-β did not alter the total pERK1/2 concentration, in addition PGE2 
did not affect the total cellular pERK content (Figure 5.11). 
TGF-β+PGE2 pERK (60 min)
Figure 5.10: Timecourse of KC pERK1/2 induction in the presence of TGF-β and 
PGE2. KCs were grown on chamber slides following exposure to TGF-β (4ng/ml) with 
and without PGE2 (10 μM) for 15, 30, and 60 minutes. Immunohistochemical staining 
(arrow) with and without DAPI nuclear staining (blue) for pERK1/2 was performed. For 
control staining see Figure 5.9.   150
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From these studies I concluded that pERK was constitutively expressed in the 
cytoplasm of normal human KCs, and that TGF-β treatment did not enhance total 
pERK expression. PGE2 did not affect pERK content or timecourse in these KCs.  
 
 
 
 
 
 
 
 
 
Figure 5.11: Western blot assay for pERK1/2 content of  TGF-β and/or PGE2 
treated KCs. Western blot of KCs for pERK1/2 after treatment with 4 ng/ml TGF-
β alone, 10 µg/ml PGE2 alone, and 4 ng/ml TGF-β + 10 µg/ml PGE2 over 1 hour. 
pERK1/2 expression after TGF-β and TGF-β + PGE2 treatment assessed at 5, 15, 
and 30 minutes (n=3). Representative figure with GAPDH loading control shown.   
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Discussion 
Wound healing is one of the most fundamental functions of the epidermis largely 
controlled by mediators secreted by epidermal KCs themselves. When the highly 
regulated process of wound healing becomes disordered, the consequences can range 
from chronic ulceration to fibrosis and even malignancy. It is therefore important to 
study the cellular events involved in wound healing and the soluble mediators that 
orchestrate these events. Two important secreted factors involved in wound healing 
regulation are PGE2 and TGF-β. 
Human KCs are known to produce prostaglandins and to express all 4 types of PGE2 
receptor (E-series PG receptors: EP1, EP2, EP3 and EP4) (S. Narumiya 1995). PGs 
are involved in wound healing, particularly in the inflammatory and proliferative 
phases. This explains the erythema, increased blood flow, vasodilation and white 
cell influx in the wounded area (E. J. Goetzl et al. 1995a). One of the mechanisms 
responsible for the PGE2 induction post tissue injury is the stabilisation of COX II 
mRNA by IL-1α through p38 and NF-kappaB expression (J. F. Di Mari et al. 
2007;J. F. Di Mari et al. 2003;M. Lasa et al. 2000). However, the exact role of PGs 
in KC function is not clear. Studies have suggested that they are pro-proliferative 
autocoids for the epidermis. For instance, intradermal injection of PGE1 and PGE2 
increases epidermal proliferation  (C. B. Bentley-Phillips et al. 1977b). NSAIDs 
(pharmacological PG inhibitors) reduce the proliferation rate of KCs. Topical 
addition of PGI2 to indomethacin-treated non-confluent KC cell cultures restores 
their normal proliferation rate (A. P. Pentland, P. Needleman 1986c). 
It is thought that overall PGE2 improves wound healing kinetics (T. Brzozowski et 
al. 1993b;B. Gonul et al. 1993b;L. E. LeDuc et al. 1993a).  152
TGF-β is known to affect nearly all aspects of wound repair, and this growth factor 
is consistently found in the wound healing environment (S. Werner, R. Grose 
2003a). It has been shown that TGF-β itself is present in excisional wounds from 
day 1 post injury (L. I. Gold et al. 1997). The overall function of TGF-β is to 
enhance wound repair in vivo (C. Amendt et al. 2002b;I. M. Freedberg et al. 
2001c;P. A. Hebda 1988d;C. J. Kane et al. 1991b;S. Werner, H. Smola 2001a;B. 
Bandyopadhyay et al. 2006d;P. A. Hebda 1988c).  
One interesting aspect of wound healing is that KCs proliferate and the epidermis 
expands in a TGF-β dominated environment which is pro-migratory but anti-
proliferative in nature (C. Amendt et al. 2002a;B. Bandyopadhyay et al. 2006c;I. M. 
Freedberg et al. 2001b;P. A. Hebda 1988b;C. J. Kane et al. 1991a;H. Smola et al. 
1993a).  
We have previously found that prostanoids are able to antagonise TGF-β signalling 
in human cells(R. Stratton et al. 2001c;R. Stratton et al. 2002b). In addition I found 
SSc epidermal KCs to have reduced COX II expression while LAP- TGF-β levels 
were raised (Chapter 3). I therefore hypothesised that one of the roles of prostanoids 
was to regulate the responses of cells to TGF-β in the epidermis, and began by 
studying the effect of PGE2 on TGF-β in normal cultured human KCs. 
In this chapter I show that COX II and PGE2 are induced in the epidermis of healing 
excisional mouse wounds (Figures 5.2, 5.3). The KC proliferation study shows that 
PGE2 is capable of reversing the anti-proliferative effect of TGF-β on human KCs in 
a concentration-dependent manner (Figure 5.4). I suggest that the antagonistic effect 
of PGE2 on KC functioning could have evolved to release KCs from the anti-
proliferative effect of TGF-β during wound healing and thus allow effective 
epidermal defect closure.    153
Previous studies show that TGF-β enhances KC motility(B. Bandyopadhyay et al. 
2006b;P. A. Hebda 1988a;E. B. Tredget et al. 2005a). I hypothesised that PGE2 
antagonised this TGF-β driven function also. Using a scratch assay the pro-
migratory influence of TGF-β on KCs was confirmed (Figure 5.5(b)), and this effect 
was antagonised by PGE2. This goes against the idea of PGE2 accelerating wound 
healing. However, PGE2 production in the epidermis is transitory, the reduction in 
its level from day 1 onwards could allow the pro-migratory function of TGF-β to 
come through.  
It went on to delineate the mechanism through which PGE2 may be inhibiting TGF-β 
functioning in KCs. Normal TGF-β  signalling involves TβR dependent 
phosphorylation of SMAD2 and 3 effector proteins, which combine with each other 
and SMAD4 to form a complex. This complex either directly binds DNA prmoters, 
or binds with various other transcription factors such as AP-1 and CREB (cAMP 
response element binding protein), which modify its function (R. Derynck et al. 
1998b). It has been shown that PGE2 interfered with TGF-β-induced SMAD-specific 
gene transactivation via a PKA-dependent mechanism which disrupted the 
interaction of SMAD3 with transcription co-activators CREB-binding protein (CBP) 
and p300 (Figure 5.12) (M. Schiller et al. 2003b;R. Derynck et al. 1998a).   154
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However, since previous work from this laboratory demonstrated that in fibroblasts 
ERK signalling inhibited TGF-β events, I decided to determine whether 
ras/MEK/ERK signalling is responsible for PGE2 driven inhibition of TGF-β 
function in KCs (R. Stratton et al. 2002a). 
Figure 5.12: Schematic diagram of interactions between PGE2 and TGF-β 
signalling pathways. PG activates EP receptor on the cell surface resulting in 
adenylate cyclase (AC) activation. AC catalyses activation of cAMP, which in 
turn activates cAMP-dependent protein kinase A (PKA). PKA phosphorylates cAMP 
response element binding protein (CREB) allowing its association with 
transcriptional coactivators CREB-binding protein (CBP) and p300. The complex 
then binds cAMP-responsive element (CRE). TGF-β acts through activation of the 
SMAD complex which also requires the binding to transcriptional coactivators 
CBP and p300. When the cAMP pathway is activated it sequesteres these 
coactivators, thus preventing effective binding of the SMAD complex to to the TGF-
β responsive genes (TRGs) (R. Derynck et al. 1998d;M. Schiller et al. 2003c).    155
Ras/MEK/ERK signalling is normally required for KC housekeeping functions 
including cell cycling (J. D. Weber et al. 1997). It is known that ERK signalling is 
essential for KC motility (M. E. Zeigler et al. 1999).  It was not surprising, therefore 
to find pERK expression in control cultured KCs under basal conditions (Figure 
5.10). A small molecule inhibitor of MEK1/2 U0126 inhibited KC migration, 
confirming that this pathway is important in TGF-β driven cell motility (Figures 5.7, 
5.8). 
However, I showed that TGF-β did not enhance pERK expression in KCs and PGE2 
did not appear to block ras/MEK/ERK signalling in these cells.  
I suggest that the overall effect of PGE2 is to allow wound edge KCs to proliferate in 
a TGF-β rich environment and partially arrest their early migration across the 
wound. As PGE2 levels decline from days 5-7 post wounding, TGF-β responses are 
restored and KCs re-acquire their migratory non-proliferative phenotype. 
 
Conclusions 
•  PGE2 inhibits TGF-β driven KC migration. 
•  PGE2 inhibits the anti-proliferative effect of TGF-β on human KCs. 
•  PGE2 antagonism of TGF-β driven KC function may have evolved to enable 
effective wound closure in the presence of TGF-β. 
•  PGE2 antagonism of TGF-β driven anti-proliferative effect on KCs may be 
partially responsible for the proliferative and carcinogenic effects of PGE2 on 
epidermal KCs. 
 
 
   156
CHAPTER 6 
 
Summary Discussion and Conclusions 
 
 
Studies into the pathogenesis of SSc skin sclerosis to date have predominantly given 
emphasis to the fibroblast activation in the dermis as key to causing fibrosis. TGF-β, 
CTGF and ET-1 have been identified as factors capable of causing fibroblast 
activation and transformation to the highly contractile myofibroblast form (A. 
Desmouliere et al. 2005a). 
Relatively little attention has been paid to the epidermis in SSc. We do know from 
clinical practice that SSc often involves areas of the skin which have had repetitive 
superficial external stimulation such as rubbing with a belt on the abdomen or 
around the neck by a heavy pendant. We also know that the SSc epidermis is often 
hyper-pigmented, a phenomenon specific to the epidermis and its melanocytes. ET-
1, a growth factor implicated in SSc skin fibrosis, is increased in the epidermal cell 
layers of SSc lesional skin and correlates with pigmentary changes in the disease (H. 
Tabata et al. 2000h;X. Shi-Wen et al. 2004c;S. W. Xu et al. 2004a). TGF-β (L. 
Rudnicka et al. 1994e), monocyte chemo-attractant protein-1 (MCP-1) (O. Distler et 
al. 2001b), VEGF (C. A. Davies et al. 2006a) and IL-21 
receptor (IL-21R) (J. H. Distler et al. 2005d) have all been shown to be up-regulated 
in the epidermis in SSc. 
Epidermal maturation is a complex process and KCs play a major role in its 
regulation. KCs synthesise structural components of the epidermal barrier through a 
programmed process of differentiation (K. S. Rao et al. 1996b). In the normal 
epidermis, proliferative cells are located in the basal layer where they strongly 
express cytokeratins 5 and 14. As they withdraw from the cell cycle and migrate   157
upwards, KCs differentiate and start expressing keratin 1 and keratin 10 (E. Fuchs 
1993). I found that in SSc forearm skin lesions, the pattern of keratin expression is 
altered. Cytokeratin 14 is seen to persist into subrabasal layers and this is 
accompanied by a delay in the expression of terminal differentiation marker keratins 
1 and 10. This change represents a disruption in terminal differentiation which 
results in a delay in epidermal maturation (Figure 3.2). I also found that in SSc the 
epidermis is expanded consistent with persistence of active proliferative KCs. These 
changes in SSc epidermis are similar to those described in wound healing during 
which the epidermis becomes expanded and shows persistence of the basal 
phenotype into superficial layers (M. L. Usui et al. 2005b;G. K. Patel et al. 
2006b;M. D. Hertle et al. 1992a). 
Integrins are transmembrane receptors, which play a crucial role in forming bonds 
between cells of the basal layer of the epidermis with the basement membrane. They 
stabilise cell-to-cell interactions and cell matrix adhesion in the epidermis (A. 
Sonnenberg et al. 1991). The hemidesmosome-associated integrin-α6, which forms a 
complex with the β4-subunit, is sharply localised at the basal surface of basal KCs in 
normal skin (M. D. Hertle et al. 1992e). However, I found that in the disease, the 
expression of the α6-integrin was no longer confined to the basal membrane zone 
and this was accompanied by loss of basal intensity (Figure 3.2). This change also 
represents a shift towards a proliferative undifferentiated poorly stratified epidermis 
seen in the disease. Persistent suprabasal integrin-α6 expression is a feature of a 
hyperproliferative wound healing epidermis (M. D. Hertle et al. 1992f). 
Following epidermal injury or in hyperproliferative disorders such as psoriasis or 
cancer, KCs become activated and express activation makers, such as keratin 6 and 
16 (K. S. Rao et al. 1996a). The positive immunostaining for the presence of keratin   158
6 and 16 which I found in SSc epidermis, provides evidence of activation of KCs in 
the disease, further supporting the view that the SSc epidermis exhibits changes 
described during wound healing (Figure 3.3) (N. Aden et al. 2008c).  
Overall, I find that the SSc epidermis is expanded, lacks terminal differentiation and 
exhibits a cytokeratin marker pattern typical for a wound healing epidermis (N. 
Aden et al. 2008d). The fact that the SSc epidermis is altered and has a wound 
healing phenotype is an important new finding based on the results of my thesis. 
Activated KCs are known regulators of wound healing in general and extracellular 
matrix production in particular (J. N. Barker et al. 1991a;I. M. Freedberg et al. 
2001a;F. Grinnell 1992b;S. Werner et al. 2007b). KCs are known to be active 
secretory cells capable of producing profibrotic mediators that via diffusion into the 
dermis cause fibroblast activation and transformation to the myofibroblasts 
phenotype (N. Maas-Szabowski et al. 1999b). Co-culture of normal human KCs and 
fibroblasts induces fibroblast transition to the myofibroblast form in a TGF-β and 
ET-1 dependent manner (B. S. Bauer et al. 2002). Evidence for KC-derived 
fibroblast activation also comes from studies of keloid KC and fibroblast co-cultures 
(W. Xia et al. 2004d).  
In wound healing, the KC-fibroblast activation loop is thought to be that of double 
paracrine signalling, with KCs instructing fibroblasts to produce and secrete growth 
factors which are in turn capable of KC activation (N. Maas-Szabowski et al. 
1999a). 
In this thesis I proposed that SSc skin fibrosis is at least partially caused by 
persistence of the wound healing phenotype of the epidermis causing production of 
pro-fibrotic mediators by KCs. This in turn would lead to continuous and 
uncontrolled activation of dermal fibroblasts.    159
First I began with a simple ELISA measurement of homogenised normal and SSc 
epidermal samples, and assayed KC-derived factors known to be involved in 
fibroblast induction (C. P. Denton, D. J. Abraham 2001;X. Shi-Wen et al. 2001a). 
Specifically, I measured levels of IL-1, ET-1, and TGF-β (free and LAP-associated). 
I found that IL-1 levels were greately elevated in SSc epidermis, but ET-1 and TGF-
β levels were similar in disease and control specimens. In SSc there was a slight 
elevation of the LAP-TGF-β form and a trend towards a higher ET-1 receptor level. 
Also, my studies of SMAD 2/3 phosphorylation are consistent with more active 
TGF-β signalling in SSc epidermis (Figures 3.5, 3.5, 3.10, 3.12, 3.13).  
These findings are important because IL-1, which is an inflammatory molecule 
stored within intact KCs and released upon cell stress or mechanical injury, has 
previously been shown to be involved in the KC-fibroblast activation loop (P. 
Shephard et al. 2004e;P. Shephard et al. 2004l). In fact, IL-1 is known to be the 
initiator of fibroblast activation in this setting and induces a large number of genes 
important for epidermal-fibroblast cross-talk (L. Florin et al. 2004a;S. Werner et al. 
2007a) 
There is some conflict in the literature because some fibroblast responses to IL-1 act 
so as to delay the induction of extracellular matrix production (D. Nowinski et al. 
2002). However, it is thought that there is a difference in the pattern of signalling 
molecule activation between KCs and fibroblasts depending on the time scale of 
their co-culture. Specifically, in the early stages IL-1 activates NF-κB - a 
transcription factor that inhibits TGF-β effects and collagen production (P. Shephard 
et al. 2004m). We have shown, however, that KCs in SSc resemble active day 7 
wound healing cells (N. Aden et al. 2008e), at which point the NF-κB effects are 
likely to become redundant and TGF-β would act to transform fibroblasts into the   160
myofibroblast form (P. Shephard et al. 2004n). Since most of the previous co-culture 
experiments have been done in the context of a wound healing environment, i.e. the 
time scale of less than 5 days, and with cultured KCs rather than intact tissue, the 
SSc skin biopsy disc - FPCL co-culture set-up used in my experiments represents a 
more life-like environment in terms of modelling SSc events. The signalling milieu 
in my experiments is likely to be different from cell co-cultures used by other 
groups. It is known, for instance, that IL-1 activates IL-6, IL-8, TNF-α, and GM-
CSF in the epidermis (H. Uchi et al. 2000b). GM-CSF is known to activate SSc 
ECM production, and its receptors are over-expressed on SSc dermal fibroblasts (L. 
Postiglione et al. 2002;L. Postiglione et al. 2005). IL-6 is also known to be pro-
fibrotic, and SSc patients homozygous for a specific allele of this interleukin are 
known to have higher disease activity scores (R. Sfrent-Cornateanu et al. 2006). 
Both IL-6 and IL-8 have been found to be inducible in SSc fibroblasts by IL-1 (T. 
Kadono et al. 1998). Activated SSc epidermal KCs are likely to be causing 
fibroblast activation indirectly via stimulation of the above mediators, the study of 
which is beyond the scope of this thesis. Overall, IL-1 most likely initiates complex 
KC-fibroblast interactions but delays ECM production until the mid phase of wound 
healing when ECM genes such as Type I collagen are induced. 
Overall, the structural and signalling changes described above represent persistent 
SSc epidermal activation. 
In addition, I went on to study signalling events in SSc and normal epidermal biopsy 
samples using phosphoprotein microarray (Kinexus). These studies demonstrated a 
significant increase in phosphoproteins associated with wound healing and cell 
cycling (including receptor kinases, transcription proteins and signalling molecules), 
and a reduction in apoptosis related phosphoproteins in SSc (Tables 3.1, 3.2). This   161
supports the notion of a chronic injury phenotype and activation in SSc epidermis. 
Most significantly, c-Jun, p38, HGF and STAT3 phosphorylated kinases have been 
found to be significantly elevated in SSc epidermis. All of these factors are known to 
be involved in epithelial-mesenchymal cross-talk. c-Jun and p38 are both 
downstream of IL-1 in its signalling cascade (Figure 1.3) (Y. Kida et al. 2005), 
which confirms a tissue injury-like process in SSc epidermis and indicates the 
presence of injured or stressed cells. I also found that HGF receptor tyrosine kinase 
has an elevated phosphoylation state in the disease. This is important because in 
injured tissues mesenchymal cells release HGF which causes epidermal cell 
activation via the HGF c-MET receptor (R. Zarnegar 1995). Also previous studies 
indicate that SSc fibroblasts do indeed hypersecrete HGF and this is IL-1 dependent 
(Y. Kawaguchi et al. 2002). 
I went on to study whether these changes in SSc epidermis translated into the ability 
to cause dermal fibroblast activation. In order to mimick the natural tissue 
architecture and cell interactions in vitro, three-dimentional co-cultures of a biopsied 
epidermis with normal human fibroblast populated collagen matrices were used. I 
demonstrated that the SSc epidermis, and not normal epidermis, caused fibroblast 
activation in a TGF-β, ET-1 and IL-1 dependent manner (Figures 4.2-4.13).  
SSc epidermis was shown to cause ET-1, TGF-β, and CTGF, but not IL-1 
overproduction by the stimulated collagen lattice fibroblasts (Figures 4.14 - 4.17).  
I therefore propose that IL-1 is the epidermis-derived cytokine triggering fibroblast 
activation, whereas ET-1 and TGF-β are involved at the level of the fibroblast 
maintaining the activated phenotype of these cells.  
I also propose a mechanism whereby the SSc epidermis is activated by a 
stimulus/insult (such as an auto-antibody or a chemical irritant), causing IL-1 release   162
from KCs that in turn causes fibroblast activation. The fibroblasts then enter an 
autocrine loop involving ET-1 and TGF-β which maintains the fibrotic matrix-
overproducing phenotype of the cells. The dermal factors are then likely to feedback 
to the epidermis setting up a paracrine activation loop similar to that seen in wound 
healing (Figure 6.1). While initially maintained by an external insult, the loop is 
likely to become autonomous in the long run. The initial inflammatory stage of the 
disease that correlates with the clinical picture of red, pruritic skin (the IL-1 phase), 
eventually burns out leaving the patient with permanent sclerosis. 
These findings have therapeutic implications because epithelial-fibroblast 
interactions could be blocked by biologic therapies. Specifically IL-1 receptor 
antagonists such as Anakinra (licensed for use in inflammatory conditions) could be 
tried in early inflammatory disease stages. In addition, blocking HGF and its 
receptor c-MET could be used to antagonise KC-fibroblast interaction in the disease. 
Expansion of the epidermis, delayed maturation, and altered α6 integrin and 
cytokeratin 1, 10, 14, 6, and 16 expression are all features of the epidermis during 
wound healing. Because of this I became interested in KC regulation during wound 
repair. During wound repair and in SSc the epidermal layer becomes thickened and 
expanded despite a TGF-β-dominated environment, which is anti-proliferative in 
nature. I reasoned that some component of epidermal cell activation during wound 
repair releases KCs from the anti-proliferative effect of TGF-β. In the past, 
prostanoids have been shown to inhibit TGF-β functioning in human cells (R. 
Stratton et al. 2002k). Kinexus phosphoprotein studies have highlighted reduced 
phosphorylation of COX II in SSc epidermis. This prompted the studies of COX II 
and its product PGE2 in wounding. I showed increased COX II and PGE2 production 
in early excisional mouse wounds (Figure 5.2).    163
I then showed that PGE2 inhibits anti-proliferative affects of TGF-β. I also found 
that PGE2 blocked the pro-migratory affects of TGF-β. I suggest that PGE2 induced 
at the wound edge on days 1-7 transiently blocks TGF-β events in KCs and enables 
their proliferation at wound margin. The mechanism of this inhibition does not seem 
to involve erk phosphorylation. Published data shows that the two pathways interact 
at the level of transcription co-factors CREB and p300 (Figure 5.12). 
Regeneration in rapidly renewing epidermal tissue requires proper functioning of 
control mechanisms of growth and differentiation, which are mainly regulated by 
epithelial-mesenchymal interactions (N. Maas-Szabowski et al. 2000). PGE2 is 
gradually emerging as an important mediator that influences the progression of 
fibrotic processes. In the lung, for instance, PGE2 is known to be protective against 
interstitial fibrosis conditions such as IPF (V. Lama et al. 2002;B. B. Moore et al. 
2000;B. B. Moore et al. 2005). Outside the lung environment, PGE2 has been shown 
to be anti-fibrogenic in the liver (L. Treffkorn et al. 2004). PGE2 has also been 
shown to inhibit keloid scar dermal fibroblast contraction and TGF-β-induced 
collagen production (V. C. Sandulache et al. 2007). Results from this laboratory 
have also previously established that prostanoids are able to antagonise TGF-β 
signalling in human dermal fibroblasts (R. Stratton et al. 2002l). 
Experimental evidence has established that at least some of the antifibrotic actions of 
PGE2 are produced through inhibition of TGF-β. For example, there is definitive 
evidence to show that PGE2 reduces fibroblast activation and collagen production in 
human lung fibroblasts via inhibition of TGF-β activity (A. Diaz et al. 1989b). It has 
also been confirmed more recently that PGE2 inhibits TGF-β-induced fibroblast to 
myofibroblast transformation and collagen I expression (J. E. Kolodsick et al. 2003).   164
In fact, it has been suggested that normally, through stimulation of endogenous 
PGE2 production, TGF-β exhibits autoregulatory control to limit connective tissue 
synthesis by human lung fibroblasts (A. Diaz et al. 1989a). 
In human skin fibroblasts the relationship between PGE2 and TGF-β is also well 
recognised. There is evidence that PGE2 inhibits collagen and fibronectin production 
by these cells (J. Varga et al. 1987).  
In clinical practice, iloprost (a synthetic analogue of prostacyclin, a prostanoid 
related to PGE2) is known to improve skin fibrosis, and has previously been shown 
to inhibit fibroblast activation (R. Stratton et al. 2002m). 
Epithelial-mesenchymal interaction involving PGE2 has also been noted. It has been 
shown that inflammatory mediators TNF-α and IL-1, known to be released from 
normal human KCs after wounding, have antifibrotic properties by inhibiting 
transcription of α1(I)procollagen gene partly via PGE2 release from human 
fibroblasts (A. Diaz et al. 1993). 
Alveolar epithelial cell (AEC) dysregulation has been directly implicated in lung 
fibroblast activation and subsequent fibrosis (M. Selman et al. 2001). More recently, 
epithelium-driven lung fibrosis has been attributed to a reduction in PGE2 
production by damaged AECs (B. B. Moore et al. 2003a). It is known that in SSc 
lung disease AEC damage is partly responsible for the underlying parenchymal 
fibrosis via a TGF-β mechanism (R. K. Hoyles et al. 2008). By drawing analogy 
between SSc lung and skin pathology I propose that the reduction in PGE2 
availability is partly responsible for abnormalities in SSc KC proliferation and 
migration (via inhibition of TGF-β driven KC function), which could in turn lead to 
the structural abnormalities seen in the disease epidermis, with fibrosis as a 
pathophysiological result of this epidermal disfunction.    165
Increasing epithelial PGE2 production has previously been put forward as a potential 
candidate for therapeutic interventions
 in fibrotic lung disease (B. B. Moore et al. 
2003b). Since the above experimental evidence confirms the role of PGE2 in 
inhibition of epithelial TGF-β function, PGE2 is a candidate therapeutic agent for the 
inhibition of epithelium-driven fibroblast activation also. One has to bear in mind, 
however, that PGE2 has been shown to induce IL-1β production in normal human 
fibroblasts. IL-1β is known to be profibrotic in the lung. Its close isoform IL-1α 
(which has identical biological properties and binds to the same receptor) has been 
shown to be an important epithelium-derived fibrotic mediator in chapter 3. This 
may mean that PGE2 on its own is not enough to suppress fibrosis, and may require 
an addition of an IL-1 inhibitor.  
Excess PGE2 is strongly linked to increased incidence of skin and gastrointestinal 
malignancy. We must keep in mind that the anti-proliferative action of TGF-β is 
known to be important in protection against epidermal carcinogenesis (B. Pasche 
2001). Early skin tumour development is suppressed by TGF-β through its effect on 
cell cycling (W. Cui et al. 1996;A. B. Glick et al. 1993). Transgenic SMAD 3+/- 
heterozygous knockout mice have a greater resistance to DMBA-induced skin 
carcinogenesis than the wild-type or SMAD 2+/- counterparts thus implicating this 
TGF-β pathway in tumour protection (S. H. Tannehill-Gregg et al. 2004).  
In the recent years COX II and prostaglandins including PGE2 have emerged as 
important mediators of epithelial carcinogenesis (K. Muller-Decker et al. 1995;Y. 
M. Sung et al. 2005). COX II over-expression has been found in basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC) (G. Gasparini et al. 2003), 
and both SCC initiation and progression have recently been shown to be enhanced 
by PGE2  (S. Brouxhon et al. 2007). PGE2 and COX II have been found to be over-  166
expressed in human KCs following UVB irradiation confirming the important role 
of PGE2 in UV-induced carcinogenesis (S. Y. Buckman et al. 1998). COX II 
inhibitors inomethacin and colecoxib have been found to be protective in this setting 
(S. M. Fischer et al. 1999b). 
PGE2 has also been implicated in the development of several gastrointestinal 
malignancies including gastric and colorectal (C. E. Eberhart et al. 1994). COX II 
inhibitors are associated with an up to 50% reduction in the morbidity and mortality 
from colorectal cancer (L. J. Marnett, R. N. DuBois 2002). Antagonism of TGF-β 
could explain in part the mechanism of pro-proliferative and tumourgenic action of 
PGE2 in epithelial structures and the protective effect of NSAIDs (M. Schiller et al. 
2003a).  
 
The set aims of this thesis were: 
1. To determine whether the SSc epidermis has an altered structural and 
signalling phenotype.  
2. To determine whether the SSc epidermis activates normal human fibroblast in 
vitro. 
3. To determine whether PGE2 modifies the responses of KCs to TGF-β. 
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I have found that: 
1. The SSc epidermis has an altered structural and signalling phenotype. The 
phenotype resembles a wound healing epidermis and has pro-fibrotic potential.  
2. The SSc epidermis activates normal human fibroblasts in vitro. 
3. PGE2 inhibits the TGF-β driven anti-proliferative and pro-migratory KC 
functions. This may explain the ability of KCs to proliferate at the wound margin 
in a TGF-β dominated environment.  
 
Figure 5.13 summarises the findings of this thesis and ties them in with known 
mechanisms of epithelial-mesenchymal intreaction. 
I therefore demonstrate that the hypothesis of the thesis was correct and SSc 
epidermis does contribute to activation of fibrotic processes in the disease. 
It is important to appreciate that the success of future therapeutic agents for SSc 
treatment will depend on changing our target from the dermal/interstitial structures 
to epidermal/epithelial ones.  
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Figure 6.1: Schematic representation of epidermal-fibroblast interaction in 
SSc. Summary of the mechanism proposed to account for epidermis-driven 
dermal fibroblast activation in SSc. Initial external stimuli (autoantibody, cell 
injury, or chemical exposure) activate KCs as well as fibroblasts. Activated KCs 
assume a wound healing phenotype with an altered structure and function 
resulting in the production of profibrotic mediators such as IL-1. These factors 
subsequently act on dermal fibroblasts setting up a positive feedback paracrine 
loop (maintained by TGF-β and ET-1) to cause pathological fibrosis seen in the 
disease. Feedback mechanisms operate from dermis to epidermis involving KGF 
and HGF. COX II is also activated post epidermal insult and causes PGE2 
production. PGE2 inhibits TGF-β-driven KC function which has anti-fibrotic 
potential.   169
CHAPTER 7 
Future Work 
 
The work presented in this thesis shows that the interaction between SSc epidermis 
and dermal fibroblasts is important in pathogenesis of fibrosis in the disease. 
However several areas were beyond the scope of the thesis. Additional experimental 
work will provide a clearer picture of the disease pathways. 
Further studies of SSc epidermis to include: 
1.  Staining of SSc and normal epidermal biopsy material for most significantly 
altered factors highlighted with Kinexus phosphoprotein assay, eg. HGF, 
members of MAPK cascade, markers of apoptosis and cell proliferation. 
2.  SSc and normal KC culture and staining for intracellular presence of IL-1.  
3.  IL-1 release from SSc KCs determined using ELISA and Western blotting of 
media.  
4.  mRNA PCR of SSc and normal epidermal KCs for IL-1 expression. 
Further studies of SSc epidermis-fibroblast co-culture to include: 
1.  Specific ET-1 A and B receptor inhibitors used in co-culture experiments. 
2.  Staining of epidermal-dermal junction from co-culture experiment for HGF 
receptor c-Met as a marker of fibroblast feedback. 
Further studies into PGE2/TGF-β interactions in human KCs to include: 
1.  Measurement of the effect of topical PGE2 on epithelial coverage of 
excisional wounds in the mouse. 
2.  Measurement of the effect of topical PGE2 on KC proliferation at the wound 
edge. 
3.  Repeating these experiments in a COX II knock-out mouse.   170
CHAPER 8 
Appendix 
 
Appendix 1: List of Antibodies 
 
Antibody  Company  ID number  Host Species 
 
αSMA 
 
DAKO  MO851  mouse 
αv integrin 
 
Abcam  ab6133  mouse 
β-Actin 
 
Sigma  A 5441  mouse 
COX II 
 
Santa Cruz 
Biotechnology 
sc-1746  goat 
CTGF 
 
Santa Cruz 
Biotechnology 
sc-14939  goat 
Cytokeratin  14 
 
Vector Laboratories  VP-C410  mouse 
Cytokeratin 16 
 
Labvision  LLO25  mouse 
Cytokeratin 7 
 
R&D  AF 1339  goat 
Cytokeratin 6 
 
Labvision  LHK6B  mouse 
Cytokeratins 1 and 
10 
Cymbus Biotech  CBL266  mouse 
ERK1/2 (p44/42) 
 
Cell Signalling 
Technology 
9122  rabbit 
ET-1 
 
Bachem  T-4049  rabbit 
ET-A Receptor 
 
Abcam  ab 12977  rabbit 
ET-B Receptor 
 
Abcam  ab 12980  rabbit 
GAPDH 
 
Abcam  ab8245-100  mouse 
IL-1α 
 
Santa Cruz 
Biotechnology 
sc-9983  mouse 
IL-1α Receptor 
 
Santa Cruz 
Biotechnology 
sc-25775  rabbit 
LAP- TGF-β 
 
R&D Systems  AB-246-NA  goat 
TGF-β 
 
Santa Cruz 
Biotechnology 
sc-146 rabbit 
pERK1/2 (Phospho-
P44/42) 
Cell Signalling 
Technology 
9101  rabbit 
pSMAD2/3 Santa  Cruz 
Biotechnology 
sc-11769  rabbit   171
Appendix 2: Patient Biopsy Cohort 
68% Female, Age range 35-67, Mean age 51 
Antibody profile: ScL 70 31%; RNA polymerase 18%; u3RNP 9%, Nucleolar 4.5%; 
Centromere 22.7%; ANA positive, ENA negative 13.6% 
 
Appendix 3: Full list of Kinexus Phosphoprotein Data 
 
Fold 
Increase 
Phosphoprotein Site 
(Human) 
Full Target Protein Name 
5.55  S70  Tyrosine hydroxylase isoform a 
2.89 Y1003  Hepatocyte  growth  factor (HGF) receptor-
tyrosine kinase 
2.63 Pan-specific  Protein-serine phosphatase 4 - regulatory 
subunit (PPX/A'2) 
2.62  S605  Synapsin 1 isoform Ia 
2.57  S674  Protein-serine kinase C eta  
2.43  Pan-specific  Male germ cell-associated protein-serine 
kinase 
2.38  Pan-specific  Wee1 protein-tyrosine kinase 
2.37 S63  Jun  proto-oncogene-encoded AP1 transcription 
factor 
2.29  Pan-specific  NIMA (never-in-mitosis)-related protein-
serine kinase 7 
2.23 T514  Protein-serine kinase C gamma 
2.18  Y705  Signal transducer and activator of transcription 
3 
2.18 Pan-specific  Dual  specificity protein kinase 
2.18 T674  Protein-serine kinase C gamma 
2.17 Pan-specific  Integrin-linked protein-serine kinase 1 
2.15 Y1189/Y1190  Insulin  receptor/Insulin-like growth factor 1 
receptor 
2.13 T180+Y182  Mitogen-activated  protein-serine kinase p38 
alpha 
2.10 Pan-specific  PCTAIRE-1  protein-serine kinase 
2.09  Pan-specific  NIMA (never-in-mitosis)-related protein-
serine kinase 4 
2.07 Pan-specific  Polo-like  protein  kinase 3 (cytokine- inducible 
kinase (CNK)) 
1.96  Pan-specific  Protein kinase C-related protein-serine kinase 
1 
1.94  S18  Tyrosine hydroxylase isoform a 
1.92 Pan-specific  Nucleotide  diphosphate kinase 7 (nm23-H7) 
1.91 S716  Microtubule-associated protein tau   172
1.86 T514  Protein-serine kinase C gamma 
1.84  Pan-specific  BNDF/NT3/4/5 receptor- tyrosine kinase 
1.84  Pan-specific  RYK tyrosine-protein kinase 
1.83 S576  Protein-tyrosine phosphatase 1D (SHP2, 
SHPTP2, Syp, PTP2C) 
1.81  Pan-specific  ZIP kinase (death associated protein-serine 
kinase 3 (DAPK3)) 
1.81 Pan-specific  MAPK/ERK  protein-serine kinase 6 (MKK6) 
1.80  Y40  Bone marrow X protein-tyrosine kinase 
1.79  Y279/ Y216  Glycogen synthase-serine kinase 3 alpha 
1.79 Pan-specific  TGF-beta-activated protein-serine kinase 1 
1.77  Pan-specific  Proliferating cell nuclear antigen 
1.77 Pan-specific  Phosphatidylinositol 4-phosphatase 5-kinase 
type 2 alpha 
1.76 Pan-specific  Aurora  Kinase  A (serine/threonine protein 
kinase 6) 
1.76  Pan-specific  p53-induced protein PIGPC1 
1.76 Pan-specific  Phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase and protein phosphatase and 
tensin homolog deleted on chromosome 10 
1.76  Y576  Focal adhesion protein-tyrosine kinase 
1.75 Y754  Platelet-derived  growth factor receptor kinase 
alpha 
1.73 Pan-specific  MAPK/ERK  protein-serine kinase 2 (MKK2) 
1.71 Pan-specific  Protein-serine phosphatase 1 - catalytic 
subunit  - beta isoform 
1.71 Pan-specific  Intestinal  cell  protein-serine kinase (MAK-
related kinase (MRK)) 
1.70 Pan-specific  Extracellular  regulated protein-serine kinase 4 
1.70 Pan-specific  TGF-beta-activated protein-serine kinase 1 
1.66 Pan-specific  Protein-serine  phosphatase 2A - A  regulatory 
subunit - alpha and beta isoforms 
1.65  Pan-specific  MAPK/ERK kinase kinase 2 
1.65  Pan-specific  p70 ribosomal protein-serine S6 kinase beta 
1.64  S465+S467  SMA- and mothers against decapentaplegic 
homolog 2 
1.64 Pan-specific  cAMP-dependent protein-serine kinase 
regulatory type 2 subunit alpha 
1.63 S738+S742  Protein-serine  kinase C mu (Protein kinase D) 
1.63 T334  Mitogen-activated  protein kinase-activated 
protein kinase 2 alpha/beta 
1.63 Y572+Y574/Y579+Y581 Platelet-derived growth factor receptor kinase 
alpha/beta 
1.62 S370  Phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase and protein phosphatase and 
tensin homolog deleted on chromosome 10 
1.62  Pan-specific  Phosphoinositide-3-kinase, regulatory subunit   173
4 
1.62 Pan-specific  Signal  transducer  and activator of transcription 
2 
1.59 Pan-specific  Tousled-like  protein-serine kinase 1 
1.58 S116  Phosphoprotein-enriched in diabetes/astrocytes 
15 
1.58 Pan-specific  Axl  proto-oncogene-encoded protein-tyrosine 
kinase 
1.57 Pan-specific  Vaccinia  related protein-serine kinase 1 
1.56 Pan-specific  Nucleotide  diphosphate kinase 6 (nm23-H6) 
1.56 Pan-specific  Protein-serine kinase C zeta 
1.56 Pan-specific  Inhibitor  of  NF-kappa-B protein-serine kinase 
beta 
1.56 Pan-specific  Src  proto-oncogene-encoded protein-tyrosine 
kinase 
1.55  Pan-specific  Tank-binding protein 1 
1.54  S218+S222, S4  MAPK/ERK protein-serine kinase 1 (MKK1) 
+ B23 (nucleophosmin, numatrin, nucleolar 
protein NO38) 
1.54 Pan-specific  Suppressor  of  cytokine signalling 4 (SOCS7) 
1.53  S645  Protein-serine kinase C delta 
1.53  T210  Polo-like protein-serine kinase 1 
1.53  S910  Focal adhesion protein-tyrosine kinase 
1.53 Pan-specific  Mitogen-activated protein-serine kinase p38 
alpha 
1.53 Pan-specific  Eukaryotic  translation initiation factor 2 alpha 
1.52  S82  Heat shock 27 kDa protein beta 1 (HspB1) 
1.52  Pan-specific  Mammalian target of rapamycin (FRAP) 
1.52  T229  p70/p85 ribosomal protein-serine S6 kinase 
alpha 
1.50  T232  Fos-c FBJ murine osteosarcoma oncoprotein-
related transcription factor 
1.50  S114  cAMP-dependent protein-serine kinase 
regulatory type 2 subunit beta 
1.50  Pan-specific  Kinase homologous to SPS1/STE20 (MAP 
kinase kinase kinase protein-serine kinase 5 
(MEKKK5) 
1.50  S8  Glial fibrillary acidic protein 
 
 
 
Fold 
Decrease 
Phosphoprotein 
Site (Human) 
Full Target Protein Name 
0.31  Pan-specific  Diacylglycerol kinase zeta 
0.33  Pan-specific  Bcl2-like protein 1 
0.34 Pan-specific  Pro-caspase  3 
0.36 Pan-specific  caspase  5   174
0.39  Pan-specific  Janus protein-tyrosine kinase 2 
0.39 Pan-specific  Cyclin-dependent protein-serine kinase 4 
0.40 Pan-specific  Cyclo-oxygenase  2  (prostaglandin G/H synthase 2 
precursor) 
0.40 Pan-specific  Cell  division cycle 25B phosphatase 
0.40  Pan-specific  Heme oxygenase 2 
0.40 T286  Calcium/calmodulin-dependent protein-serine kinase 2 
alpha 
0.40  Y612  Insulin receptor substrate 1 
0.41  Pan-specific  Cell division cycle 2-like protein-serine kinase 5  
0.41  S129+S133  cAMP response element binding protein 1 
0.42 Pan-specific  Cyclin-dependent protein-serine kinase 5 
0.43 Pan-specific  Calcium/calmodulin-dependent protein-serine kinase 2 
beta 
0.43  Pan-specific  p21-activated serine kinase 5 (Serine/threonine-protein 
kinase PAK 7) 
0.44  Pan-specific  Leukocyte common antigen CD45 receptor-tyrosine 
phosphatase (LCA, T200) 
0.44 S36  Caveolin  2 
0.45 Pan-specific  Calcium/calmodulin-dependent protein-serine kinase 1 
delta 
0.46  Pan-specific  Heat shock 70 kDa protein 1 
0.47  Pan-specific  Large tumor suppressor 1 protein-serine kinase 
(WARTS) 
0.48 S789  Caldesmon 
0.50 Pan-specific  Calcium/calmodulin-dependent protein-serine kinase 2 
gamma 
0.51 S45  Catenin  (cadherin-associated protein) beta 1 
0.52 Pan-specific  Cyclin-dependent protein-serine kinase 1  
0.52 Pan-specific  Calmodulin-dependent  protein-serine kinase kinase 
0.52 S1107  Eukaryotic  translation  initiation factor 4 gamma 1 
0.53  S80  Acetyl coenzyme A carboxylase 
0.53 S530  Microtubule-associated protein tau 
0.53  T183+Y185  Jun N-terminus protein-serine kinases (stress-activated 
protein kinase (SAPK)) 1/2/3 
0.54 Pan-specific  Cyclin-dependent protein-serine kinase 6 
0.54 Y412  Abelson  proto-oncogene-encoded protein-tyrosine 
kinase 
0.55 Pan-specific  Cyclin-dependent protein-serine kinase 8 
0.55  Pan-specific  Anaplastic lymphoma kinase 
0.55 Pan-specific  Pro-caspase  4  (ICH2 protease, ICE(rel)-II) 
0.56 Pan-specific  Pro-caspase  8  (ICE-like apoptotic protease 5 (ICE-
LAP5), Mch5, FLICE, CAP4) 
0.56  S676  Protein-serine kinase C theta 
0.57  Pan-specific  Jun N-terminus protein-serine kinases (stress-activated 
protein kinase (SAPK)) 1/2/3 
0.57 Y15  Cyclin-dependent  protein-serine kinase 1/2   175
0.57 Y999  Insulin  receptor 
0.57  S722  Focal adhesion protein-tyrosine kinase 
0.57 Pan-specific  Heat  shock  transcription factor 4 
0.57 Pan-specific  Calcium/calmodulin-dependent protein-serine kinase 2 
delta 
0.58 T218+Y220  Extracellular  regulated  protein-serine kinase 5 (Big 
MAP kinase 1 (BMK1)) 
 
0.58 Pan-specific  Extracellular  regulated protein-serine kinase 2 (p42 
MAP kinase) 
0.59 Pan-specific  Pro-caspase  12  (mouse) 
0.59  T320  Protein-serine phosphatase 1 - catalytic subunit  - 
alpha isoform 
0.59  Pan-specific  Aurora Kinase A (serine/threonine protein kinase 6) 
0.60 Pan-specific  Putative  protein-serine kinase WNK4 
0.61  T199  B23 (nucleophosmin, numatrin, nucleolar protein 
NO38) 
0.62 Pan-specific  STE20-like  protein-serine kinase 
0.63 Pan-specific  Cyclin-dependent protein-serine kinase 7 
0.63 S10  Histone  H3.3 
0.63  Pan-specific  ER protein 57 kDa (protein disulfide isomerase-
associated 3; 58 kDa glucose regulated protein) 
0.64  S15  Heat shock 27 kDa protein beta 1 (HspB1) 
0.64 Y15  Cyclin-dependent  protein-serine kinase 1/2 
0.64  Pan-specific  Heme oxygenase 1 
0.65  Pan-specific  C-terminus of Src tyrosine kinase 
0.66 Pan-specific  Casein  protein-serine kinase 1 epsilon 
0.66 Pan-specific  Cyclin-dependent protein-serine kinase 7 
0.66 Pan-specific  Hematopoetic  progenitor protein-serine kinase 1 
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Appendix 3: Publications 
 
‘Proteomic analysis of scleroderma lesional skin reveals activated wound healing 
phenotype of epidermal cell layer’ Aden,N.; Shiwen,X.; Black,C.; Nuttall,A.; 
Denton,C.P.; Leask,A.; Abraham,D.; Stratton,R.   
Rheumatology (Oxford) 2008 Dec; 47(12):1754-60 
 
Abstract: OBJECTIVE: To identify using proteomic analysis, proteins of altered 
abundance in the skin of patients with SSc. METHODS: 4 mm excision biopsies 
were obtained from the forearm involved skin of 12 diffuse SSc patients and 12 
healthy controls. Two-dimensional gel electrophoresis was used to separate and 
define proteins in normal and SSc skin biopsy material. Proteins of altered 
abundance in the disease were formally identified by mass spectroscopy. 
Abnormalities of the epidermis were confirmed by immunohistochemistry. 
RESULTS: Proteomic analysis revealed altered abundance of proteins involved in 
extracellular matrix production, myofibroblast contractility, energy metabolism and 
response to oxidative stress. In addition, proteins specific to the epidermis and 
involved in epidermal cell differentiation were altered in abundance in the disease. 
SSc epidermis is thickened, has an expanded nucleated cell layer, and exhibits 
abnormal persistence of basal marker keratin 14, delayed expression of maturation 
markers keratin 1/10 and the induction of keratins 6 and 16, normally absent from 
interfollicular skin and induced following epidermal injury. These changes closely 
resemble the activated phenotype seen during wound healing. CONCLUSIONS: 
Consistent with previous models of SSc pathogenesis these data are showing 
increased contractility, increased extracellular matrix and response to oxidative 
stress in the involved skin of recent onset SSc patients. In addition, we show that 
SSc epidermis has an activated, wound healing phenotype. These findings are 
important because epidermal cells activated by injury induce and regulate local 
fibroblasts during wound repair. 
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‘Scleroderma Epidermis Promotes TGF-β and ET-1 Dependent Fibroblast 
Activation’ 
Nuttall,A.; Shiwen,X.; Aden,N.; Denton,C.P.; Abraham,D.; Stratton,R.   
ACR Supplement, November 2007, F 220 
 
BACKGROUND: Scleroderma (SSc) is a systemic disorder of unknown aetiology, 
characterised by uncontrolled scarring of skin and internal organs. We have found 
previously that SSc epidermis has an activated wound-healing phenotype. When 
injured, wound healing keratinocytes can promote fibroblast activation which 
depends on TGF-β and ET-1. Epithelial-mesenchymal interactions are a well 
recognised phenomenon in scarring conditions and wound environments. Since both 
TGF-β and ET-1 are important in SSc pathogenesis, we set out to determine whether 
epithelial stimulation of fibroblasts could be important in SSc skin fibrosis. 
We have previously demonstrated the ability of SSc epidermal biopsies to cause 
contraction of normal human fibroblasts in vitro, and shown that TGF-β is involved 
in the process. Here we address the involvement of ET-1 in fibroblast activation by 
the epidermis and look at the characteristics of the SSc vs normal epidermis in terms 
of their TGF-β and ET-1 content. 
METHODS: 2 skin punch biopsies (4 mm) were obtained from each of the forearms 
of 3 patients with recent onset active diffuse SSc (within 24 months), and 3 control 
subjects. The epidermis was separated with trypsin. Fibroblast-populated stress 
collagen lattices (FPCL) were set up in wells. Control wells were left untreated. The 
other wells were exposed to either SSc or normal epidermal discs for 48 hrs. Further 
FPCL containing ET inhibitor bosentan (10μM) were also exposed as above.  
Further biopsies collected from 4 patients with SSc and 4 control subjects were snap 
frozen in liquid nitrogen and the epidermises surgically cut off. Lysates of epidermal 
discs were assayed for TGF-β and ET-1 content using ELISA (R&D Systems).  
Further biopsies were stained using immunohistochemistry for TGF-β and LAP-
TGF-β.  
RESULTS: We found similar levels of ET-1 in SSc and normal epidermal lysates 
(18.4 pg/ml, vs 18.3 pg/ml, p=0.1117). Free TGF-β content was slightly reduced in 
the SSc epidermal lysates vs normal controls (135.3 pg/ml vs 168 pg/ml, p=0.129).   178
There was a significant difference between SSc and normal epidermal LAP-TGF-β 
content (1436 pg/ml vs 1222.7 pg/ml, p=0.04). This was confirmed by 
immunohistochemical staining of epidermal biopsies. 
SSc epidermis caused FPCL contraction (gel size 56.26% of original). This 
contraction was significantly inhibited by ET inhibitor bosentan (gel size 90.7% of 
original), p=0.01.  
CONCLUSIONS: SSc epidermis has fibroblast activating properties in vitro, which 
are dependent on ET-1 and TGF-β. We suggest that activated epithelial cells 
maintain fibrosis by interaction with dermal fibroblasts. Since ET-1 and free TGF-β 
content of the SSc epidermis is not significantly increased, we believe a double 
paracrine epithelial-mesenchymal loop potentiates dermal activation and could 
therefore be a target for theraputic intervention. 
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